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ABSTRACT 
 
The identification of biomarkers to predict risk and clinical outcomes beyond clinical 
observation in psychiatry is a key priority in contemporary mental health research. 
Individuals at elevated risk for mental disorders have been the focus of such efforts as 
they represent a potentially viable target group for early intervention and indicated 
prevention. Early intervention and indicated prevention efforts for individuals at ultra-
high risk (UHR) for psychosis might benefit from such biomarkers to enable better risk 
prediction and to discern who will benefit from treatment. Alterations in 
neuroendocrine, immune and oxidative stress markers as well as abnormalities in lipid 
biology are robust findings in biological psychiatry. On the other hand, mounting 
evidence suggests that First Nations people including the Aboriginal and/or Torres 
Strait Islander people of Australia have a higher risk for common and severe mental 
illness, most likely attributable to social and environmental health determinants. 
However the role of stress-related biomarkers in this context remains poorly 
understood. Consequently, the aims of this thesis were to examine (1) a multisystem 
biomarker index known as allostatic load in two high-risk populations and to (2) 
examine the role of lipid biology in these groups.   
 
The first part of this thesis explores the role of allostatic load (AL) and omega-3 (ω-3) 
polyunsaturated fatty acids (PUFA) in two clinical studies of patients with 
schizophrenia, first-episode psychosis and individuals at UHR for psychosis. The 
second part explores the role of AL and dietary ω-3 PUFA in a community-based study 
of Aboriginal and/or Torres Strait Islander people, who are at increased risk for mental 
ill-health according to recent national reports. The above aims are achieved through 
meta-analysis of existing studies of cortisol in psychotic disorders, secondary analysis 
of two clinical studies, and in a cross-sectional multi-site community-based study of 
Aboriginal and/or Torres Straight Islander adolescents and young adults attending a 
health check.  
 
First, flattened cortisol-awakening response is reported in patients with schizophrenia 
and first-episode psychosis relative to controls, but not in UHR individuals, suggesting 
neuroendocrine dysregulation during some stages of the psychosis spectrum. 
Secondly, informed by these findings, a study of AL demonstrated elevated AL in 
patients with schizophrenia and first-episode psychosis that was positively correlated 
with positive psychotic symptoms and negatively correlated with functioning at trend 
level. No prospective association of AL and treatment response and symptomatic 
 ix 
remission was identified. Next, secondary analysis of a multi-centre randomised 
controlled trial investigated AL in youth at UHR for psychosis. This study revealed 
prospective associations of high AL with impairments in social and occupational 
functioning. Next, the prospective association of PUFA status and clinical outcomes in 
a 12-month follow-up is reported, which demonstrated a selective relationship of low 
ω-3 PUFA levels with mood disorders and no association with psychotic or anxiety 
disorders. The second part of the thesis reports depression rates in three remote 
communities, explores the relationship of depression with hair cortisol and AL, and 
reports an association of low plasma levels of o ω-3 PUFA with depressive symptoms.  
 
Collectively, the data presented in this thesis demonstrate complex associations of a 
multisystem biomarker index and ω-3 PUFA with mental ill-health. Ultimately, 
multisystem indices like AL may be used in future research to establish their utility as a 
clinical prognostic risk index. By studying membrane lipids in an ethnic minority group, 
this thesis was able to show an association of high dietary intake of ω-3 PUFA and low 
levels of depression, which may serve as a protective factor.  
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 1 
1 Introduction 
Common and severe mental disorders such as depression and psychotic disorders are 
among the largest contributors to disease burden globally. A substantial proportion of 
these disorders typically have their onset during adolescence and early adulthood and 
lead to considerable morbidity and disability throughout the lifespan. Understanding 
the processes characterising the period prior to the emergence of psychiatric disorders 
offers opportunities for potential prevention strategies. Consequently, a key research 
priority in current psychiatric research is the identification of individuals at risk for 
psychiatric disorders with the promise to improve long-term outcomes through early 
intervention. The last two decades have seen much progress in the development of 
clinical criteria and attempts to evaluate suitable interventions, yet risk factors for 
progression and adverse clinical outcomes remain poorly understood. If successful, 
such risk biomarkers may assist in identifying individuals with need for care, who will 
benefit from specific interventions, or point toward potential intervention targets. 
 
In this thesis, two biological processes thought to contribute to the early phases of 
mental disorders are examined in regard to clinical symptoms and functional outcomes 
in a series of individual papers focusing on patients with psychotic disorders, help-
seeking individuals with at-risk mental states (ARMS)i and non-clinical populations. 
More specifically, the allostatic load (AL) framework is applied to a psychiatric context 
and evaluated in regard to its cross-sectional association with symptoms and 
prospective relationship with clinical and functional outcomes. Similarly, 
polyunsaturated fatty acids (PUFA), known to be relevant for several 
pathophysiological processes related to inflammation, are examined in terms of their 
relevance for psychiatric disorders. 
 
In accordance with the HDR Thesis Preparation Guidelines of James Cook University, 
this thesis by publication is presented as a series of published papers and manuscripts 
                                               
i The terms “ultra-high risk (UHR) for psychosis” “clinical high risk (CHR) for psychosis” and “at-risk mental 
state (ARMS)” are used throughout the literature to refer to people who present with varying degrees of 
sub-clinical symptoms and are at increased risk of developing a psychiatric disorder. While the term UHR 
typically indicates the presence of a risk state identified through the application of operationally defined 
criteria such as those discussed in this chapter, ARMS is sometimes used to refer to at-risk groups more 
generally, although there is substantial overlap in the use of these two terms. Some authors have argued 
that ARMS is in fact the preferred terminology by service users, carries less stigma and reflects the 
pluripotent outcomes of these phenotypes that extend beyond psychotic disorders. In this thesis, the 
terms UHR and ARMS are used to reflect the different study populations as well as the preferences of the 
journals in which the thesis chapters have been published. 
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submitted or in preparation for publication, preceded by an introduction and followed 
by a discussion of the main findings.  
 
The General Introduction (Chapter 1) outlines the general background to the topic, 
includes a focused review of literature relevant to the topic and concludes with the 
aims of the thesis and an overview of the following chapters. As the scope of this 
thesis is not confined to a single diagnostic entity but rather broadened to a range of 
possible outcomes in mood and psychotic disorders, the General Introduction is not 
focused on a specific disorder but rather on risk mechanisms more generally. First, the 
mental health burden and disorders relevant to this thesis are briefly introduced. Next, 
literature pertinent to the concepts discussed in the thesis is reviewed. Focused 
reviews relevant to the specific objectives of the thesis are presented in the 
introductions of the subsequent chapters.  
1.1 Disease burden - depression and psychotic disorders 
Mental disorders are major contributors to the non-fatal disease burden globally. In 
Australia, it is estimated that one in two people will experience a mental health 
condition at some point in their life, with mental disorders accounting for 24% of the 
non-fatal disease burden 1. Importantly, 75% of all mental disorders have their onset 
before the age of 24 2, highlighting the importance of mental health for young people. 
In fact, mental disorders are the largest contributor to disease burden in young people 
in developed countries 3, lead to significant disability in many cases and have 
consequently been termed  “chronic diseases of the young” by some authors 4.  This is 
mirrored by the 2017 Australian Youth Survey, which highlighted mental health as the 
most critical concern raised by young people 5. 
 
The largest contributors to the disease burden in mental disorders include high-
prevalence conditions such as anxiety disorders, mood disorders, attention deficit and 
hyperactivity disorder (ADHD) but also disorders associated with substantial disability 
such as psychotic disorders 6. As much of this thesis refers to patients with or at risk 
for psychosis as well as to depressive symptoms in the community, a brief overview is 
included here. 
 
Mood disorders include unipolar depression (e.g. Major Depressive Disorder (MDD)) 
and disorders that cycle between elevated and depressed mood (e.g. Bipolar 
Disorder). These disorders are characterised by alterations in mood (depressed or 
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elevated), inability to experience pleasure, excessive rumination, hopelessness, 
inappropriate guilt, but also somatic symptoms including sleep disturbances or 
changes in appetite. In youth, irritability is more commonly seen and depressed mood 
less frequent 7. MDD is one of the most common psychiatric disorders, with prevalence 
estimates of approximately 3% globally 8 and lifetime prevalence estimates of 3 to 20% 
between different countries 2, 9. Higher rates are commonly observed in developed 
countries compared to developing countries 9 and in females compared to males (rate 
ratio: approximately 2:1). MDD is estimated to be among the largest contributors to 
non-fatal disease burden globally with an upward trajectory 10, 11, making it a significant 
public health concern. In young people, depression is similarly or even more common, 
affecting approximately 2% of children and 4 to 8% of adolescents 12. Importantly, high 
rates of comorbidity and increased risk for suicide contribute to the morbidity and 
mortality of MDD and other depressive disorders.  
 
The vulnerability for depression is determined by both genetic and environmental 
factors. In addition to family history, established risk factors include stressful life events 
such as childhood trauma and adversity 13, 14 or low socioeconomic status 15.  
Alterations in monoaminergic neurotransmission are a core feature of the biology of 
depression and are addressed by antidepressant medication 16. Mounting evidence 
suggests that systemic factors including immune activation 17, activation of the 
hypothalamic-pituitary-adrenal (HPA) axis 18 and alterations in the commensal bacterial 
flora contribute to the pathophysiology of depression 19, 20. 
 
Psychotic disorders are illnesses characterised by psychotic symptoms, i.e. primarily 
delusions and hallucinations 7. More generally, psychotic disorders can entail positive 
symptoms (characterised by an excess or alteration of normal functions), negative 
symptoms (reflecting a loss of function) and cognitive symptoms. In addition to 
delusions and hallucinations, positive symptoms include disordered thinking, speech 
and movement and are often evident in abnormal behaviour. Negative symptoms on 
the other hand consist of symptoms such as loss of emotional expression/affective 
flattening, lack of motivation, reduced verbal expression or social withdrawal. 
Psychosis is a characteristic feature of Schizophrenia Spectrum Disorders, a group of 
disorders consisting of Schizophrenia, Schizoaffective Disorder, Delusional Disorder, 
Substance-Induced Psychosis and others, but may also be present in other disorders. 
For example, Bipolar Disorder I, Depressive Disorder with Psychotic Features, and 
Obsessive Compulsive Disorder are also included in the umbrella category of 
psychotic disorders in the DSM-V 7. Psychosis is sometimes conceptualised as a 
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psychosis continuum or “extended psychosis phenotype” 21, which recognises that 
psychosis is not limited to severe and chronic clinical presentations but may be 
present in attenuated form in otherwise healthy individuals in the general population. 
Similarly and in addition to the “horizontal” extended psychosis phenotype, a “vertical” 
psychosis continuum describes the progression from subtle clinical signs and 
functional impairment to psychosis below the diagnostic threshold and more severe 
stages 22, 23 (see 1.2).  
 
The epidemiology of psychotic disorder has long been thought to be homogenous 
across countries and ethnicities, with the prevalence believed to be approximately 1% 
based on the WHO 10-country study 24. More recent studies, however, have refined 
this assumption and called for a more nuanced view. These studies show substantial 
variation in the treated incidence of psychotic disorders between countries ranging 
from 8 to 60 per 100000 person years with higher rates in men compared to women 
(rate ratio 1.4:1) 25 and a lifetime prevalence of 0.55% for schizophrenia 26 and 3% to 
3.5% for any psychotic disorder 27. Additional to detection rates and access to care, 
several factors including sex, migration and urbanicity might explain some of this 
variation 28, 29.  
 
Psychotic disorders, in particular schizophrenia, are serious disorders that are 
associated with significant morbidity and mortality. While long-term remission from a 
first psychotic episode and functional recovery are seen in some cases, a substantial 
proportion of cases does not recover and are affected by persisting symptoms and 
disability 30. Importantly, suicide as well as cardiovascular and metabolic diseases are 
common causes of death in patients with schizophrenia and contribute to the excess 
mortality 31. In addition to absence of clinically relevant symptoms, functional recovery 
(that is, meaningful relationships, education and employment, etc.) as well as absence 
of medication-related side effects are important outcomes.  
 
The exact aetiology and pathophysiology of psychosis remain elusive. However, it is 
clear that psychotic disorders including schizophrenia entail a complex and 
heterogeneous constellation of disease processes, many of which are present before 
the onset of clinically relevant symptoms 32. These include aberrations in 
neurotransmitter function, in particular dopamine and glutamate 33, 34, sensitisation of 
immune cells in the brain 35, alterations in energy metabolism 36, 37, synapse formation 
and dendritic arborisation and brain structural and functional abnormalities 38. 
Aetiological factors include genetic predisposition 39, pre-natal and environmental 
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insults 40, 41 or cannabis use in adolescence 42 as well as pathophysiological processes 
including dopaminergic and glutamatergic dysfunction 23, 34, brain structural and 
functional abnormalities 43 and alterations in immune function and oxidative defence at 
least in a subset of patients 44. Importantly, these processes likely interact with each 
other and do not occur in isolation, and it should be noted that many factors overlap 
with other condition and are likely transdiagnostic. For example, many genetic risk 
variants for schizophrenia are shared with bipolar disorder and vice versa 45 and 
childhood adversity predisposes to a variety of disorders 14. 
1.2 Studying high-risk groups  
The last two decades have seen growing interest in early intervention strategies for 
populations at risk for mental disorders, most notably for psychotic disorders. Such 
strategies are grounded in the paradigm of early intervention with the aim to improve 
clinical outcomes for patients by identifying individuals at elevated risk for psychosis 
early and offering targeted interventions to reduce the risk for progression. 
Considerable effort has been made to define and characterise high-risk groups, to 
estimate the risk for transition to frank psychosis, to identify predictors of transition and 
to evaluate novel interventions appropriate to prodromal stages. The translation of 
these research efforts has resulted in the development and implementation of clinical 
services for people – particularly adolescents and young adults – who seek help for 
symptoms below the threshold for conventional mental health services (e.g. 
headspace in Australia). In addition to clinical criteria aimed at identifying people at risk 
for mental disorders early on in the disease course, epidemiological studies also 
revealed population groups at increased risk for mental ill-health 
 
While a multitude of social, environmental, biological and genetic risk factors for 
psychotic disorders have been identified (reviewed elsewhere 29), their effect sizes are 
often small. A recent comprehensive umbrella review of 55 meta-analyses and 
systematic reviews of risk factors for psychosis concluded that the most convincing 
and robust evidence exists for the ultra-high risk (UHR) state for psychosis (OR=9.32, 
95%CI 4.81 – 17.32) and ethnic minorities in the UK (OR=4.87, 95%CI 3.96 – 6.00), 
closely followed by ethnic minority status more generally and first and second-
generation immigrants 29.  
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1.2.1 Ultra-high risk for psychosis and clinical staging 
The observation that psychotic disorders are commonly preceded by a prodromal 
phase characterised by sub-clinical yet detectable and distressing symptoms 
(psychotic and non-psychotic) has led to the development of criteria to identify people 
at imminent risk for developing first-episode psychosis. First operationalised in the 
1990s by Yung and colleagues 46, these criteria propose the prospective identification 
of people at UHR for psychosis to advance and overcome the retrospective concept of 
a prodromal phase. The construct of the UHR state is now widely used to study the 
phase preceding first-episode psychosis and inclusion requires one or more of the 
following criteria to be present: Attenuated psychotic symptoms (APS), characterised 
by sub-clinical psychotic features; brief limited intermittent psychotic episode (BLIPS), 
a psychotic episode of shorter duration than required for a DSM-V diagnosis; and 
genetic high risk accompanied by a marked decline in psychosocial functioning (Table 
1.1). To date, several validated diagnostic interviews have been developed, for 
example the Comprehensive Assessment of At-Risk Mental States (CAARMS) 47 in 
Australia, the Structured Interview for Prodromal Syndromes (SIPS) 48 in the United 
States and the Basel Screening Instrument for Psychosis (BSIP) 49 in Switzerland. 
These interviews are now commonly used in help-seeking populations in research and 
in clinical services and have excellent sensitivity but only moderate specificity 50. The 
prevention of psychosis in the UHR group (“indicated prevention”) thus represents a 
promising strategy to reduce the disease burden and to improve long-term outcomes 
in individuals who might otherwise develop psychosis and has been recognised in 
guidelines in several countries including Australia 51, the United Kingdom 52 or by the 
European Psychiatric Association 53. 
Table 1.1 Ultra-high risk (UHR) for psychosis criteria according to the Comprehensive 
Assessment of At-Risk Mental States (CAARMS) 
APS BLIPS Genetic High Risk 
? Sub-threshold 
attenuated positive 
symptoms (ideas 
of reference, 
“magical” thinking, 
perceptual 
disturbance, 
paranoid ideation, 
odd thinking and 
speech)  
? either sub-
threshold 
frequency or sub-
threshold intensity 
? Transient psychotic 
symptoms (thought 
content, perceptual 
abnormalities, 
disorganized 
speech) 
? duration of the 
episode of 1 week 
in the past 12 
months 
? spontaneous 
remission 
? decline in 
functioning or 
? Family history of 
psychosis or an 
individual with 
schizotypal 
personality 
disorder  
? decline in 
functioning or 
sustained low 
functioning1 
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? present for 1 week 
in the past 12 
months  
? decline in 
functioning or 
sustained low 
functioning1 
sustained low 
functioning1 
APS= attenuated psychotic symptoms, BLIPS= brief limited intermittent psychotic 
episode; 1Defined as a decline in Social and Occupational Functioning Assessment 
Scale (SOFAS) score of 30% since the last assessment, or a score of 50 or less 
sustained for the past 12 months or longer 
 
The notion that early phases of illness are detectable in clinical settings and indicative 
of risk for more severe conditions has led to the development of clinical staging 
frameworks. Such staging frameworks build on evidence for a continuum of 
psychopathological phenomena and propose distinct stages that can be differentiated 
by clinical presentation, risk for progression and need for care. Common to staging 
systems proposed in psychiatry in the last decade that purposefully include early risk 
stages is that they extend beyond traditional diagnostic boundaries to include less 
differentiated or unspecific symptoms, following the idea of the UHR phenotype. 
McGorry and colleagues 22 proposed a staging system consisting of five stages 
ranging from asymptomatic risk for mental disorders through family history (Stage 0); 
mild, non-specific symptoms and decline in functioning, overlapping substantially with 
the UHR criteria discussed above (Stage 1a/b), first episode of a severe mental 
disorder (Stage 2); incomplete remission, recurrence or multiple relapse (Stage 
3a/b/c); and severe, persistent illness associated with significant disability (Stage 4). 
An overview of different staging systems and their criteria is provided in Table 1.2. In 
order to provide empirical support for clinical staging, the authors have argued for 
large, trans-diagnostic longitudinal studies including high-risk individuals to examine a 
multitude of outcomes, stage-adequate treatments and biomarkers for progression and 
treatment response 54, 55. Such biomarkers may include markers for HPA-axis activity, 
oxidative stress, immune activation, lipid metabolism or AL 55-58 but also neuroimaging 
biomarkers 59. Accordingly, staged-care approaches are currently being tested (e.g. 
ACTRN12616000098437). Ultimately, stratifying patients across molecular features 
instead of a diagnosis might assist in identifying subsets of patients that benefit for 
particular interventions. However, identifying biological signatures that are associated 
with discrete outcomes remains challenging for complex syndromes such as psychotic 
disorders. Unlike in oncology for example, where clear pathological boundaries exist 
between stages that are associated with distinct changes in mortality risk and 
treatment efficacy, translation from clinical to pathophysiological staging in psychiatry 
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is challenging and will likely involve a broad range of biological information rather than 
single biomarkers. 
 
 
 
Table 1.2 Clinical Staging Criteria in Psychiatry 
 McGorry et al. 2006 Fusar-Poli et al. 2017 
Stage Description Description 
0 Asymptomatic genetic risk 
 
Asymptomatic genetic risk 
1a Mild or non-specific symptoms, 
including neurocognitive deficits, of 
psychosis or severe mood disorder. 
Mild functional change or decline 
 
Negative and cognitive symptoms 
1b Ultra high risk: moderate but 
subthreshold symptoms, with 
moderate neurocognitive changes and 
functional decline (GAF ??70) 
 
Attenduated psychotic symptoms 
1c N/A Brief limited intermittent psychotic 
symptoms (BLIPS) 
2 First episode of psychotic or severe 
mood disorder 
Full threshold disorder with moderate-
severe symptoms, neurocognitive 
deficits and functional decline (GAF 30–
50) 
 
First-episode psychosis (FEP) 
3a Incomplete remission from first episode 
of care 
 
N/A 
3b Recurrence or relapse of psychotic or 
mood disorder which stabilises 
with treatment at a level of GAF, 
residual symptoms, or neurocognition 
below the best level achieved following 
remission from first episode 
 
N/A 
3c Multiple relapses, provided worsening in 
clinical extent and 
impact of illness is objectively present 
 
N/A 
4 Severe, persistent or unremitting illness 
as judged on symptoms, 
neurocogntion and disability criteria  
N/A 
 
The utility of the UHR criteria and their benefits for early intervention strategies rely 
heavily on their ability to predict who will develop psychosis and other mental 
 9 
disorders. The most recent meta-analytical estimates suggest that 20% (95%CI 17-
25%) of individuals at UHR for psychosis convert to first-episode psychosis (FEP) 
within 2 years 60. Recent research has revealed critical issues regarding the risk for 
psychotic and non-psychotic outcomes. For example, the risk for transition is highly 
heterogeneous, with individuals who fulfil BLIPS criteria having the highest transition 
rates (38%), followed by people with APS (18%), while those at genetic high risk on 
the other hand have substantially lower risks for transition at approximately 4% 60, 
suggesting that these categories may represent distinct subgroups characterised by 
different prognoses 61. In contrast, long-term non-psychotic outcomes do not differ 
between these sub-groups, which led some authors to argue that the current criteria 
should be maintained 62. Another important observation is that transition rates have 
declined since the first UHR studies were published 63 with a recent large randomised-
controlled trial (RCT) reporting only 11.2% in the placebo group within one year 64. The 
reasons for the declining transition rates may include low pre-test risk enrichment due 
to the fact that with increasing awareness of UHR stages study participants are not 
only recruited from people seeking help at specialist services but also from a variety of 
settings (“false positives”) 65, 66. While psychotic-like experiences are common in the 
general population 67-69, particularly in youth 70, 71, with point prevalence estimates 
ranging from 5% to 17%, and are associated with future mental health service use 72, 
73, applying CAARMS criteria to non-help-seeking populations may lead to excessive 
risk dilution and a higher rate of false-positive cases. Consequently, UHR criteria 
should only be applied in help-seeking populations. However, the hypothesis that risk 
enrichment contributes to declining transition rates has been also questioned based on 
the observation that symptom severity and level of functioning do not seem to differ 
between studies with high and low transition rates 74 and re-analyses of older studies 
using current criteria did not result in higher transition rates  75. A complementary 
explanation for declining transition rates may be the fact that recent clinical trails and 
observational studies provided background interventions such as high quality 
psychosocial care to study participants, which may have led to lower transition rates 
even in the control groups 76.  
 
Psychosis is not the only outcome of interest in the UHR group. In addition to the 
paradigmatic outcome of transition to psychosis, which arguably remains as an 
important outcome of interest in people at UHR for psychosis, it has become clear that 
other psychiatric disorders are common in this group. Lin and colleagues 77 conducted 
one of the largest long-term follow-up studies in non-transitioned UHR individuals to 
date (median duration of follow-up=5.7 years) and found that 49% experienced mood 
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disorders, 35% had an anxiety disorder, 29% a substance abuse disorder, and 28% 
had persistent attenuated psychotic symptoms. Of these, 90% were already present at 
baseline and 36% of participants received a new diagnosis during the follow-up period. 
Only 7.3% did not have an Axis I diagnosis at any point during the follow-up period. 
Other studies with longer follow-up duration showed similar rates of non-psychotic 
disorders in youth at UHR for psychosis 78. An analysis of two large North American 
UHR cohorts on the other hand found that non-psychotic outcomes were in fact not 
more common in people at UHR for psychosis compared to those who were screened 
but did not satisfy UHR criteria when only incident (newly occurring) diagnoses are 
considered 79. Non-psychotic outcomes in people at UHR for psychosis are further 
discussed in Chapter 5. 
 
Currently, no biological tests are available to increase the accuracy of outcome 
prediction beyond clinical characteristics. This is in stark contrast to most other 
branches of medicine, where biomarkers are used to estimate the risk for a disease 
outcome of interest (e.g. pre-diabetes 80) and consequently the need for care. This 
question is particularly relevant in the context of UHR for psychosis, as psychosis 
prediction criteria identify a substantial proportion of individuals who will not develop 
psychosis but still require care for other reasons. A recent meta-analysis examined the 
presence of known environmental risk factors for psychosis in the UHR group 81.  This 
study confirmed that obstetric complications, childhood trauma including emotional 
abuse and neglect, low functioning during childhood and adolescence, high perceived 
stress, social deficits and affective comorbidities, male gender and low educational 
attainment were significantly more prevalent in the UHR group. However, much less is 
known about risk factors that directly modify psychosis risk within the UHR group. 
Long-term follow-up studies of UHR cohorts provided insights into clinical risk factors 
for transition by showing that longer duration of symptoms before accessing specialist 
services 82, 83, low baseline functional capacity 82-89, negative symptoms and thought 
disorder 82, 83 and total Positive and Negative Symptoms Scale (PANSS) scores 84, 85 
were associated with higher risk for transition. Biological predictors of transition have 
been explored less with only a few smaller clinical trials and case-control studies 
providing evidence. These include increases in the omega-3 (ω-3) PUFA EPA during 
supplementation trials 84, 90, low total ω-3 PUFA 85, low levels of the ω-9 FA nervonic 
acid 85, 91, low levels of glutathione (GSH) 92 and cortisol 93-95 (see Chapter 2). 
Collectively, these studies provide preliminary evidence that antioxidant and immune 
mechanisms might be involved in modulating risk for psychosis transition. Even less is 
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known about the antecedents of non-psychotic outcomes with the limited available 
evidence pointing to negative symptoms at baseline 77. 
1.2.2 Indigenous mental health 
Indigenous people and other ethnic minority groups are often confronted with social 
challenges that can affect their mental health. Indigenous people suffer from a broad 
range of communicable and chronic conditions at higher rates compared to the 
mainstream society 96. Similarly, there is evidence that Indigenous people experience 
poor mental health more commonly, including Aboriginal Canadians 97, 98, Maori in New 
Zealand 99 and the Aboriginal and Torres Strait Islander people in Australia, who are 
more than twice as likely to be hospitalised due to a mental disorder 100. In the 
Australian context, mental health disparities are also documented through higher rates 
of non-specific psychological distress, with 30-44% reporting high or very high levels of 
distress 100-103; significantly higher rates of suicide, particularly in youth 104, 105; higher 
rates of most mental and substance abuse disorders in Aboriginal and Torres Strait 
Islander youth 103; high prevalence of risk factors for mental illness in adolescent 
populations 106; and evidence of higher rates of psychotic disorders of approximately 
twice the Australian national estimate in the geographical area relevant to this thesis 
107. Higher depression rates have been described in several studies: in one of the 
largest community surveys in Aboriginal youth in Melbourne, Luke et al. 108 report 
prevalence rates for moderate to severe depressive symptoms measured with the 
Patient Health Questionnaire-9 (PHQ-9) of 18-23%. The Darwin Region Urban 
Indigenous Diabetes (DRUID) study, a cross-sectional study of 185 adults, reported 
rates of 13%109. More recently, Taylor et al. reported comparatively low rates of 
moderate/severe depressive symptoms (PHQ-9) in the Torres Strait of 12%. Finally, in 
the adolescent population from which participants for Chapter 7 were recruited, 
moderate/severe symptoms measured with the PHQ-9 were found in 18% of study 
participants. Together, these studies provide evidence for high rates of depression at 
population level, with higher rates possibly found in youth.  
 
Evidence for health inequalities between ethnic minority groups and the general 
population is not limited to First Nations groups. In fact, migration remains as one of 
the best established risk factors for poor mental health 110, 111. For example, the 
psychosis risk in migrant groups in several European countries ranges from 1 to 2-fold 
increases (intra-European migrants) to 5 to 10-fold increases (Caribbean and African 
migrants) compared to the majority white population 111-114.  There is also evidence for 
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higher treated incidence of psychotic disorders in ethnic minority groups across 
Europe and South America 25 and that ethnic minorities are overrepresented in first-
episode psychosis services 115. While psychotic disorders are arguable the most 
studied outcome, the existing evidence suggests that this trend extends to other 
disorders including affective and anxiety disorders 110. Importantly, the relative risk is 
not only increased compared to the majority population of the host country, but also 
relative to the same ethnic group in the country of origin 116, 117, suggesting that genetic 
factors alone cannot explain the heterogeneity in psychosis risk. Furthermore, early 
assumptions that the selective migration of vulnerable individuals explains higher rates 
of psychosis have been refuted 118. However, it has to be noted that higher incidence 
of psychotic disorders is not found in every setting, with a recent meta-analysis 
reporting heterogeneity in psychosis risk for example in Asian migrants in England 112 
and a Canadian study reporting somewhat lower 12-month prevalence rates of mood 
and anxiety disorders in overseas-born people 119. Nevertheless, the evidence for 
higher rates of a range of disorders, most notably psychotic disorders, in ethnic 
minority groups remains strong and may not so much depend on migration than on 
factors relating to minority group status.   
 
While migration clearly poses a significant stressor that may affect psychosis risk, 
particularly during sensitive periods of neurodevelopment 114, the observation that the 
risk persists into the second generation 114, 120 suggests that it is not simply the 
experience of migration itself that drives the increased mental health risk. Rather, 
being in a minority position may expose people to various stressors associated with 
poor mental health outcomes and may render them more vulnerable to their 
consequences. If migration itself and genetic factors do not sufficiently explain the 
higher rates of mental disorders in minority groups, post-migratory factors and social 
determinants more generally have to be considered as they may affect migrant and 
First Nations groups alike.  
 
Despite higher rates for mental disorders in Aboriginal and Torres Strait Islander 
people and other First Nations groups being documented in national survey data and 
smaller community studies, few studies have directly examined factors that determine 
vulnerability for psychiatric risk in this population. Social determinants of health are 
thought to contribute substantially to the existing health disparities between Aboriginal 
and Torres Strait Islander people and non-Indigenous people living in Australia. Social 
determinants of health are the “conditions in which people are born, grow, work, live 
and age, and the wider set of forces and systems shaping the conditions of daily life” 
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121. These commonly include education and employment, adequate housing 
conditions, culturally appropriate access to health care and health literacy 121, but in a 
wider sense also freedom from discrimination, control over life circumstances and 
social inclusion 122. There is empirical evidence that rates of poor mental health 
between different Aboriginal and Torres Strait Islander communities depend heavily on 
socioeconomic factors 123.  
 
The pathways through which social determinants contribute to poor mental health 
outcomes in minority groups at heightened risk for mental ill-health are manifold but 
only partially understood 124, 125. In addition to effects on health behaviour (e.g. diet, 
self-medication) and service use (e.g. barriers to access to culturally appropriate 
health care), biological pathways are though to contributing to health inequalities. For 
example, there is evidence pointing to a converging pathway on stress processing, 
resulting in sequalae of chronic stress that likely impact on the risk mental illness. 
Chronic stressors commonly experienced by minority groups such as racial 
discrimination are though to lead to heightened allostatic load (see 1.3.1) and impact 
on brain regions relevant to stress processing such as the anterior cingulate cortex 
(ACC) (reviewed elsewhere by the author 126). Chronic stress elicits differential 
responses to an acute stressor in the perigenual ACC, a key region of the limbic stress 
regulatory system, in ethnic minority groups in Germany, which correlated with 
perceived racial discrimination, suggesting that social stressors may at least partially 
lead to higher risk for mental ill-health through effects on this brain region 127. We have 
recently shown that perceived racial discrimination is similarly associated with the 
cortisol response to stress in Aboriginal and Torres Strait Islander university students 
and that chronic self-reported stress is differentially associated with blunted cortisol 
awakening response (CAR in Aboriginal and Torres Strait Islander and non-Indigenous 
students 128. Altered reactivity to acute stress as well as elevated levels of cortisol, the 
body’s main stress mediator and a powerful glucocorticoid, are frequently found in 
subsets of patients with mood 129, 130 and psychotic disorders 131-133 and might also 
indicate risk for these disorders 94, 95. However, the hypothesised relevance of the 
biological effects of stress in risk for mental ill-health remains unclear in the Aboriginal 
and Torres Strait Islander population as there is a lack of empirical research.  
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1.3 Risk biomarkers 
1.3.1 Allostatic load 
Allostatis has been described as a concept characterised by physiological recalibration 
to changing demands and complementary to that of homeostasis 134. More specifically, 
the term allostasis describes dynamic biological processes that maintain the stability of 
physiological systems through adjustment of (homeostatic) states in response to 
environmental stimuli such as stress 134. Allostatic load (AL) is the result of sustained 
allostatic states, characterised by excess or imbalance of allostatic mediators, the role 
of which is normally to maintain stability in an organism 135. A commonly used example 
for an allostatic process is the regulation of blood glucose levels in the case of type-2 
diabetes mellitus. Glucose levels are primarily maintained by insulin and its functional 
antagonist glucagon in response to dietary intake of nutrients and dynamic changes in 
energy demand. In a homeostatic state, postprandial blood glucose levels rise in 
response to energy intake before returning back to baseline levels through glucose 
uptake facilitated by the release of insulin. However, excessive exposure to glucose 
may cause insulin resistance and subsequently lead to chronically elevated blood 
glucose levels. This may be seen as an allostatic state in which homeostasis has been 
replaced by allostasis.  
 
Primary mediators of AL that are released in response to stress, such as the 
glucocorticoid cortisol, pro-inflammatory immune mediators or the sympathetic nervous 
system, lead to primary effects such as oxidative stress or a chronic low-grade 
inflammatory state. This is then believed to contribute to primary outcomes such as 
cellular dysfunction, epigenetic alterations or effects on neurotransmission, and finally 
secondary and tertiary outcomes such as cardiovascular disease, diabetes mellitus, 
cognitive decline or accelerated ageing 136. This framework offers an opportunity to 
measure AL at the level of primary mediators in the hope to detect allostatic processes 
leading to adverse health outcomes. 
 
The mediators of AL generally consist of neuroendocrine, metabolic, immune and 
cardiovascular biomarkers that collectively represent a multisystem approach to detect 
subclinical disturbances 137. Biomarkers that have been used and evaluated in 
previous studies include neuroendocrine markers, most importantly cortisol (e.g., 12hr 
urinary free cortisol), cortisol’s endogenous functional antagonist 
dehydroepiandrosterone (DHEA) and adrenaline/noradrenaline. Immune markers 
include c-reactive protein (CRP), interleukin 6 (IL6), tumor necrosis factor-α (TNF-α) 
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and fibrinogen. Metabolic markers including total cholesterol, high and low density 
lipoproteins (HDL/LDL), glycosylated haemoglobin (HbA1c) as well as body mass 
index (BMI) and waist-to-hip ratio 137. Cardiovascular functioning is assessed with 
resting blood pressure or more recently heart rate variability 138. The majority of studies 
have used an AL index consisting of 10 biomarkers first used by Seeman et al. 139, 
though the authors noted that “[…] the measure of AL used in these analyses should 
be seen as initial”.  
 
Many of these biomarkers are commonly used in daily clinical practice and if elevated 
are diagnostic markers for specific diseases. In the AL model, however, chronic sub-
thresholds of numerous biomarkers taken together is seen as a mirror image of 
metabolic disturbances with strong predictive value for health outcomes. AL also 
allows studying the underling interacting systems in the same individual, e.g. 
interactions between chronic low-grade inflammation and exaggerated stress systems, 
both of which are highly relevant to several mental disorders but are often studied 
separately. Cluster analysis of the biomarkers used in AL indices demonstrates that 
the totality of all markers predict health outcomes significantly better than single 
markers such as waist-to-hip ratio or HbA1c and also significantly better than systemic 
clusters, for instance, of metabolic parameters 137.  
 
The term AL is used throughout this thesis to refer a state of physiological imbalance 
characterised by excessive release of primary AL mediators. This thesis takes a 
pragmatic standpoint in viewing AL as a state of multisystem dysregulation that may 
have detrimental effects on mental health. For this purpose, AL is operationalised as a 
composite index of multiple AL primary mediators (further discussed in Chapters 3, 4 
and 7).  
 
One application of the AL framework in the past has been to measure the excess 
biological risk observed in disadvantaged groups of society. Increased AL is often 
found in impoverished and marginalised populations and is thought to partially mediate 
the effect of low socioeconomic status on health. Activation of the endogenous stress 
systems, most notably the HPA axis, is a core feature of the body’s response to social 
stress and central to the concept of allostasis 140. Low socioeconomic status early in 
life has been identified as a predictor of such HPA-axis alterations later in life in a large 
birth cohort study 141. Similar associations have also been found as a result of 
discrimination 128. AL is predicted by several factors associated with socioeconomic 
disadvantage such as household overcrowding 142 and adverse childhood experiences 
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143. Social support, sense of coherence and positive parental bonding on the other 
hand have been found to be associated with lower AL 137, indicating a role for social 
factors that protect against chronic stress. Given the findings that AL is high in 
disadvantaged populations and strongly associated with low socioeconomic status, AL 
may be an important factor in health inequalities. 
 
Social stress does not necessarily leave the same traces on the body at every 
developmental stage. Both animal and human studies have demonstrated that several 
different critical windows of vulnerability exist whereby the individual is particularly 
sensitive to environmental stressors 144 and such observations have been integrated 
into life-course models of health and disease 145. These vulnerable phases are tightly 
linked to neurodevelopment and may explain why children are especially vulnerable to 
the long-lasting effects of an adverse environment.  
 
Importantly, AL may be highly relevant for psychiatric disorders. While the effects of AL 
on the brain have been central to the concepts since its inception 140, 146, 147 few studies 
to date have directly investigated AL with relevance to psychiatric outcomes or in 
psychiatric populations. Seeman and colleagues were among the first to conduct a 
systematic longitudinal investigation of AL in a large cohort of older adults 139. In 1118 
individuals (age range: 70-79 years), AL was measured and participants were 
followed-up for 7 years (median). This study found increased risk for overall mortality 
in individuals with the highest AL (OR=1.23) independent of pre-existing conditions or 
other relevant potential confounders. However, the strongest association was found for 
cognitive decline, with individuals with the highest AL being at significantly higher odds 
for cognitive decline. Early evidence for a link between AL and depressive symptoms 
comes from the Taiwanese Social Environmental and Biomarkers of Ageing Study 
(SEBAS), a large cohort of Taiwanese adults aged 50 years and older, which 
demonstrated associations of AL biomarkers with depressive symptoms 148. However, 
while the 10-item AL index was associated with poor cognitive performance, no such 
relationship was found with depressive symptoms (measured with the CES-D) 149. 
Juster and colleagues reported that AL was prospectively associated with depressive 
symptoms three years later in a cohort of 58 healthy older adults (mean age: 67 
years), although the authors note that the power of the analysis was low (0.6) and the 
effect marginally significant when age and gender were entered as covariates. 
Similarly, Kobrosly and colleagues reported associations of a multisystem index 
conceptually similar to AL with depressive symptoms (measured with the PHQ-9) in a 
large cohort of healthy older adults, with associations with somatic symptoms being 
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greater than those with affective symptoms 150. A secondary analysis of a clinical trial 
in 125 adults aged 65 years and older subsequently published by the same group 
investigated AL found associations of a simplified AL index with more severe 
depressive symptoms (PHQ-9) in a dose-response type fashion 151. In contrast to 
these studies, a recent study measured AL in a large and ethnically diverse cohort 
(n=12272) and found no effect of AL on depressive symptoms, irrespective of ethnicity. 
The differences in methodology and study population preclude conclusions about the 
reasons why some studies find elevated AL in depressed individuals or associations 
with depressive symptoms while others do not. However, age emerges as an 
important confounding factor from these reports.  
 
While the relevance of the AL concept for psychotic disorders has been postulated and 
discussed in several review articles 56, 152, 153, it has not been applied to clinical 
populations until very recently. The first published account of AL in patients with 
schizophrenia reported elevated AL that was associated with more severe psychotic 
symptoms and decreased psychosocial functioning 154. The same group also 
measured AL in structural and functional magnetic resonance imaging (fMRI) studies, 
demonstrating that AL was associated with reduced global cortisol thickness 155 and 
reduced functional connectivity in the fornix 156 in patients with schizophrenia, 
suggesting that AL is related to grey matter loss and white matter integrity.  
1.3.2 Polyunsaturated fatty acids 
Long-chain PUFA (LCPUFA) play important roles in neuronal function and are key 
regulators of cell membrane properties 157, 158. Membrane lipids are part of the lipid 
bilayer assembly that forms the cellular membrane in mammalian cells, separating the 
cytosol from the extracellular space 159. PUFA are commonly found in phospholipids, 
where they are attached to glycerol through phosphodiester linkages. Phospholipids 
found in human cell membranes include phosphatidylcholines, 
phosphatidylethanolamines, phospohatidylserines and phosphatidylinsositols, with 
PUFA found in each of these sub-types 159. However, it should be noted that PUFA 
levels are commonly (but not exclusively) quantified from the 
phosphatidylethanolamine fraction, which is located at the inner side of the lipid bilayer 
and contains a high abundance of PUFA 160. PUFA concentrations can also be 
quantified in plasma, for example using a dried blood spot test and mass spectrometric 
analysis 161. The main types of PUFA relevant to this thesis are omega ?-3 and ?-6 
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PUFA, referring to the location of the first double bond between the third and fourth (?
-3) and sixth and seventh (?-6) carbon atom, counted from the omega (-CH3) end.
Both ?-3 and ?-6 PUFA are considered to be essential fatty acids 159. That means 
they cannot be synthesised by mammalian cells and must be obtained from the diet. 
The most important primary sources of long-chain ?-3 PUFA, particularly EPA and 
DHA, are phytoplankton and marine algae 162. PUFA from these sources accumulate in 
the food chain and can be found in high abundance in fatty fish including sardines and 
salmon 162. Other animal based sources include eggs and meat from animals fed with 
?-3 rich diets. Common sources of plant oils abundant in ?-3 PUFA include walnuts, 
flaxseed and other seeds 162. In addition to natural sources, supplementation with ?-3 
PUFA (“fish oil”) is becoming increasingly popular. However, both ?-3 and 6 PUFA 
undergo conversion from short-chain to long-chain PUFA via elongation and 
desaturation in humans 163. However, this process is only moderately efficient 164, 
meaning that short-chain PUFA are only partially metabolised to the longer-chain 
PUFA thought to be relevant for psychiatric disorders. Both ?-3 and 6 PUFA compete 
for the same enzymes, namely Δ-6-Desaturase, Elongase and Δ-5-Desaturase. The 
metabolism of PUFA in humans also includes downstream metabolic products 
including eicosanoids and docosanoids, which possess pro- and anti-inflammatory 
properties 165, 166.  
Several lines of evidence point to a link between the consumption of ?-3 PUFA from 
dietary sources, their composition in cell membranes and several psychiatric disorders. 
First, there is evidence that fish consumption is inversely related to the prevalence of 
psychiatric disorders, including mood disorders and psychotic disorders. The first study 
to suggest a link between dietary intake and depression was published two decades 
ago and reported a strong negative correlation (r=-0.84) between national fish 
consumption and depression prevalence across several European, American and East 
Asian countries 167. The observation that depression rates are higher in those countries 
with lower fish consumption sparked interest in the role of PUFA in depression. 
Subsequent studies have replicated this finding using person-level data, for example in 
a longitudinal study in Australia 168 and one in Japan 169. By contrast, ‘Western’ diets 
high in saturated fats and low in ?-3 PUFA are known to be associated with higher 
prevalence of depression 170, 171. In addition to mood disorders, associations of fish 
consumption have also been reported for psychotic-like symptoms and suicide risk. 
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Hedelin and colleagues conducted a study among 33623 woman in Sweden and 
reported that the intake of ?-3 PUFA was associated with a decreased relative risk for 
psychotic-like symptoms, taking into account relevant confounding variables 172. The 
evidence for a relationship between fish consumption and suicide risk is conflicting. A 
Japanese cohort study (n=256118) reported lower risk for suicide in individuals with 
daily fish consumption (OR=0.81) compared to ate fish less often 173. However, a more 
recent analysis of three American cohort studies (pooled n=205357) failed to replicate 
this observation, identifying no relationship between self-reported intake of ?-3 PUFA, 
?-6 PUFA and subsequent suicide 174.  
 
Second, increased turnover of PUFA may be present in patients with schizophrenia 
and depression. A key family of enzymes involved in the metabolism of PUFA are 
phospholipases A2 (PLA2), a group of housekeeping enzymes that catalyse the 
cleavage of fatty acids and lysophospholipids from PUFA. Additional to this function, 
PLA2 is also believed to be involved in the regulation of apoptosis 175, 176, oxidative 
stress and inflammation 177. Increased activity of PLA2 has been reported in patients 
with schizophrenia relative to both controls and non-psychotic patients 178-181 where it is 
associated with illness severity 182 and brain structural changes 182, and reduced by 
antipsychotic treatment 180. In people at UHR for psychosis, intracellular PLA2 levels 
correlate with ?-3 and ?-6 PUFA levels and are normalised by supplementation with 
?-3 PUFA 160. The evidence for the role of PLA2 in depression is less clear and clinical 
data are limited, but suggestive of higher PLA2 activity in patients with MDD 181. 
However, the BanI polymorphism in the cytosolic PLA2 gene - associated with higher 
transcription of PLA2 - was associated with MDD in a case-control study 183. Moreover, 
PLA2 appears to modulate the risk for depression in patients treated with interferon 
alpha through modulation of plasma PUFA levels 184. Similar to schizophrenia, 
supplementation with the?-3 PUFA EPA and DHA also increased cytosolic 
concentrations of PLA2 in patients with MDD in one study 185.  
 
Third, low blood levels of ?-3 PUFA have been reported in patients with MDD 186, 
anxiety disorders 187, schizophrenia 188 and at-risk mental states 189. The balance 
between ?-6 and ?-3 PUFA is similarly associated with depressive symptoms 190 and 
with psychotic symptoms in people at UHR for psychosis 191. While these observations 
are cross-sectional and preclude causal inferences, they provide additional support for 
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the notion that decreased intake or increased depletion of ?-3 PUFA may be relevant 
to these conditions.  
 
Finally, clinical trials have provided evidence for the efficacy of supplementation with 
?-3 PUFA at improving symptoms and clinical outcomes in mood disorders and 
anxiety disorders. Meta-analyses of clinical trials in patients with MDD have revealed 
heterogeneous findings but demonstrated that EPA-dominant formulations are 
effective while DHA-dominant formulations are not 192-195. One study provides evidence 
of the efficacy of ?-3 PUFA supplementation for anxiety symptoms in healthy 
volunteers, which was related to increases in the ?-6/3 PUFA ratio 196. Ω-3 PUFA 
have also been evaluated in youth at UHR for psychosis. In these trials, transition to 
psychosis was the primary outcome. The first trial demonstrated superiority of ?-3 
PUFA over placebo for the prevention or delay of psychosis transition with large effect 
size 197, which persisted at the 7-year follow-up 78. However, two subsequent 
replication trials did not confirm the efficacy of ?-3 PUFA for transition to psychosis or 
other clinical or functional outcomes 64, 198.  
 
Collectively, the studies discussed above strongly suggest that PUFA play a role in 
several psychiatric disorders and potentially in psychosis risk. The implications of the 
involvement of ?-3 PUFA in the pathophysiology of psychiatric disorders include that 
supplementation represents a potential treatment approach with few clinically relevant 
side effects, that their dietary intake may be a potentially modifiable risk factor and that 
plasma/erythrocyte levels of ?-3 PUFA have potential as biomarkers to inform risk 
and treatment response. However, the latter hypothesis has not been empirically 
tested.  
1.4 Aims 
If our growing understanding of the pathophysiology of mental disorders is to improve 
prognosis and treatment, identifying and testing potential biomarkers is a crucial step. 
Cross-sectional and longitudinal studies in populations at risk for or at the transition 
from sub-clinical distressing symptoms to mental disorders offer a unique opportunity 
to study the biology and corresponding biomarkers.  
 
The overall aim of the studies presented in this thesis was to examine associations of 
AL and lipid biology with clinical and functional outcomes in three distinct populations. 
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These include (a) patients with chronic schizophrenia (SCZ) and FEP, (b) people at 
UHR for psychosis and (c) Aboriginal and Torres Strait Islander people. To achieve 
this aim, this thesis employs meta-analysis of existing studies (Chapter 2), cross-
sectional (Chapter 3) and longitudinal (Chapters 4 and 5) clinical studies and cross-
sectional population studies (Chapters 6 and 7). 
1.5 Thesis outline 
Chapter 1 outlined the background, rationale and objectives of the work presented in 
this thesis. The seven chapters that follow consist of six original research articles 
(Chapters 2 - 7), each containing a separate abstract, introduction, a description of the 
methods, results and discussion. Finally, Chapter 8 concludes the thesis, draws 
together key conclusions of the research presented in this thesis and highlights 
avenues for future research. A list of references is given at the end of each chapter. 
The six original research articles are organised as follows: 
 
Chapter 2 investigates cortisol awakening response (CAR), a cortisol biomarker 
standardised to the circadian rhythm or cortisol excretion, in patients with psychosis. 
This is achieved through meta-analysis of observational studies in patients with SCZ, 
FEP and people at UHR for psychosis. The qualitative analysis in this chapter also 
evaluates the existing evidence for association with relevant outcomes (e.g., psychosis 
transition or treatment response) in these studies.  
 
Chapter 3 reports a study of AL in patients with SZC and FEP. In this study, an AL 
index was calculated from neuroendocrine, cardiovascular, immune and metabolic 
biomarkers and contrasted between patients and healthy controls. Associations with 
clinical symptoms and global functioning are reported and the temporal dynamics of 
AL are explored at two follow-up time points.  
 
The study reported in Chapter 4 extends the data reported in the preceding chapter by 
applying the AL index to a cohort of youth at UHR for psychosis. Six and 12-month 
follow-up assessments provided an opportunity to examine associations of baseline AL 
and clinical and functional outcomes in this sample.  
 
Chapter 5 explores the role of selected ?-3 and ?-6 PUFA with relevance to clinical 
outcomes in youth at UHR for psychosis. By drawing on long-term follow-up data from 
the Vienna ?-3 study, a placebo-controlled RCT of fish oil for UHR for psychosis, this 
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chapter reports longitudinal associations with PUFA with Axis I diagnoses 7 years 
later.  
 
Chapter 6 reports a cross-sectional observational study of Aboriginal and Torres Strait 
Islander adolescents and adults attending health screens in three communities. The 
aim of the study reported in this chapter was to examine the relationship between hair 
cortisol, AL and depressive symptoms. 
 
Chapter 7 is an analysis of the study reported in the preceding chapter. This chapter 
focuses on the nature of the association between fish/seafood consumption, plasma 
levels of ?-3 and ?-6 PUFA and depressive symptoms in communities with a diet 
that is traditionally rich in fish and seafood and low in processed foods.   
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Preface 
Cortisol is the end product of the HPA axis and an important mediator of the body’s 
response to stress. While cortisol been investigated in schizophrenia for decades, 
much of the existing research has focused on single morning cortisol samples and little 
is known about cortisol in the early stages of psychosis.  
 
Chapter 2 explores cortisol abnormalities across the postulated stages of psychotic 
disorders (UHR – FEP – SCZ) in a systematic review and meta-analysis of existing 
literature. In doing this, it fills an important gap in the literature by focusing on CAR as 
a standardised cortisol readout and by taking into account the different stages 
mentioned above. Given the lack of direct evidence of AL in psychosis at the time this 
chapter was written, it was a necessary first step to examine a primary mediator of the 
AL framework.  
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Abstract  
Neuroendocrine abnormalities are common in patients with schizophrenia and are 
thought to interact with pathophysiological mechanisms of psychosis. The cortisol 
awakening response (CAR), defined as the increase in cortisol release in response to 
waking up, shows associations with social and environmental risk factors of 
schizophrenia and has been studied as a potential biomarker in schizophrenia. Here, 
we provide a systematic review and meta-analysis of 11 studies and 879 participants 
focusing on the CAR of patients with schizophrenia, first episode psychosis, and at-risk 
mental states. Random-effects meta-analysis showed that patients along the 
psychosis continuum have an attenuated CAR compared to healthy controls (g=-
0.426, 95% CI -0.585 to -0.267, p<0.001, 11 between-group comparisons, n=879). 
Subgroup analysis showed that CAR alterations can be found in patients with 
schizophrenia (g=-0.556, 95% CI -1.069 to -0.044, p<0.05, 2 between-group 
comparisons, n=114) and are already present in patients with first episode psychosis 
(g=-0.544, 95% CI -0.731 to -0.358, p<0.001, 6 between-group comparisons, n=505), 
but not in individuals with at-risk mental states. These distinctive alterations of the 
hypothalamic-pituitary-adrenal axis function may have important implications for a role 
of CAR as a marker for transition risk. However, the lack of objective verification of 
sampling adherence in these studies may limit the interpretation of the results. 
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2.1 Introduction 
Neuroendocrine abnormalities are a commonly observed feature in patients with 
schizophrenia and are thought to interact with the multifactorial etiology of the disorder. 
One of the most consistently reported neuroendocrine findings in schizophrenia is 
elevation of plasma and saliva cortisol levels 1, 2, an important observation as cortisol is 
both a marker and mediator of the body’s multisystem response to stress 3. Cortisol is 
the hormonal endpoint of the HPA axis and a powerful glucocorticoid with multiple 
effects on brain and body. As such, cortisol interacts with multiple target tissues 
including immune cells, metabolic organs and brain areas with high density of 
glucocorticoid receptors (GR), including the prefrontal cortex and limbic circuitry 4, 5. 
Consequently, exposure to excessive cortisol can contribute to neurodevelopmental 
insults and in the context of contemporary frameworks of psychosis onset it is thought 
to be relevant for onset and progression of psychosis 6. However, the role of cortisol in 
schizophrenia pathophysiology from early risk states to chronic schizophrenia remains 
mostly unclear. 
 
Aberrations in stress processing in patients with schizophrenia that potentially lead to 
increased cortisol release and, over time, to dysregulations of the HPA axis are 
thought to explain the hypercortisolemia found in cross-sectional studies 7. Lower 
stress threshold in response to a stressful stimulus and prolonged activation of the 
limbic system have been observed in patients 8. The neuroendocrine response to 
laboratory stress on the other hand is blunted in patients with schizophrenia 9 and 
dexamethasone suppression is reduced, indicating impaired negative feedback 
mechanisms 10.  Moreover, brain areas with inhibitory function on the HPA-axis such 
as the hippocampus are commonly found to be reduced in volume. Furthermore, 
increased volume of the pituitary gland has been observed in patients with 
schizophrenia 11-13.  
 
Studying proxy markers for HPA-axis dysregulation at different stages of psychosis 
may help to elucidate the role of cortisol in schizophrenia. The rapid increase in 
cortisol levels within the first 30-45 minutes after waking, termed cortisol awakening 
response (CAR), has received increasing attention in the last decade 14-24. The CAR 
appears to be a distinct feature of the diurnal cortisol rhythm that is not necessarily 
related to overall diurnal cortisol levels 25 or acute stress reactivity 26 and represents a 
standardised variable that is synchronised with awakening. Importantly, several 
epidemiological risk factors for schizophrenia appear to be associated with alterations 
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in stress processing generally and with a blunted CAR specifically. Exposure to 
childhood adversity was associated with flattening of the CAR in two large cohorts 27, 
28, an effect that possibly takes place through epigenetic mechanisms 29. Additionally, 
urban upbringing, one of the strongest environmental risk factors for schizophrenia 30, 
31, is associated with a similarly blunted CAR 32. Indeed, urban upbringing has 
previously been shown to be associated with alterations in social stress processing in 
the perigenual anterior cingulate cortex 33, a region also involved in the regulation of 
the CAR 34. Studies on the association of CAR with chronic perceived stress have 
reported mixed results but meta-analysis shows that general life stress is associated 
with a stronger CAR 35.   
 
Focusing on CAR eliminates some of the considerable heterogeneity in previous 
studies on single cortisol samples, as measuring CAR is inherently a standardized 
method that allows little variation. Additionally, expert consensus guidelines for the 
assessment of CAR have been published recently and facilitate the critical 
interpretation of existing studies 36. Several studies have reported on CAR in patients 
along the psychosis spectrum over the last few years with heterogeneous results. As 
the number of studies focusing on individuals at early stages of schizophrenia and in 
at-risk states increases, this provides an opportunity to compare cortisol alterations at 
these different stages. In doing this, we can address the question of whether HPA axis 
alterations represent vulnerability or rather a consequence of mental disorders 37. 
Here, we report on a systematic review of the literature and a meta-analysis of CAR in 
patients along the psychosis continuum. We describe the state of HPA-axis 
dysregulation in patients with chronic SCZ, patients with FEP and individuals with 
ARMS, a risk state for psychosis characterized by sub-threshold psychotic symptoms 
and/or genetic susceptibility, and discuss the implications of these findings on future 
research. 
2.2 Methods 
2.2.1 Study Selection 
Original research investigating CAR in patients with SCZ, FEP and ARMS was 
systematically identified by two authors (MB, ZS) by searching the databases 
MEDLINE, Scopus, PsycINFO and Web of Science in July 2015. The search strategy 
included the search terms “schizophrenia” OR “psychosis” OR “psychotic disorder” OR 
“clinical high risk” OR “CHR” OR “ultra high risk” OR “UHR” OR “first episode” OR 
“prodromal” AND “morning cortisol” OR “cortisol awakening response” OR “daily 
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cortisol” OR “diurnal cortisol” OR “circadian cortisol”. Hand search of relevant journals 
and reference lists of included articles was performed in addition to the systematic 
literature search.  
2.2.2 Inclusion and Exclusion Criteria 
Included studies reported CAR or used a sampling procedure that allowed 
computation of CAR from patients with SCZ, FEP, or ARMS, and a healthy control 
group without psychiatric diagnosis. Eligible articles defined SCZ according to DSM or 
ICD criteria. Patients with FEP had to be defined as presenting with psychotic illness 
for the first time. Eligible studies with ARMS individuals included participants of any of 
the three high-risk groups defined by the ARMS criteria 38, 39: (1) BLIPS, defined as 
transient psychotic symptoms with spontaneous remission within one week, (2) 
attenuated positive symptoms, defined as sub-threshold psychotic symptoms present 
for more than one week in the past twelve months, and (3) individuals with genetic 
susceptibility paired with a >30% decline in global functioning. We included cross 
sectional studies and longitudinal studies if they provided baseline data on CAR. 
Eligible articles collected samples upon awakening and 30-45 minutes later, as this is 
the time frame where the highest cortisol concentration is expected to occur 25, 40, 41. 
We included peer reviewed full text articles published in English, German, French, 
Spanish or Hungarian, languages spoken by one or more of the authors. Date of 
publication was not limited. Exclusion criteria were: (1) Studies without a control group, 
(2) studies that either did not report CAR or used a sampling schedule that does not 
allow computation of CAR (e.g. fixed times or single sample), (3) studies that analysed 
cortisol from specimen that does not allow detection of short term cortisol fluctuations 
(i.e. urine, hair), (4) studies that reported cortisol measures only after an intervention 
and (5) studies that did not satisfy minimum quality requirements. Furthermore, we 
included studies reporting on individuals under the age of 15 only if they had a control 
group matched for age, as data on changes in diurnal cortisol rhythms with age in the 
pubertal period is inconsistent but suggests ongoing maturation of the HPA axis until 
early adulthood 25, 42. All abstracts identified through the primary search and hand 
search were screened for relevance in duplicates by four authors (MB, AK, DR, PM) 
and selected full text articles were screened for inclusion based on the above criteria in 
duplicates by two authors (MB and AK). (Figure 2.1) 
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2.2.3 Inclusion of Primary Studies with Subgroup Analyses 
Four studies included in this meta-analysis reported data for two subgroups separately 
15, 18, 19, 21. In all four studies, both patient subgroups were eligible for inclusion as 
patients were included irrespectively of the a posteriori subgroup status; hence we 
included both subgroups pooled together in the quantitative analysis as recommended 
by the Cochrane Handbook for Systematic Reviews and Meta-Analyses 43. These 
were: FEP patients who responded to first-line treatment and non-responders 19, 
ARMS individuals who developed FEP during follow-up and ARMS individuals who did 
not transition 18, children with clinical high risk (CHR) and children with family history 
(FHx) 15, and patients with SCZ with and without cannabis exposure 21. In order to 
include these studies, the combined means were computed by weighting the means of 
both groups.  
??? ?
????? ? ?????
?? ? ??
 
And the combined standard deviation was computed as 
? ? ?
??? ? ????? ? ??? ? ????? ?
????
?? ? ??
???? ? ?????
?? ? ?? ? ?
 
Where ???? ??? are the subgroup means, ??, ??are the subgroup sample sizes and 
??? ??the subgroup standard deviations.  
2.2.4 Correction of Primary Study Sample Overlap 
We adjusted the weighting of the study according to the overlap in samples for those 
studies that reported sample overlap with other studies included in the meta-analysis. 
We adopted a procedure previously described 44 to avoid bias from excluding studies 
with overlapping samples. Briefly, if samples between two studies had 100% overlap, 
each study was weighted only 50%. Consequently, every subject was included only 
once into the meta-analysis.   
2.2.5 Data Extraction 
Data were extracted independently by two authors (MB and AK). We extracted (1) 
means and standard deviations of CAR, defined as the area under the curve with 
respect to increase (AUCi) between wake-up and peak post wake-up cortisol levels or, 
where available, CAR, wake-up cortisol and +30 min post wake-up cortisol, (2) clinical 
status (illness stage, medication status and comorbid ICD and DSM diagnoses), (3) 
number of individuals in each group and (4) socio-demographic information (including 
age, gender and socio-economic status). We contacted the authors of those studies 
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where a suitable data collection schedule was reported but CAR could not be 
calculated from published data to request additional data. 
2.2.6 Assessment of Study Quality  
The quality of the included studies was assessed by two authors (MB and AK) using 
the Newcastle Ottawa Scale (NOS) for non-randomized studies 45 as recommended by 
the Cochrane Collaboration 43. Additionally, the methodological quality if the included 
studies was assessed based on the recently published expert consensus guidelines 
for the assessment of CAR 36. As quality assessment in meta-analysis of observational 
studies remains controversial and clear consensus is lacking, we also used sensitivity 
analysis to determine the effects of lower quality studies on the overall model 46.  
2.2.7 Data Analysis 
We used the software Open Meta-Analyst for the quantitative analysis (Tufts, Boston, 
MA) 47. Standardised mean difference estimates of differences in CAR between 
patients and healthy controls were calculated using Hedge’s g, a measure of effect 
size that is suited for small sample sizes 48. Confidence intervals (CI) were also 
computed. Heterogeneity between studies was assessed using Higgins’ I2 statistic 49. 
A p-value of 0.05 was considered significant. Separate subset meta-analyses were 
performed for ARMS vs. controls, FEP vs. controls and SCZ vs. controls. We expected 
systematic differences between studies based on the assumption that studies would 
differ in patient characteristics and therefore chose a random effects model 50. Finally, 
leave-one-out meta-analysis was performed to assess the contribution of each study to 
the overall model.  
2.3 Results 
2.3.1 Search Results  
The initial database search identified 326 records after removal of duplicates (Figure 
2.1). Of these, 315 had an abstract and were screened for inclusion. We excluded 248 
studies during this step on the basis of their title and abstract and for the remaining 67 
and one additional abstract identified through hand search, full-text versions were 
retrieved and again screened for inclusion. Full texts could not be obtained for 18 
abstracts, nine articles did not focus on patients with psychosis, three articles had no 
control group and 26 used a sampling schedule that was not suitable for calculation of 
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the CAR. Finally, 11 studies were included into the qualitative and quantitative 
analysis. 
 
 
Figure 2.1 Flow diagram of literature search and study inclusion 
 
2.3.2 Study Characteristics 
Of the 11 full text articles identified through our literature search and screening 
procedure, two studied patients with SCZ, six studied patients with FEP and three 
studied ARMS individuals, all defined as CHR with one study also having a small 
subgroup with FHx. Consequently, our initial aim to include studies with ARMS more 
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generally was narrowed down to CHR criteria. ARMS criteria were assessed with the 
CAARMS 16, 18 and a community screening instrument for psychotic-like experiences 15.
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Table 2.1 Characteristics of included studies 
a Unadjusted sample size; sample size was adjusted in the random-effects meta-analysis to account for sample overlap between studies. b CAR was assessed on two 
days in a subset of the sample * female participants, ** male participants; ± represents standard deviation; ARMS = at-risk mental state, FEP = first episode psychosis, 
SCZ = schizophrenia, NOS = Newcastle Ottawa Scale; OVSA = objective verification of sample adherence (e.g. electronic monitoring systems or time-stamped 
photographs of collected samples as recommended by Stalder et al., 2016). 
 
 
Study 
Patient 
characteristics Cases : controls (n)a Cases : controls (f) Cases : controls (age) Study quality 
 
Cullen et al. 2014 AMRS 33 : 40 10 : 23 12.8 ± 0.2 : 13.1 ± 0.2 
NOS 8.0; CAR assessed on 2 days; 0, +15, +30, +60 
min; no OVSA 
 
Day et al. 2014 ARMS 43 : 38 20 : 15 22.9 ± 0.6 : 24.3 ± 0.7 
 
NOS 6.0; CAR assessed on 1 day; 0, +30, +60 min;  no 
OVSA , negative CAR excluded 
 
 
Labad et al. 2015 ARMS 29 : 44 7 : 15 22.3 ± 4.6 : 23.2 ± 4.4 
NOS 7.0; CAR assessed on 1 day; 0, +30, +60 min;   
no OVSA 
Pruessner et al. 2008 FEP 27 : 40 11 : 20 22.0 ± 3.2 : 22.3 ± 2.6*   24.0 ± 4.0 : 23.1 ± 2.4** NOS 6.0; 0, +30, +60 min;   no OVSA 
Mondelli et al. 2010 FEP 50 : 36 18 :10 29.2 ± 1.1 : 27.3 ± 0.8 NOS 6.0; CAR assessed on 2 days
b; 0, +15, +30, +60 
min;  no OVSA 
Aas et al 2011 FEP 30 : 26 10 : 8 30.1 ± 7.2 : 27.5 ± 4.8 
 
NOS 7.0; CAR assessed on 2 daysb; 0, +15, +30, +60 
min;  no OVSA 
Pruessner et al. 2013 FEP 56 : 30 19 : 17 23.5 ± 3.6 : 22.7 ± 4.5 NOS 7.0; 0, +30, +60 min;   no OVSA 
Pruessner et al. 2015 FEP 58 : 27 11 : 12 23.9 ± 3.7 : 22.3 ± 3.6 NOS 7.0; 0, +30, +60 min;  no OVSA 
Mondelli et al. 2015 FEP 30 : 57 12 : 21 29.2 ± 1.4 : 26.8 ± 0.6 NOS 6.0; CAR assessed on 1 day; 0, +15, +30, +60 min;   no OVSA 
Hempel et al 2010 SCZ 26 : 45 7 : 12 22.0 ± 3.4 : 23.1 ± 5.3 NOS 5.0; CAR assessed on 1 day; 0, +30 min;  no OVSA 
Moteleone et al. 2014 SCZ 12 : 15 6 : 3 41.0 ± 7.3 : 37.6 ± 6.9 NOS 5.0; CAR assessed on 2 days
b; 0, +15, +30, +60 
min;  no OVSA 
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2.3.3 Study Quality 
The mean NOS score was 6.4 (range 5-8). All studies satisfied the minimum quality 
requirements defined a priori as satisfying at least one criterion in each category of the 
NOS, having a control group and assessing cortisol at awakening and 30 minutes 
thereafter. Ten studies used community controls whereas one study 21 recruited 
controls from hospital staff. Eight studies collected saliva samples on one day only 
while three studies collected them on two days. Seven studies provided details about 
samples that were not returned, and overall there was no significant difference 
between patients (315/351 = 89.74%) and controls (242/285 = 84.91%) (p=0.6359, χ2). 
However, none of the included studies used objective verification of sampling 
adherence (e.g. electronic monitoring systems or time-stamped photographs of 
collected samples) as recommended by the recent consensus report on CAR 36.  
2.3.4 Overall Model  
Overall, random-effects between-group meta-analysis demonstrated a lower CAR in 
patients compared to healthy controls (g=-0.426, 95% CI -0.585 to -0.267, p<0.001, 11 
between-group comparisons, n=879). Heterogeneity between studies was not 
significant (I2=24%, p=0.213), indicating that differences between the 11 studies 
included in the overall model were not explained by any factor other than group status 
(Figure 2.2).  
2.3.5 Subgroup Analysis 
We performed sub group meta-analyses for patients with SCZ, FEP and ARMS to 
assess if blunting of the CAR was present at earlier stages of the psychosis 
continuum. This subgroup-analysis revealed similar effects in patients SCZ (g=-0.556, 
95% CI -1.069 to -0.044, p<0.05, 2 between-group comparisons, n=114) and FEP (g=-
0.544, 95% CI -0.731 to -0.358, p<0.001, 6 between-group comparisons, n=505), but 
no significant effect was found in ARMS individuals (g=-0.170, 95% CI -0.435 to -
0.095, p=0.207, 3 between-group comparisons, n=259) (Figure 2.2).  
 
Our meta-analysis included two longitudinal studies that studied the predictive value of 
CAR for clinical outcomes. One study found that ARMS individuals who transitioned to 
psychosis within one year had a significantly higher CAR at baseline after controlling 
for several covariates including awakening time and BMI 18; however, the authors 
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mention that this is based on a small sub-sample (n=10) and that 38% of participants 
did not return their saliva samples The other study grouped FEP patients based on 
their treatment response to antipsychotic medication over 12 weeks and found that 
those who did not respond with reduction in symptoms had a significantly more blunted 
CAR at baseline compared to responders and healthy controls 19.   
2.3.6 Meta-regression  
We performed a meta-regression of medication status in the three groups to examine if 
medication status had an effect on CAR. For this, we collected data on how many 
study participants were receiving antipsychotic medication when the CAR was 
assessed and included the percentage of medicated patients as a covariate. 
Antipsychotic medication has previously been shown to affect cortisol levels 20, 51. The 
random-effects meta-regression model found a small but significant influence of 
antipsychotic medication on CAR when all three groups were included (R2=-0.004, 
95%CI -.008 to -.001, p<0.05) but this effect became non-significant when the analysis 
was limited to FEP and SCZ studies (R2=-0.006, 95%CI -0.036 to 0.025, p=0.712) 
(Figure 3.3A).  
 
Across all studies, meta-regression of sample size revealed no significant effect of 
sample size on CAR (R2=-0.006, 95%CI -0.016 to 0.004, p=0.236) (Figure 3.3B). For 
publication date, no effect was found when all studies were included (R2=-0.014, 
95%CI -0.081 to 0.053, p=0.679) (Figure 3.3C); however, a modest but non-significant 
Hedge’??? ??????
???????? ??
??????
???????? ??
Figure 2.2 Forest plot for random effects between-group meta-analysis comparing cortisol 
awakening response of individuals at high risk for psychosis (ARMS), patients with first episode 
psychosis (FEP) and patients with schizophrenia (SCZ) to controls. 
2
2
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effect was found in FEP and SCZ samples (R2=-0.065, 95%CI -0.131 to 0.002, 
p=0.057), indicating greater effects in more recent publications.  
 
Meta regression for age demonstrated a significant effect of age on CAR when all 
studies were included such that older samples had a more blunted CAR (R2=-0.030, 
95%CI -0.052 to -0.007, p<0.05) (Figure 3.3D), but this effect became non-significant 
when the analysis was restricted to FEP and SCZ samples (R2=-0.024, 95%CI -0.061 
to -0.012, p=0.191).  
 
Figure 2.3 Meta-regression on the effects of medication status (A), sample size (B), publication 
date (C) and age (D) on CAR in patients with FEP and SCZ (A) and patients with ARMS, FEP and 
SCZ (B,C,D). Circle size reflects the weight of studies in the random-effects meta-regression. 
2.3.7 Sensitivity analysis 
No study affected the overall estimate by more than 12%. Included studies had sample 
sizes ranging from 26 to 68, and consequently relative weights differed only 
moderately between studies. Removing the study with the lowest quality score 
decreased the estimate by only 6% (Fig 3.4). 
? ?
? ?Medication status Sampe size
Publication date Age
2
2
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Figure 2.4 Leave-one-out meta-analysis. 
 
2.4 Discussion 
Our meta-analysis found that patients along the psychosis-continuum have a blunted 
CAR compared to healthy controls. Subgroup analysis revealed that this difference is 
only present in patients with FEP and SCZ, but not in individuals at high risk for 
psychosis, who did not show a blunted CAR compared to controls. This effect 
remained significant in a secondary analysis with studies with overlapping samples 
excluded (S2.1).  
Studies
Overall
− Labad 2015
− Day 2014
− Cullen 2014
− Mondelli 2015
− Pruessner 2015
− Pruessner 2013
− Aas 2011
− Mondelli 2010
− Pruessner 2008
− Hempel 2010
− Monteleone 2014
????????????????????
−0.424 (−0.584, −0.263)
−0.480 (−0.627, −0.333)
−0.426 (−0.606, −0.247)
−0.453 (−0.623, −0.283)
−0.365 (−0.517, −0.213)
−0.406 (−0.578, −0.234)
−0.423 (−0.600, −0.245)
−0.410 (−0.583, −0.237)
−0.423 (−0.603, −0.244)
−0.439 (−0.613, −0.265)
−0.432 (−0.609, −0.256)
−0.399 (−0.560, −0.239)
−0.6 −0.5 −0.4 −0.3
Standardized Mean Difference
Figure S2.1 Random effects between-group meta-analysis comparing cortisol awakening 
response of individuals at high risk for psychosis (ARMS), patients with first episode psychosis 
(FEP) and patients with schizophrenia (SCZ) to controls. Studies that had overlapping samples with 
another study included in the quantitative analysis were excluded in this model. 
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Previous meta-analysis of cortisol levels in patients with SCZ showed elevated 
morning cortisol compared to controls 1 and altered HPA-axis response to 
psychosocial stress that was characterized by lower anticipation and peak cortisol 
levels 9. Together with our analysis of existing studies on CAR, this represents strong 
evidence for dysregulated HPA-axis activity in patients with SCZ, characterised by a 
flat diurnal cortisol curve with overall high cortisol levels, and alterations in HPA-axis 
reactivity to laboratory-induced psychosocial stress.  
 
The increasing number of studies in at-risk individuals and medication-naive FEP 
patients provides important insight into HPA-axis activity in samples that are not 
affected by the potentially confounding effects of antipsychotic medication and long 
illness duration. Our analysis of existing studies in these groups showed that CAR is 
blunted in FEP patients to a similar extent as in patients with SCZ, but is normal 
overall in ARMS individuals, with one study finding a blunted CAR in medication free 
ARMS individuals 16. Two explanations seem plausible to reconcile this finding: Firstly, 
changes in HPA axis function may occur only after the onset of a full psychotic 
episode. Following this logic, HPA-axis dysregulation may be regarded as an 
epiphenomenon of psychosis, or may be attributable to the stress of experiencing 
psychosis. While the data synthesized here may support this view, another recent 
meta-analysis on morning cortisol in high risk individuals found significant elevations of 
cortisol in ARMS individuals 52. The other possible explanation is that within ARMS 
samples, only those who eventually transition to psychosis (or any other mental 
disorder) have a blunted CAR before a diagnosis is made. Generally, one third of 
ARMS individuals will go on to develop psychosis within 3 years 53, but the remaining 
two thirds are also at risk for developing other mental disorders including anxiety and 
mood disorders 54.  This within-group heterogeneity would be masked in case-control 
designs and the question of whether some particularly vulnerable individuals present 
with a blunted CAR can only be clarified with longitudinal studies or retrospective 
subgroup analysis. One study in our meta-analysis found significantly higher CAR in 
ARMS individuals who transitioned to psychosis (ARMS-P) compared to those who did 
not (ARMS-NP) and compared to healthy controls after adjusting for awakening time 
18. This suggests differential HPA-axis activity between ARMS-P and ARMS-NP, but 
seems difficult to reconcile with the finding of lower rather than higher CAR in patients 
with psychosis in the present meta-analysis. However, previous longitudinal research 
has shown that ARMS-P are characterized by higher cortisol than ARMS-NP in a large 
sample 55, and in the same cohort cortisol was found to have significant predictive 
value for transition from prodromal states to FEP 56. A recent meta-analysis, however, 
 54 
did not confirm this finding 52. Moreover, there is evidence that pituitary volume, a 
proxy measure of HPA axis function that underlies dynamic changes, is increased in 
ARMS-P, adding to the line of evidence demonstrating that HPA axis alterations are 
present before the onset of psychosis 57. Consistent with this, another study found 
larger hippocampal volume in at-risk individuals who transitioned to psychosis 58. 
Taken together, these findings provide strong evidence for a role of stress hormones in 
psychosis and discourage the view that cortisol aberrations are merely caused by the 
stress of experiencing a mental disorder.  
 
Meta-regression of medication status, age, publication data and sample size found that 
age and medication status were associated with flatter CAR across all studies. Studies 
with older subjects in this meta-analysis tended to include chronic patients rather than 
high-risk individuals, and subjects with longer illness duration. However, CAR may also 
generally decrease with age. Previous studies have shown that the HPA-axis does 
indeed change with puberty during adolescence and children generally have different 
diurnal cortisol rhythms compared to adults 41, but less is known about effects of age 
on the CAR 25, 35 and age differences within adult samples. Illness duration (years lived 
with psychosis) may also moderate this relationship as older samples tended to have 
progressed further compared to younger samples. The latter explanation appears most 
plausible, as the effect of age became non-significant when the analysis was restricted 
to FEP and SCZ patients. We also examined effects of medication status on CAR as 
antipsychotic medication was shown to be associated with lower morning cortisol in 
patients with SCZ 1. Meta-regression showed that medicated patients had flatter CAR 
across all studies, but this effect disappeared when only FEP and SCZ studies were 
taken into account, where significant between-group differences were observed in the 
meta-analysis. While we cannot exclude the possibility that antipsychotic medication 
has a causal effect in flattening CAR, this seems unlikely given that one longitudinal 
study found no changes in CAR in response to antipsychotic treatment over 12 weeks 
in medication naïve FEP patients 19.  
 
Evidence suggesting a mechanistic link between blunted CAR and schizophrenia 
pathophysiology comes from previous human studies showing that individuals with 
blunted CAR have reduced grey matter volume and increased stress-related activity in 
brain areas involved in the regulation of the HPA-axis, including the pACC 34. HPA axis 
dysregulation is furthermore associated with disruption of the functional connectivity 
between subACC and hypothalamus in patients with psychotic depression 59.  Chronic 
dysregulation of the HPA axis and excessive cortisol signaling affect brain regions with 
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high GR density through genomic and non-genomic mechanisms, thereby contributing 
to cognitive deficits 60 and possibly to progressive decline in cognitive functioning in 
patients with psychosis. Over time, chronic exposure to heightened levels of 
glucocorticoids as a consequence of a dysregulated HPA axis can alter cortical and 
limbic function through changes in gene expression, neural plasticity and 
neuroendocrine function 61, 62. More severe symptoms are associated with worse 
cognitive functions in patients with a flat CAR 14, 63. Furthermore, neuroimaging data 
show that changes in dopamine signaling induced by a standardized stress test 
correspond with cortisol response 64. Antipsychotic medication in turn decreases 
cortisol levels in patients with SCZ 65. Moreover, one study showed similar increases in 
the dopamine metabolite homovanillic acid and cortisol in response to metabolic stress 
induced by administration of the glycolysis inhibitor 2-deoxy-D-glucose in patients with 
SCZ 66. Collectively, these results suggest that CAR may play a functional role in 
linking stress and cognitive processes. 
 
Finally, bi-directional interactions between HPA-axis and the immune system may 
contribute to mutually sustained neuroendocrine dysregulations and chronic low-grade 
inflammation (see 67 for a review). Chronic low-grade inflammation is common in 
patients with SCZ and is already present in ARMS 68 and such pro-inflammatory states 
are thought to be a risk factor for the development of psychosis 69, although more 
recent studies show that only a subgroup of patients are characterized by elevations in 
peripheral cytokines and central microglial activation 70, 71. It is well known that 
glucocorticoids can trigger inflammatory processes in the CNS including stress-
dependent sensitization of microglia 72, 73, and that exposure to high levels of 
glucocorticoids can exacerbate the immune system’s response to lipopolysaccharide 
(LPS) 74. Importantly, healthy individuals with flat CAR indeed have higher levels of IL6 
75 and glucocorticoids can furthermore increase the production of the IL6 receptor in 
human epithelial cells 76. Similarly, pro-inflammatory cytokines directly interact with GR 
signaling on different levels, including transcription of the GR and translocation of the 
GR into the nucleus 77, 78. Finally, administration of interferon alpha (INF-α) for 12 
weeks led to flattening of the diurnal cortisol curve, directly indicating that cytokines 
alter HPA-axis function 79. Understanding such interactions in clinical samples could 
help to differentiate between patients with certain risk profiles and clarify further how 
neuroendocrine and immune systems work together in psychosis.  
 
One of the strengths of this meta-analysis is that we were able to compare ARMS, 
FEP and SCZ, thus providing insight into changes in HPA axis function across 
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diagnostic categories. While longitudinal studies are clearly needed, this allows some 
analysis of putative changes in HPA axis function during different stages of psychotic 
illness. Furthermore, sensitivity analysis showed that no single study disproportionally 
affected the overall effect.  
 
However, some limitations need to be acknowledged when interpreting these results. 
Firstly, our subgroup analyses for ARMS and SCZ included only a small number of 
studies and a relatively small total sample. There is currently limited knowledge on 
CAR in ARMS and in chronic patients with treatment resistance. Secondly, some of 
the studies also included subjects with psychiatric comorbidities, or a diagnosis of 
bipolar I or schizoaffective disorder. Thirdly, while the included studies were consistent 
in their methodology, none of them employed objective verification of saliva sampling. 
A recent consensus paper has highlighted objective sampling verification as a crucial 
step in ensuring validity of CAR data, as even small delays in collection of saliva 
samples can result in inaccurate CAR estimates 36. If one group in case-control 
designs is less adherent to the sampling schedule than the other, this could 
consequently introduce systematic bias. As none of the included studies objectively 
verified adherence to saliva sampling, we tested the percentage of participants who 
were initially recruited but had missing cortisol data in the included studies and found 
that this rate was not significantly different between patients and controls (89.74% vs. 
84.91% respectively, p=0.636), suggesting that return rates were not lower among 
patients or controls across the included studies. However, in the absence of objective 
measures to verify adherence to sampling schedules, the potential for bias remains 
and the results of this meta-analysis need to be interpreted with caution. Future 
studies should use these quality control measures. Finally, we were not able to 
examine associations of several covariates of interest with CAR, e.g. symptom 
severity, BMI or cognitive function as only few of the included studies assessed these 
covariates and different scales are used to assess symptom scores in ARMS 
individuals, FEP and SCZ patients. Adjusting the results for BMI would be important to 
rule out any confounding effect of body weight on HPA-axis function, and associations 
with symptom and functioning scores could provide important insights into potential 
mechanisms that link HPA-axis dysregulation to clinical outcomes.  
 
In conclusion, the present meta-analysis found flattened CAR in patients with SCZ and 
FEP, but not in ARMS. Future studies on cortisol alterations in patients with psychosis 
should use longitudinal designs to further determine the potential use of CAR as a 
biomarker with predictive value. Additionally, focusing on functional outcomes of 
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interest in the context of HPA-activity, and studying other markers such as 
inflammatory and metabolic markers together with neuroendocrine systems may help 
to elucidate their interactions.  Ultimately, these findings may have clinical implications 
as the limited evidence today suggests that cortisol dysregulations can implicate 
treatment resistance and higher risk for transition from ARMS to FEP.  
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Preface 
As we have seen in Chapter 2, there is evidence to suggest that the production of 
cortisol follows a different pattern in patients with SCZ and FEP compared to healthy 
controls, and some evidence to suggest a possible link to transition to psychosis and 
treatment response. Importantly, cortisol is not only a marker of the biological stress 
response but also a powerful glucocorticoid with downstream effects on multiple 
tissues including immune cells, neurons and metabolism.   
 
The AL concept has received increasing attention recently as it relates to complex 
interactions between glucocorticoids, the immune system and the brain. Despite 
growing interest in the role of AL in psychiatric disorders, few studies to date have 
measured AL in psychiatric populations. Consequently, there is a strong need to 
identify whether patients with psychotic disorders have elevated AL, which is 
hypothesised to indicate risk for adverse physical health outcomes, and to test if high 
AL is indicative of adverse psychiatric outcomes. The primary aim of Chapter 3 was to 
quantify AL in patients with SCZ and FEP and to examine associations with symptom 
domains, treatment response and remission. We reasoned that AL, if elevated in 
patients relative to controls, would be associated with illness severity and poor 
outcomes. The study reported in Chapter 3 was conducted in collaboration with the 
Department of Psychiatry at the University of Magdeburg, Germany, and is published 
in Psychoneuroendocrinology.  
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Abstract 
Current pathophysiological models of schizophrenia suggest that stress contributes to 
the etiology and trajectory of the disorder. We investigated if AL, an integrative index of 
neuroendocrine, immune and metabolic dysregulation in response to chronic stress, is 
elevated in patients with SCZ and FEP and related to psychotic symptoms and social 
and occupational functioning. Additionally, we assessed the temporal dynamics of AL 
in response to treatment with second-generation antipsychotics. AL, psychotic 
symptoms and psychosocial functioning were assessed in a longitudinal design in 
patients with SCZ (n=28), FEP (n=28), and healthy controls (n=53) at baseline and 6 
and 12 weeks after commencement of antipsychotic therapy. AL at baseline was 
higher in patients with SCZ and FEP relative to controls, but not different between 
patients with SCZ and FEP. Adjusting for age and smoking, we found that positive 
symptoms were positively correlated with AL and psychosocial functioning was 
negatively correlated with AL at trend level. Linear mixed model analysis demonstrated 
that AL decreased after treatment was commenced in patients with SCZ and FEP 
between the baseline assessment and the 6 and 12-week follow-up. AL was not 
predictive of treatment response or symptomatic remission. Our data provide evidence 
for cumulative physiological dysregulation in patients with SCZ and FEP that is linked 
to the experience of current positive psychotic symptoms. AL could be a useful tool to 
monitor biological signatures related to chronic stress and unhealthy behaviors in 
schizophrenia.  
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3.1 Introduction 
A large body of studies supports the notion that chronic experiences of chronic stress 
and malfunctioning of the biological stress response are associated with the onset and 
progression of psychotic disorders 1, 2. This is evidenced by findings of dysregulations 
of the stress hormone cortisol in patients with psychotic disorders 3, 4. Observations 
that stressful life events can trigger and/or worsen psychotic symptoms lend support to 
a causative role of stress processes 5. The stressful experience of psychosis itself in 
turn can activate the body’s stress systems, thus contributing further to physiological 
dysregulation. Recently, these observations have reshaped pathophysiological 
theories of the disorder and have contributed to contemporary reconceptualizations of 
psychosis 6, 7.  
 
The AL model is a framework aimed at understanding stress pathophysiology by 
encompassing a range of physiological systems 8. AL is measured by indexing 
neuroendocrine, immune, metabolic and cardiovascular dysregulation. AL algorithms 
characterize subtle pathogenic deviations of peripheral biomarkers involved in chronic 
adaptation to situational demands 9, 10. Unlike homeostasis, which describes precise 
regulation of physiological parameters within a narrow range, allostasis refers to 
dynamic adaptation in response to external stimuli such as stressful life events. 
Central to these processes is the brain that mediates biobehavioral adaptations 10. 
Within the AL framework, environmental stressors induce the release of primary 
mediators such as cortisol that over time lead to primary effects including elevations of 
pro-inflammatory cytokines, oxidative stress or mitochondrial dysfunction 11, 12. These 
then contribute to damaging effects to the CNS and other organs, including altered 
gene expression, telomere shortening and ultimately affect blood pressure, lipid 
metabolism, cognition and neurodegeneration 11, 12. Thus, chronic or repeated 
exposure to stress is believed to cause elevated AL in the long term and elevated AL 
in turn has been shown to predict adverse health indicators. For example, longitudinal 
studies demonstrate that high AL is associated with all-cause mortality and cognitive 
decline 13 and reductions in AL are conversely associated with reductions in mortality 
14.  
 
Elevated levels of AL primary mediators and primary effects are frequently observed in 
patients with psychotic disorders 3, 15-19. This suggests that AL may be elevated in 
patients with SCZ. In accordance, a recent study found increased AL in a small sample 
of patients with chronic SCZ that was related to positive symptoms and impaired 
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functional capacity 20. AL may contribute to the excess mortality observed in patients 
with SCZ 21 and possibly to the pathophysiology of the disorder, given that AL entails 
heightened levels of pro-inflammatory cytokines, glucocorticoids and oxidative and 
metabolic stress 10, 11.  
 
Collectively, pathogenic AL processes are known to have damaging effects on the 
brain, including regions that are important to the etiopathogenesis of psychotic 
disorders, such as the hippocampus and the prefrontal cortex 10, 22-25. Psychotic 
disorders on the other hand may contribute to heightened allostatic load through 
stress-mediated release of glucocorticoids and sympathetic activation, but also 
through unhealthy lifestyle factors associated with psychotic disorders such as 
smoking and through the metabolic side effects of antipsychotic medication. While it is 
unknown if AL is a risk for or the consequence of psychosis, AL and psychopathology 
may mutually sustain each other in a bi-directional fashion through the above 
mechanisms.   
 
Given its associations with adverse health outcomes, the AL model may be helpful in 
detecting multisystem dysfunction of and risk for physiological comorbidities in severe 
mental illness that commonly accompany psychotic disorders. Beyond associations of 
AL with adverse physical health outcomes, the multisystem dysregulation 
encompassed by the AL framework might also contribute to the progression of severe 
mental illnesses 26, 27. This is relevant, as biomarkers are urgently needed for current 
attempts at staging in psychiatry 28. This concept proposes that it is possible to 
differentiate illness stages based on clinical characteristics and biological phenotypes. 
Although no study to date has directly addressed the question of whether AL is related 
to the staging and neuroprogression frameworks, one study in a small sample of 
patients with bipolar disorder used a ‘systemic toxicity index’ that was conceptually 
similar to AL and observed higher systemic toxicity in patients with acute mania or 
dysthymia but not in euthymic patients 29.  
 
The aims of the present study were twofold. First, we aimed to test whether AL is 
elevated in unmedicated patients with SCZ relative to healthy controls and predictive 
of clinically relevant outcomes. Second, we aimed to study dynamic changes in AL in 
patients with SCZ. We hypothesized that AL would be associated with disease severity 
in patients with psychosis. Specifically, AL would be higher in patients with SCZ 
relative to patients with FEP and healthy controls and elevations in AL would be 
related to the duration of psychosis. We also hypothesized that AL would be 
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associated with clinical symptoms and psychosocial functioning, predictive of 
treatment response to second-generation antipsychotic medication and associated 
with symptomatic remission.  
3.2 Methods  
3.2.1 Study design 
Data for this study came from a blood bank of patients with schizophrenia, first-
episode psychosis and healthy controls at the Department of Psychiatry, University of 
Magdeburg, Germany 30. The biospecimens used in this study were collected in a 
naturalistic study of acutely ill in-patients who were un-medicated for at least 6 weeks 
prior to inclusion into the study. AL and relevant psychometric variables were 
assessed at baseline and 6 and 12 weeks later. All patients received second-
generation antipsychotic medication after the baseline assessment.  
Exclusion criteria were substance abuse disorder and/or psychosis induced by another 
medical condition. Patients with a history of immune diseases, immunomodulatory 
treatment, cancer, chronic terminal disease, cardiovascular disorders including 
hypertension, dyslipidemia, diabetes mellitus, substance abuse, severe trauma or 
clinical/paraclinical findings indicative of these disorders were excluded. Controls were 
screened for personal or family history of neuropsychiatric disorders. The study was 
approved by the institutional review board and written informed consent was obtained 
from all participants. Details concerning the study design have been published 
previously 30.  
3.2.2 Sample 
Participants included 28 patients with schizophrenia, 28 patients with first-episode 
psychosis (26 with a final diagnosis of schizophrenia and 2 with a final diagnosis of 
schizoaffective disorder; mean duration of untreated psychosis = 7.3 months, standard 
deviation = 8.9 months) and 53 healthy controls were recruited into the present study 
(Table 1). All patients were acutely ill in-patients who were un-medicated for at least 6 
weeks prior to inclusion into the study, and received one of the second-generation 
antipsychotics risperidone, olanzapine and quetiapine after inclusion into the study. 
Patients were recruited from all eligible consecutive admissions to the psychiatric 
inpatient unit between February 2008 and March 2010 who fulfilled all inclusion criteria 
and none of the exclusion criteria. Healthy controls were recruited from the community 
and consisted mainly of blood donors, tertiary students and hospital staff/their family 
 70 
members. Controls were screened for personal or family history of neuropsychiatric 
disorders using the Mini-International Neuropsychiatric Interview 31. 
 
Psychometric assessments 
Diagnoses were ascertained according to DSM-IV criteria with the Structured Clinical 
Interview (SCID-I). The PANSS was used to assess psychotic symptoms 32. The 
Global Assessment of Functioning (GAF) scale was used to measure social, 
occupational and psychological functioning 33.  
3.2.3 Allostatic load 
Biomarkers for the AL index were selected based on (i) representation of several 
physiological systems including, neuroendocrine, immune, metabolic and 
cardiovascular parameters, (ii) use in previous AL research 13, 34, and (iii) associations 
with disease risk. Cardiovascular markers included heart rate, systolic blood pressure, 
diastolic blood pressure and creatinine kinase. Neuroendocrine markers included 
cortisol, copeptin, which is derived from a pre-pro-hormone containing arginine-
vasopressin and is a surrogate marker for arginine-vasopressin release 35 and the 
urinary adrenalin and noradrenalin metabolites metanephrine and normetanephrine. 
Immune markers were IL-6, TNFα, CRP, and e-selectin. Metabolic markers included 
triglycerides, HDL, LDL, total cholesterol, insulin, fasting glucose, HbA1c, the ligand for 
the receptor for advanced glycation end products (enrage), waist-to-hip ratio and body 
mass index.  
Fasting blood samples were collected between 8am and 9am. The Human 
DiscoveryMAP™ multiplex immunoassay platform was used to measure the serum 
concentrations of cortisol, TNFα, IL-6R, CRP, E-selectin, insulin, enRAGE and CK as 
described previously 36. Urinary levels of metanephrine and normetanephrine were 
measured simultaneously by a commercially available high-performance liquid 
chromatography (HPLC) method with electrochemical detection (Chromsystems 
Instruments & Chemicals GmbH, Munich, Germany). An internal standard (3-hydroxy-
2-methylbutanoic acid) was used as a comparison to estimate both analyte 
concentrations. The limits of quantification for metanephrine and normetanephrine 
were 10 and 30 μg/L, respectively. The ratio of metanephrines to creatinine for each 
urine sample was calculated to correct for internal dilution. Measurement of creatinine 
was carried out using standard methods on the Modular platform (Roche Diagnostics, 
Penzberg, Germany). Copeptin was measured using an ultrasensitive method on a 
BRAHMS Kryptor compact plus (B.R.A.H.M.S.). The lower limit of sensitivity was 0.9 
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pmol/L. The concentrations of triglycerides, LDL, HDL and cholesterol were 
determined by commercial enzymatic methods in a random-access analyzer (Hitachi 
911, Roche Diagnostics, Germany). HbA1c was determined in EDTA blood by HPLC 
(Variant II, Bio-Rad, Munich, Germany). Both intra-assay as well as inter-assay 
coefficients of variation were <5% for all laboratory assays. 
 
For the computation of the AL index, the 75th percentile (25th percentile for HDL) was 
determined based on the distribution in the healthy matched control group. We then 
used a ‘scaling’ approach previously described to calculate the AL index 37. Briefly, for 
each individual, every marker with values above the cut-off (below for HDL) was 
defined as ‘1’, and the sum of all markers in each systemic category (cardiovascular, 
immune, neuroendocrine, metabolic) was divided by the number of markers in each 
category to allow for equal weighting of the four systemic categories. For those 
markers where the distribution differed between male and female controls, sex-specific 
cut-offs were calculated and used to compute the AL index as previously done 38. The 
rationale for using the ‘scaling’ approach is included as Supplementary Material. 
3.2.4 Statistical analysis 
As an alternative to the conservative Kolmogorov–Smirnov test, normality of the data 
was ascertained by assessing the skewness of data distribution and the associated 
standard errors. Normality was assumed if skewness divided by the standard error of 
skewness was between -3 and +3. For the exploration of longitudinal associations of 
the AL index with psychopathology, we used standardized PANSS scores to compute 
percent change  39.  
 
To determine if patients with symptomatic remission after 6 and 12 weeks had lower or 
higher AL at baseline, we adopted the remission criteria by Andreasen, Carpenter 40, 
defined as a score of 3 or lower in the PANSS items P1 (delusions), P2 (conceptual 
disorganization), P3 (hallucinatory behavior), N1 (blunted affect), N4 
(passive/apathetic social withdrawal), N6 (lack of spontaneity and flow of 
conversation), G5 (mannerism and posturing) and G9 (unusual thought content). 
Associations between AL and responses to antipsychotic treatment were examined 
using the treatment response criteria by Leucht, Davis 41, defined as a 50% reduction 
in PANSS scores.  
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Unadjusted and adjusted differences between patients with SCZ, FEP and controls in 
demographic variables and AL were tested with ANOVA or ANCOVA, and Χ2 tests or 
Fisher’s exact test for continuous and categorical variables respectively. Partial 
correlations adjusting for covariates were used to test associations between AL and 
psychological variables with adjustment for multiple comparisons using the Bonferroni-
Holm method 42. We estimated the 95% confidence intervals (CI) using a bootstrap 
estimation approach with 10000 samples. Effect sizes (Cohen’s d) were estimated for 
the comparison of AL between patients with SCZ, FEP and controls at baseline.  
We considered age, sex, smoking, cannabis, and illicit drug consumption as covariates 
because these variables are potential confounders and are common covariates in the 
AL literature 11. As AL was not different between participants who consumed cannabis 
and participants who did not consume cannabis (p=0.881) – or between participants 
who did or did not consume any other illicit drugs (p=0.427) – we included age, sex 
and smoking as covariates in subsequent analyses.  
 
Longitudinal associations of AL with psychological variables and differences 
between the three second-generation antipsychotics used in this study were tested 
with repeated measures linear mixed model analysis (LMMRM) with random 
intercept using a Toeplitz covariance structure to account for heterogeneous 
variances. Binominal logistic regression analysis was used to examine longitudinal 
associations of AL at baseline (independent variable) and treatment response and 
symptomatic remission after 12 weeks (dependent variables). Linear regression 
models were used to test the relationship between AL at baseline (independent 
variable) and symptom scores after 6 and 12 weeks to delineate associations of 
baseline AL with clinical symptoms at these follow-up assessments separately. All 
regression models were fitted as unadjusted models and as models adjusted for 
baseline PANSS scores, age, sex and smoking, which correlated with the AL index 
and are common covariates in the AL literature. The Hosmer-Lemeshow test was 
used to test model calibration. All tests were 2-tailed and a p-value of <0.05 was 
considered significant. SPSS version 24 was used for all analyses.  
3.3 Results  
3.3.1 Demographic results 
Relative to controls, patients with SCZ and FEP were more likely to smoke and to 
consume cannabis or other illicit drugs (Table 3.1).  
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Table 3.1 Demographic and psychometric characteristics. 
 Patients 
 
Controls p-value 
 Schizophrenia First-episode   
 (n=28) (n=28) (n=53)  
Sex female, n (%) 9 (32.1) 13 (46.4) 17 (32.1) .3951 
Age at baseline, mean (SD) 40.07 (10.12) 32.96 (11.49) 36.34 (11.49) .0632 
Cannabis, yes, n (%) 6 (26.1) 4 (14.3) 1 (1.9) .0033 
Smoking, yes, n (%) 19 (67.9) 20 (71.4) 20 (37.7) .0041 
Any illicit drug, n (%) 8 (34.8) 5 (19.2) 0 (0) < .0013 
Antipsychotic naïve n (%) 0 (0) 24 (85.7)  < .0001 
PANSS score, baseline 91.30 (17.13) 86.07 (19.18)  .2922 
     PANSS positive,  mean (SD) 25.78 (7.00) 22.68 (6.27)  .0892 
     PANSS negative, mean (SD) 20.56 (9.05) 19.04 (8.99)  .5352 
     PANSS general, mean (SD) 44.96 (9.44) 44.36 (10.27)  .8212 
PANSS score, week 6 58.89 (22.08) 55.14 (16.78)  .4772 
     PANSS positive, mean (SD) 14.82 (6.03) 11.61 (3.97)  .0222 
     PANSS negative, mean (SD) 13.43 (7.48) 15.39 (6.64)  .3032 
     PANSS general, mean (SD) 30.64 (10.78) 28.14 (8.76)  .3412 
PANSS score, week 12 44.40 (13.17)4 51.44 (15.56)5  .1862 
     PANSS positive, mean (SD) 10.07 (3.06)4 11.13 (4.15)5  .4272 
     PANSS negative, mean (SD) 9.40 (3.09)4 13.69 (6.64)5  .0302 
     PANSS general, mean (SD) 24.93 (8.92)4 26.63 (7.69)5  .5732 
GAF score baseline, mean (SD) 28.36 (8.07)4 35.43 (13.43)5  .0202 
GAF score, week 6, mean (SD) 53.70 (15.41)4 61.46 (14.52)5  .0602 
GAF score, week 12, mean 
(SD) 
67.67 (14.92)4 63.94 (12.63)5  .0632 
PANSS = positive and negative symptom scale, GAF = global assessment of functioning, 1 Chi2, 2 One-
way ANOVA, 3Fisher’s exact, 4n=15, 5n=16 
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3.3.2 Cross-sectional results 
Allostatic load 
A one-way ANCOVA adjusted for age, sex and smoking demonstrated significant 
between-group differences in AL at baseline between patients with SCZ, FEP and 
controls (F(4, 106)=11.288, p<0.001; Figure 3.1). Post-hoc tests with Bonferroni 
correction showed significantly higher AL in patients with SCZ compared to controls 
(4.91 (95%CI 4.23 – 5.61) ± 1.89 (95%CI 1.43 – 2.23) vs. 2.87 (95%CI 2.44 – 3.31) ± 
1.62 (95%CI 1.34 – 1.85), Cohen’s d=1.16, p<0.001), patients with FEP compared to 
controls (3.80 (95%CI 3.19 – 4.41) ± 1.66 (95%CI 1.43 – 2.23) vs. 2.87 (95%CI 2.44 – 
3.31) ± 1.62 (95%CI 1.34 – 1.85), Cohen’s d=0.57, p=0.011), but not between patients 
with SCZ and patients with FEP (p=0.136). We repeated our analyses using a 
traditional AL index 13 and confirmed the main findings (Appendix A). 
 
 
Figure 3.1 Allostatic load (AL) at baseline in patients with schizophrenia (SCZ), first-episode 
psychosis (FEP) and controls. Error bars represent standard deviations. 
Associations between allostatic load with other variables  
We next examined associations between AL and psychometric variables at baseline 
using partial correlations to test the relationship of AL with psychotic symptoms and 
social and occupational functioning (Figure 3.2A, B). Adjusting for age, sex and 
smoking, we found that positive psychotic symptoms (PANSS positive subscale) were 
positively correlated with AL across all patients with a psychotic disorder (adjusted R = 
0.510 (95%CI 0.247 – 0.715), p<0.001) and GAF scores were negatively correlated 
with AL at trend level (adjusted R = -0.224 (95%CI -0.441 – 0.016), p=0.103). No 
significant associations were found for negative symptoms and the general 
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psychopathology subscale of the PANSS (p>0.582). Subgroup analysis revealed that 
positive symptoms were significantly positively associated with AL in patients with SCZ 
(adjusted R = 0.506 (95%CI 0.076 – 0.789), p=0.012) and in patients with FEP at trend 
level (adjusted R = 0.445 (95%CI -0.103 – 0.713), p=0.086).  
 
Figure 3.2 Pearson correlations between allostatic load (AL) and positive symptoms and social 
and occupational functioning in patients with schizophrenia (A) and first-episode psychosis (B) at 
baseline. 
We examined if AL was associated with duration of illness, controlling for age, sex and 
smoking, and found no significant associations in patients with SCZ (p=0.707).   
Lastly for descriptive purposes, we examined group means and standard deviations for 
all markers that were included in the AL index as well as their correlations with the AL 
index to examine the contribution of each marker to the overall index (Table 3.2).  
3.3.3 Longitudinal results 
Predictive value of allostatic load for functional improvement and symptomatic 
remission 
LMMRM analysis did not show an effect of AL at baseline on PANSS scores at the 
follow-up assessments (week 6 and 12) in FEP (p=0.184) or SCZ (p=0.159). Linear 
regression analysis testing the association between AL and symptom scores at the 
time of the two follow-up assessments individually, however, showed that AL was 
associated with positive symptoms at 12 weeks (β=-1.182, 95%CI -2.262 - -0.103, 
p=0.034) but not at 6 weeks after the baseline assessment in patients with FEP. The 
effect at 12 weeks remained significant when the model controlled for age, sex, 
smoking, baseline PANSS positive score and medication dosage (chlorpromazine 
equivalent) (β=-1.944, 95%CI -3.438 - -0.451, p=0.016). No significant associations 
were found for negative symptoms or GAF scores at follow-up.  
 
In patients with SCZ, AL at baseline was not associated with positive symptoms at 6 
or12 weeks. AL, however, was associated with GAF scores at 12 weeks (β=3.899, 
95%CI -0.816 – 8.616, p=0.097) at trend level. Regression analysis with symptomatic 
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Table 3.2 Individual biomarkers included in the allostatic load index at baseline. 
Biomarker  Psychosis 
 
Controls  
(n=53) 
Group 
difference 
Correlation 
with AL 
index 
 Schizophrenia First-episode    
 (n=28) (n=28)    
 mean (SD) mean (SD) mean (SD) p-value Pearson-R 
Allostatic Load  4.91 (1.89) 3.80 (1.66) 2.87 (1.62) <.001  
Neuroendocrine      
     Cortisol 243.79 (87.95) 285.36 (141.84) 217.63 (66.69) .014 .062 
     Metanephrine 122.74 (102.04) 93.35 (71.77) 56.79 (36.20) <.001 .439*** 
     Normetanephrine 321.32 (423.54) 170.14 (130.11) 111.89 (72.96) .001 .323*** 
     Copeptin 6.94 (4.42) 11.82 (14.73) 5.70 (3.68) .007 .032 
Immune      
     TNFα 6.36 (5.50) 4.79 (3.29) 6.17 (7.11) .535 .237** 
     IL-6R 25.42 (12.52) 28.33 (10.81) 24.74 (8.27) .317 .197* 
     CRP 4.27 (9.77) 2.62 (5.24) 1.86 (4.33) .274 .225** 
     E-Selectin 10.07 (5.05) 9.66 (4.86) 10.22 (3.46) .855 .243** 
Lipids      
     Triglycerides 1.18 (0.53) 1.17 (0.66) 1.41 (0.91) .279 .256** 
     LDL 3.26 (1.35) 2.57 (1.27) 2.90 (0.84) .073 .221** 
     HDL 1.45 (0.37) 1.53 (0.38) 1.51 (0.37) .678 -.085 
     Cholesterol 5.32 (1.68) 4.64 (1.33) 5.07 (1.02) .141 .235** 
Glucose      
     Insulin 3.80 (6.37) 5.78 (6.81) 2.65 (1.66) .026 .176 
     HbA1c 5.33 (0.39) 5.31 (0.87) 5.24 (0.40) .721 .345*** 
     Glucose 5.12 (1.44) 5.33 (0.98) 4.79 (0.53) .044 .326*** 
     enRAGE 142.93 (138.58) 130.48 (98.36) 66.45 (56.29) .001 .331*** 
Cardiovascular      
     CK 2.99 (3.97) 2.01 (2.78) 1.48 (1.02) .045 .401*** 
     HR 88.00 (12.21) 80.11 (12.54) 67.77 (8.68) <.001 .482*** 
     BPsys 131.68 (15.23) 125.54 (17.50) 120.45 (14.31) .009 .585*** 
     BPdia 84.39 (10.75) 76.79 (13.35) 74.06 (8.66) <.001 .511*** 
Anthropometric      
     W/H ratio 0.91 (0.06) 0.86 (0.06) 0.88 (0.07) .037 .346*** 
     BMI 26.08 (4.72) 23.99 (4.11) 25.58 (3.73) .131 .434*** 
SD = standard deviation, TNFα = tumor necrosis factor alpha, IL-6r= soluble interleukin-6 receptor, CRP = 
c-reactive protein, LDL = low-density lipoprotein, HDL = high density lipoprotein, HbA1c = glycosylated 
haemoglobin, enrage = receptor for advanced glycation endproducts, CK = creatinine kinase, HR = heart 
rate, BPsys = systolic blood pressure, BPSdia = diastolic blood pressure, W/H ratio = waist-to-hip ratio, 
BMI = body mass index; *p<0.05, **p<0.01, ***p<0.001
 77 
remission according to Andreasen, Carpenter 40 as the dependent variable 
demonstrated no significant association with AL in patients with FEP or SCZ (OR=1.36 
(95%CI 0.78 – 2.36), p=0.275; n=28/54 (51.9%) in remission). And yet, change in AL 
between baseline and 6 weeks and change in positive symptoms between baseline 
and 6 weeks were significantly correlated (R=0.434, p<0.001). 
Predictive value of allostatic load for treatment response 
We tested if AL predicted treatment response according to the criteria by Leucht 41 and 
found no relationship between AL at baseline and treatment response (OR=1.04 
(95%CI 0.62 – 1.76), p=0.884). Moreover, we found no significant difference in AL at 
the baseline assessment (F(4, 80)=1.977, p=0.578) or change in AL between baseline 
and follow-up assessments (F(4, 81)=0.365, p=0.812) by treatment response.  
Effect of antipsychotic medication on allostatic load 
 
AL decreased significantly between the baseline and 6 and 12-week follow-up 
assessments in patients with SCZ and FEP (both p<0.001; Figure 3.3A). LMMRM 
analysis revealed no statistically significant differences in change in AL index between 
patients receiving either risperidone (n=26), quetiapine (n=14) or olanzapine (n=18) 
(p=0.569) (Figure 3B).  
3.4 Discussion 
This study examined AL in patients with FEP and SCZ at baseline and 6 and 12 weeks 
after commencing treatment. We found that (i) AL is elevated in patients with SCZ and 
FEP relative to healthy controls, (ii) AL is associated with more positive symptoms and 
lower social and occupational functioning, and (iii) AL decreases over 12 weeks in 
Figure 3.3 Temporal dynamics of allostatic load (AL) in patients with schizophrenia (SCZ) and 
first-episode psychosis (FEP). (A) AL decreased significantly in both groups between baseline and 
the 6 and 12 week follow-up (both p<0.0001). (B) A significant decrease in AL was observed in patients 
receiving olanzapine, quetiapine and risperidone (all p<0.009). 
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acutely psychotic patients who receive second-generation antipsychotics, but is not 
predictive of treatment response or functional remission. Our data thus confirm the 
results of previous cross-sectional reports of AL in patients with SCZ 20, 43, 44 by 
showing elevated AL and associations of positive symptoms and functioning in 
patients with SCZ. Furthermore, we extend existing knowledge by including drug-naïve 
FEP patients and by assessing the temporal dynamics of AL in a longitudinal design 
that demonstrated dynamic changes in AL in patients with psychosis. These short-term 
changes may be attributable to reductions in symptom severity or therapeutic 
interventions.  
 
AL is a composite measure of the chronic ‘wear and tear’ on the body and brain that is 
thought to be a consequence of chronic or repeated exposure to stress. The high AL in 
patients with SCZ and FEP in our study may reflect the multisystem dysregulation 
accompanying and/or leading to acute psychosis. For example, increased metabolic 
stress 12 may be indicative of stress-related changes in hippocampal volume, which 
are similarly linked to positive symptoms 24. While we did not measure perceived 
chronic stress, stress exposure in the preceding weeks has been shown to be 
unrelated to AL 20 and may thus be unrelated to the stressfulness of experiencing a 
psychotic episode.  
 
Importantly, AL is associated with a range of adverse health outcomes including 
cardiovascular disease and cognitive decline 13, and with proxies of poor health 
outcomes and ageing such as telomere attrition 45. In light of these observations and 
the high prevalence of other cardiovascular risk factors in patients with SCZ 46, the 
increased AL observed in our study might have implications for the prediction of 
pathophysiology in SCZ. We thus propose that the elevated AL found in our study 
represents a primary biological pathway for multisystem damage in patients with SCZ. 
While our study only followed-up for 12 weeks and was thus not suited to investigate 
longer-term metabolic and cardiovascular outcomes, the high AL speaks to the need 
for investigation of the relationship with long-term physical diseases in patients with 
psychotic disorders, given their elevated risk of multimorbidity and comorbidity. 
 
A critical finding of this study is that AL was increased in patients with FEP and SCZ 
relative to controls and not associated with duration of disease. Contrary to our 
hypothesis and recent conceptualizations of neuroprogression in bipolar disorder and 
SCZ 26, our findings suggest that AL may not increase with longer disease duration or 
higher illness stage 47. Rather, AL was associated with positive symptoms and poor 
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functional capacity in our sample and decreased markedly within 6 weeks of treatment. 
A possible conclusion from this observation is that AL is high in acutely ill patients but 
not in patients who are treated with anti-psychotic medication. Studies that follow 
remediated patients over longer time periods are necessary to confirm this.  
In the present study, FEP patients with the highest AL also showed the largest 
improvement in PANSS scores. Our finding that the magnitude of decrease in AL over 
the 12 week follow-up correlated significantly with the decrease in positive symptoms 
further supports this hypothesis. Following this line of argumentation, AL may be a 
state marker or a marker of disease acuity rather than a trait (diagnosis) or stage 
marker 48. Additional support for this notion comes from studies showing that 
elevations in cytokines (e.g., IL-1beta and IL-6) that are commonly observed in at least 
a subset of patients with SCZ 49 are present predominantly in acute disease states 50. 
While the AL index included a variety of markers, some of which may only change 
slowly, it might similarly reflect acute disease states rather than diagnostic entities. 
However, care must be taken in interpreting these findings as our study only included 
acutely psychotic patients at baseline and did not include patients in longer-term 
remission.  
 
An important question is how the increases of AL observed in schizophrenia relate to 
the well documented brain structural alterations also related to positive symptoms 24.  
To answer this question it is critical to understand whether the hippocampal volume 
loss that is not related to illness duration reflects a steadily ongoing decline or rather a 
highly flexible temporal course of the disease as might be indicated by our findings 
regarding AL assessing peripheral biomarkers. Two recent studies directly addressed 
the relationship of AL with brain structures and showed that elevated AL in SCZ is 
related to reduced global cortical thickness 43 and negatively correlated with white 
matter fractional anisotropy in the fornix 44. Future studies that combine repeated 
measures of brain imaging and AL throughout the disease course would be useful in 
addressing this.  
 
Previous studies investigating AL have not taken the dynamic changes of AL in 
response to therapeutic interventions into account. Our observation that AL decreased 
over 12 weeks of combined antipsychotic and psychosocial therapy raises the 
question of whether antipsychotic medication dampens AL. Two explanations seem 
plausible. Firstly, in light of the above findings that AL was associated with positive 
symptoms and the observation that AL decreased across all patients within the follow-
up period, one may speculate that AL is associated with acute psychosis. An 
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alternative explanation would be that antipsychotic drugs actually decrease AL, which 
conflicts with the view that antipsychotics may worsen AL though their adverse 
metabolic side effects 18, 51. However, our 12-week observation time frame might not 
be long enough to see adverse changes in AL.  
 
Limitations of this study include the small sample size and the naturalistic design. This 
makes it difficult to delineate the contribution of antipsychotic medication to reductions 
in AL over a short time frame (12 weeks). Moreover, excluding patients with 
hypertension and dyslipidemia reduces bias in the relationship between caseness and 
AL on one hand but may not be representative of the SCZ population more generally. 
Another limitation is that we did not assess recent chronic perceived stress, which may 
impact on AL. Similarly, we only took into account smoking as a lifestyle factor with 
potential relevance for AL. Psychometrically, the GAF is not ideal if intended as a pure 
measure of social functioning as symptom severity contributes to high GAF scores.  
Finally, a limitation inherent to all current AL research is that the AL index is not 
standardized across studies, making it difficult to draw conclusions from multiple 
studies. Notwithstanding, a recent study demonstrated that the overall AL index is not 
sensitive to the addition or removal of individual biomarkers 52. To ameliorate this 
problem, we confirmed our results with a simplified AL index similar to the one used by 
other studies 13. Strengths of our study are the inclusion of patients with SCZ, FEP and 
controls, the well characterized sample which allowed us to exclude confounding 
factors (for example, diabetes or other chronic diseases), the use of standardized 
psychometric instruments, and the 6 and 12 week follow-up investigations that made a 
dynamic assessment of AL possible. 
 
In conclusion, our data highlight the temporal dynamics of multisystem dysregulation 
indexed by AL and suggest that AL correlates with positive symptom severity in 
patients with psychosis. The challenges in the study of AL across illness stages in 
association with symptom domains and antipsychotic treatment highlight the 
importance of longitudinal studies, which are pertinent to clarify the questions raised by 
our data. Future studies should explore the temporality of AL beyond 12 weeks and 
address the question if AL is a cause or consequence of schizophrenia, clarify in larger 
samples if AL is a trait or state marker in patients who are not acutely ill but in 
remission, and confirm if AL is already elevated in at-risk individuals or in those who 
make a transition to psychosis.  
 81 
Acknowledgements 
The original study was funded by the University of Magdeburg, Center for Behavioral 
Brain Sciences (CBBS) in Magdeburg and a grant from Psynova Neurotech Ltd, 
Cambridge, UK. We thank Dr Petra Buttner for providing assistance with the statistical 
analysis. 
Conflict of Interest 
SB is a director of Psynova Neurotech Ltd and PsyOmics Ltd. The other authors 
declare that there is no conflict of interest. 
Role of Funding Source 
The study sponsors had no role in the design of the study, analysis of the data or 
writing of the article.  
 
References 
1. Howes OD, Murray RM. Schizophrenia: an integrated sociodevelopmental-
cognitive model. Lancet 2014; 383(9929): 1677-1687. 
 
2. Moghaddam B. Stress activation of glutamate neurotransmission in the 
prefrontal cortex: implications for dopamine-associated psychiatric disorders. 
Biol Psychiatry 2002; 51(10): 775-787. 
 
3. Berger M, Kraeuter AK, Romanik D, Malouf P, Amminger GP, Sarnyai Z. 
Cortisol Awakening Response in Patients with Psychosis: Systematic Review 
and Meta-Analysis. Neurosci Biobehav Rev 2016; 68: 157-166. 
 
4. Girshkin L, Matheson SL, Shepherd AM, Green MJ. Morning cortisol levels in 
schizophrenia and bipolar disorder: a meta-analysis. 
Psychoneuroendocrinology 2014; 49: 187-206. 
 
5. Reininghaus U, Kempton MJ, Valmaggia L, Craig TK, Garety P, Onyejiaka A et 
al. Stress Sensitivity, Aberrant Salience, and Threat Anticipation in Early 
Psychosis: An Experience Sampling Study. Schizophr Bull 2016. 
 
6. Davis J, Eyre H, Jacka FN, Dodd S, Dean O, McEwen S et al. A review of 
vulnerability and risks for schizophrenia: Beyond the two hit hypothesis. 
Neurosci Biobehav Rev 2016; 65: 185-194. 
 
7. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet 2016; 388(10039): 
86-97. 
 
8. McEwen BS, Stellar E. Stress and the individual. Mechanisms leading to 
disease. Arch Int Med 1993; 153(18): 2093-2101. 
 
 82 
9. McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: 
links to socioeconomic status, health, and disease. Ann N Y Acad Sci 2010; 
1186: 190-222. 
 
10. McEwen BS. Protective and damaging effects of stress mediators. N Eng J 
Med 1998; 338(3): 171-179. 
 
11. Juster RP, McEwen BS, Lupien SJ. Allostatic load biomarkers of chronic stress 
and impact on health and cognition. Neurosci Biobehav Rev 2010; 35(1): 2-16. 
 
12. Picard M, Juster RP, McEwen BS. Mitochondrial allostatic load puts the 'gluc' 
back in glucocorticoids. Nat Rev Endocrinology 2014; 10(5): 303-310. 
 
13. Seeman TE, McEwen BS, Rowe JW, Singer BH. Allostatic load as a marker of 
cumulative biological risk: MacArthur studies of successful aging. Proc Natl 
Acad Sci U S A 2001; 98(8): 4770-4775. 
 
14. Karlamangla AS, Singer BH, Seeman TE. Reduction in allostatic load in older 
adults is associated with lower all-cause mortality risk: MacArthur studies of 
successful aging. Psychosom Med 2006; 68(3): 500-507. 
 
15. Fillman SG, Sinclair D, Fung SJ, Webster MJ, Shannon Weickert C. Markers of 
inflammation and stress distinguish subsets of individuals with schizophrenia 
and bipolar disorder. Transl Psychiatry 2014; 4: e365. 
 
16. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine 
network alterations in psychiatric patients: comparisons between 
schizophrenia, bipolar disorder and depression. Mol Psychiatry 2016. 
 
17. Misiak B, Frydecka D, Zawadzki M, Krefft M, Kiejna A. Refining and integrating 
schizophrenia pathophysiology - Relevance of the allostatic load concept. 
Neurosci Biobehav Rev 2014; 45c: 183-201. 
 
18. Bizik G, Picard M, Nijjar R, Tourjman V, McEwen BS, Lupien SJ et al. Allostatic 
load as a tool for monitoring physiological dysregulations and comorbidities in 
patients with severe mental illnesses. Harvard Rev Psychiatry 2013; 21(6): 
296-313. 
 
19. Schwarz E, Guest PC, Steiner J, Bogerts B, Bahn S. Identification of blood-
based molecular signatures for prediction of response and relapse in 
schizophrenia patients. Transl Psychiatry 2012; 2: e82. 
 
20. Nugent KL, Chiappelli J, Rowland LM, Hong LE. Cumulative stress 
pathophysiology in schizophrenia as indexed by allostatic load. 
Psychoneuroendocrinology 2015; 60: 120-129. 
 
21. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: 
is the differential mortality gap worsening over time? Arch Gen Psychiatry 
2007; 64(10): 1123-1131. 
 
22. McEwen BS. Effects of adverse experiences for brain structure and function. 
Biol Psychiatry 2000; 48(8): 721-731. 
 
 83 
23. Booth T, Royle NA, Corley J, Gow AJ, Valdes Hernandez MD, Munoz Maniega 
S et al. Association of allostatic load with brain structure and cognitive ability in 
later life. Neurobiol Aging 2014. 
 
24. Zierhut KC, Grassmann R, Kaufmann J, Steiner J, Bogerts B, Schiltz K. 
Hippocampal CA1 deformity is related to symptom severity and antipsychotic 
dosage in schizophrenia. Brain 2013; 136(Pt 3): 804-814. 
 
25. Zierhut KC, Schulte-Kemna A, Kaufmann J, Steiner J, Bogerts B, Schiltz K. 
Distinct structural alterations independently contributing to working memory 
deficits and symptomatology in paranoid schizophrenia. Cortex 2013; 49(4): 
1063-1072. 
 
26. Kapczinski NS, Mwangi B, Cassidy RM, Librenza-Garcia D, Bermudez MB, 
Kauer-Sant'anna M et al. Neuroprogression and illness trajectories in bipolar 
disorder. Expert Rev Neurother 2017; 17(3): 1-9. 
 
27. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M et al. 
Pathways underlying neuroprogression in bipolar disorder: focus on 
inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav 
Rev 2011; 35(3): 804-817. 
 
28. Kupfer DJ, Frank E, Ritchey FC. Staging bipolar disorder: what data and what 
models are needed? Lancet Psychiatry 2015; 2(6): 564-570. 
 
29. Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, 
Klamt F et al. A systemic toxicity index developed to assess peripheral 
changes in mood episodes. Mol Psychiatry 2010; 15(8): 784-786. 
 
30. Steiner J, Walter M, Glanz W, Sarnyai Z, Bernstein HG, Vielhaber S et al. 
Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor 
antibodies in patients with an initial diagnosis of schizophrenia: specific 
relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate 
glutamate receptor encephalitis. JAMA Psychiatry 2013; 70(3): 271-278. 
 
31. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. 
The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development 
and validation of a structured diagnostic psychiatric interview for DSM-IV and 
ICD-10. J Clin Psychiatry 1998; 59 Suppl 20: 22-33;quiz 34-57. 
 
32. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale 
(PANSS) for schizophrenia. Schizophr Bull 1987; 13(2): 261-276. 
 
33. Startup M, Jackson MC, Bendix S. The concurrent validity of the Global 
Assessment of Functioning (GAF). Br J Psychology 2002; 41(Pt 4): 417-422. 
 
34. Juster RP, Marin MF, Sindi S, Nair NP, Ng YK, Pruessner JC et al. Allostatic 
load associations to acute, 3-year and 6-year prospective depressive 
symptoms in healthy older adults. Physiol Behav 2011; 104(2): 360-364. 
 
35. Morgenthaler NG, Struck J, Jochberger S, Dunser MW. Copeptin: clinical use 
of a new biomarker. Trends Endocrinol Metab 2008; 19(2): 43-49. 
 
 84 
36. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM et al. 
Identification of a biological signature for schizophrenia in serum. Mol 
Psychiatry 2012; 17(5): 494-502. 
 
37. Chen E, Miller GE, Lachman ME, Gruenewald TL, Seeman TE. Protective 
factors for adults from low-childhood socioeconomic circumstances: the 
benefits of shift-and-persist for allostatic load. Psychosom Med 2012; 74(2): 
178-186. 
 
38. Juster RP, Pruessner JC, Desrochers AB, Bourdon O, Durand N, Wan N et al. 
Sex and Gender Roles in Relation to Mental Health and Allostatic Load. 
Psychosom Med 2016; 78(7): 788-804. 
 
39. Obermeier M, Schennach-Wolff R, Meyer S, Möller H-J, Riedel M, Krause D et 
al. Is the PANSS used correctly? a systematic review. BMC Psychiatry 2011; 
11(1): 1-5. 
 
40. Andreasen NC, Carpenter WT, Jr., Kane JM, Lasser RA, Marder SR, 
Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for 
consensus. Am J Psychiatry 2005; 162(3): 441-449. 
 
41. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response 
and remission in schizophrenia: recommendations for their use and their 
presentation. Acta Psychiatr Scand Suppl 2009; (438): 7-14. 
 
42. Holm S. A simple sequentially rejective multiple test procedure. Scand Stat 
Theory Appl 1979; 6: 65-70. 
 
43. Chiappelli J, Kochunov P, Savransky A, Fisseha F, Wisner K, Du X et al. 
Allostatic load and reduced cortical thickness in schizophrenia. 
Psychoneuroendocrinology 2017; 77: 105-111. 
 
44. Savransky A, Chiappelli J, Rowland LM, Wisner K, Shukla DK, Kochunov P et 
al. Fornix Structural Connectivity and Allostatic Load: Empirical Evidence from 
Schizophrenia Patients and Healthy Controls. Psychosom Med 2017. 
 
45. Zalli A, Carvalho LA, Lin J, Hamer M, Erusalimsky JD, Blackburn EH et al. 
Shorter telomeres with high telomerase activity are associated with raised 
allostatic load and impoverished psychosocial resources. Proc Natl Acad Sci U 
S A 2014; 111(12): 4519-4524. 
 
46. Perry BI, McIntosh G, Weich S, Singh S, Rees K. The association between 
first-episode psychosis and abnormal glycaemic control: systematic review and 
meta-analysis. Lancet Psychiatry. 
 
47. McGorry P, Keshavan M, Goldstone S, Amminger P, Allott K, Berk M et al. 
Biomarkers and clinical staging in psychiatry. World Psychiatry 2014; 13(3): 
211-223. 
 
48. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M. Towards a 
classification of biomarkers of neuropsychiatric disease: from encompass to 
compass. Mol Psychiatry 2015; 20(2): 152-153. 
 
49. Fillman SG, Weickert TW, Lenroot RK, Catts SV, Bruggemann JM, Catts VS et 
al. Elevated peripheral cytokines characterize a subgroup of people with 
 85 
schizophrenia displaying poor verbal fluency and reduced Broca/'s area 
volume. Mol Psychiatry 2016; 21(8): 1090-1098 
 
50. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of 
cytokine alterations in schizophrenia: clinical status and antipsychotic effects. 
Biol Psychiatry 2011; 70(7): 663-671. 
 
51. Juster RP, Bizik G, Picard M, Arsenault-Lapierre G, Sindi S, Trepanier L et al. 
A transdisciplinary perspective of chronic stress in relation to psychopathology 
throughout life span development. Dev Psychopathol 2011; 23(3): 725-776. 
 
52. Wiley JF, Gruenewald TL, Karlamangla AS, Seeman TE. Modeling Multisystem 
Physiological Dysregulation. Psychosom Med 2016; 78(3): 290-301. 
 
 
 
 
 
 
 
 
 86 
4 Relationship between allostatic load and clinical outcomes in youth at 
ultra-high risk for psychosis in the NEURAPRO study.  
 
 
Maximus Berger1, 2, 3, Suzie Lavoie1, Patrick D. McGorry1, Barnaby Nelson1, Conny 
Markulev1, Hok-Pan Yuen1, Miriam Schaefer1, Zoltan Sarnyai 2, G. Paul Amminger1 
 
1 Orygen, The National Centre of Excellence in Youth Mental Health, Centre for Youth 
Mental Health, University of Melbourne, Parkville, Australia  
2 Laboratory of Psychiatric Neuroscience, College of Public Health, Medical and 
Veterinary Sciences, James Cook University, Townsville, Australia 
3 Centre for Chronic Disease Prevention, College of Public Health, Medical and 
Veterinary Sciences, James Cook University, Cairns, Australia 
 
 
 
 
 
 
 
This chapter is in preparation for publication as: 
Berger M, Lavoie S, McGorry PD, Nelson B, Markulev C, Yuen HP, Schaefer M, 
Sarnyai Z, Amminger GP, Relationship between allostatic load and clinical outcomes 
in youth at ultra-high risk for psychosis in the NEURAPRO study. (under review) 
 
 
 
 
 
 
86
 87 
Preface 
The observation that multisystem dysregulation is present in patients with SCZ and 
even in patients with FEP and related to illness severity posits the question if the 
mediators of AL precede the onset of psychosis and are indicative of psychosis risk in 
those who have not yet developed the full-blown disorder. Longitudinal studies in 
people at UHR psychosis can reveal important insight into the pathophysiological 
changes during the critical prodromal phase. While limited evidence for cortisol 
abnormalities and other individual primary mediators of AL in UHR exists, 
comprehensive studies of biomarkers remain scarce and it is unclear if AL represents 
a risk factor for psychosis in this group.  
 
The objective of Chapter 4 was to apply to the AL framework to a cohort of people at 
UHR for psychosis and to examine whether the relationships of AL with symptom 
dimensions observed in Chapter 3 extend to the UHR phenotype. First, cross-sectional 
associations of AL with symptom scores are examined. Next, the longitudinal design of 
the study enabled us to extend the examination of the predictive role of allostatic load 
as a risk biomarker to a diverse range of clinical outcomes. Being the first study of 
allostatic load in this population, Chapter 4 affords important insight into multisystem 
dysregulation as it affects young people with sub-threshold clinical symptoms.  
This study used data from the NEUARPRO study, a multi-centre RCT of fish oil versus 
placebo, and was conducted during the a research visit at Orygen, The National 
Centre for Excellence in Youth Mental Health.  
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Abstract 
Individuals at UHR for psychosis have an elevated risk of developing psychosis and 
other psychiatric outcomes. Risk biomarkers can assist in delineating individual risk 
and allow better prediction of longer-term outcomes. The aim of the present study was 
to examine if AL, a multisystem index of neuroendocrine, cardiovascular, immune and 
metabolic dysregulation, is associated with clinical outcomes in youth at UHR for 
psychosis. 
 
AL was measured in 106 participants of the NEURAPRO study, a multicentre 
randomized-controlled trial of long-chain omega-3 polyunsaturated fatty acids versus 
placebo in people at UHR for psychosis. Psychiatric symptoms and social and 
occupational functioning were assessed at baseline and 6 and 12 months after study 
intake. Multivariate linear and logistic regression models were used to test the 
relationship between AL and clinical outcomes.  
 
High AL at baseline was associated with poor social and occupational functioning at 6 
months (β =-0.224, p=0.025) and with more severe manic symptoms at 6 months 
(β=0.207, p=0.026), taking into account relevant covariates including age and smoking 
status. No significant associations were observed at the 12-month follow-up 
assessment or with any other clinical outcome measures.  
 
Our data provide initial evidence for a link between AL and impaired functioning in 
individuals at UHR for psychosis. Further studies are needed to evaluate AL as a 
potential predictor of early treatment response. 
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4.1 Introduction 
People who seek help for distressing psychiatric symptoms and meet UHR for 
psychosis criteria have an elevated risk of developing psychotic disorders of 
approximately 20% (95%CI 17-25%) within two years 1. In addition to the increased 
risk for psychosis, impaired psychosocial functioning and comorbid mental disorders 
are often associated with the UHR phenotype 2, 3. Over the last two decades, 
substantial efforts have been made toward the early identification of people at UHR for 
psychosis and for the provision of stage-specific treatments. However, it is becoming 
increasingly clear that psychosis risk in the UHR group is heterogeneous and may 
depend on symptom severity at presentation, as well as on psychosocial and biological 
risk factors 4, 5. Identifying biomarkers and endophenotypes can assist in determining 
who will benefit most from treatment, and to better estimate the risk for psychosis 
transition and other adverse outcomes 6, 7. To date, several studies have examined 
candidate biomarkers in UHR groups including markers of oxidative defence 8, 
membrane fatty acids 9, 10, cortisol 11, 12, niacin skin sensitivity 13 and multi-analyte 
indices 14. 
 
AL, the cumulative adverse effects of chronic stress and maladaptation, has been 
linked to somatic comorbidity in psychiatric populations and may be implicated in the 
pathophysiology of psychotic disorders 15. AL characterises subtle elevations in 
peripheral neuroendocrine, immune, cardiovascular and metabolic biomarkers and, as 
such, represents a multisystem biomarker index 16. In the AL framework, chronic or 
repeated exposure to stress and adverse events triggers the release of stress 
mediators, which subsequently lead to immune activation and metabolic dysregulation 
17. There is mounting evidence to suggest that AL is implicated in the pathophysiology 
of psychosis, with two recent studies showing that AL is elevated in patients with 
schizophrenia and first-episode psychosis relative to healthy matched controls, and 
related to positive symptoms and reduced functioning 18, 19. Recent studies also 
suggest that AL is associated with reduced hippocampal volume and impaired 
cognition in non-psychiatric populations 20, and with reduced global cortical thickness 
in patients with schizophrenia 21. AL has traditionally been viewed as the long-term 
consequence of exposure to stressful circumstances and several studies 
demonstrated that it is elevated as a consequence of early life trauma and 
socioeconomic disadvantage and predictive of adverse health outcomes 20, 22, 23. 
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Indeed, perceived stress, childhood trauma, unemployment and low educational 
attainment are also risk factors for psychosis in the UHR group, as evidenced by a 
recent meta-analysis 5. Consequently, allostatic load may be relevant for the 
pathophysiology of psychotic disorders but it is unclear if high AL predisposes to 
enhanced psychosis risk. However, despite the growing interest in the AL concept in 
psychiatry 15, 24, no study to date has applied it to a UHR group. As such, further 
investigation of AL is warranted.  
 
This study aims to investigate the relationship between AL and clinical outcomes in 
individuals at UHR for psychosis. Specifically, it was hypothesised that AL would be 
associated with more severe positive symptoms and poor functional outcomes, as 
previously observed in patients with schizophrenia and first-episode psychosis (Berger 
et al., 2018).  
4.2 Methods 
4.2.1 Study Design and Participants 
The present study is an analysis of a subgroup of participants (n=106) aged 15 to 24 
years of the NEURAPRO study, who provided consent for additional biomarker 
analyses. The NEURAPRO study is a double-blind placebo-controlled randomized 
clinical trial (RCT) (ANZCTR Identifier: 12608000475347) of 1.4g ω-3 PUFA (n=53) or 
placebo (n=53), in addition to 6-20 sessions of cognitive behavioural case 
management (CBCM) over the 6-month treatment period. This 6-month treatment 
period was followed by a 6-month follow-up, during which CBCM was provided on an 
as-need basis. The study protocol was approved by the Melbourne Health Human 
Research Ethics Committee (MH-HREC 2008.628). Details of this RCT including trial 
design, randomization, interventions, and inclusion and exclusion criteria are published 
elsewhere 25, 26.  
?
All participants were recruited from Orygen Youth Health (Orygen), Parkville, Australia 
and headspace, Sunshine, Australia between March 2010 and September 2014. To be 
eligible for the present analysis, participants had to provide complete biomarker data in 
addition to fulfilling the inclusion criteria for the RCT, i.e. being aged 15 to 24 years, 
ability to provide informed consent, having been identified as a UHR for psychosis 
person and having low levels of functioning (SOFAS score lower than 50) for at least 
one year or having experienced a decrease in functioning in the past year (reduction in 
SOFAS score of at least 30%). The exclusion criteria were past history of treated or 
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untreated psychotic episode or past treatment with antipsychotic medication equivalent 
to a lifetime dose of >50mg haloperidol, organic brain disease, current treatment with a 
mood stabiliser, a diagnosis of a developmental disorder or a history of developmental 
delay or intellectual disability, acute suicidality, self-harm or aggression toward others, 
pregnancy, or regular supplementation with n-3 PUFAs. All participants provided 
written informed consent (parent/legal guardian consent for participants aged 17 or 
younger) for their participation in the RCT and for the analyses of biomarker data.  
4.2.2 Data collection 
Participants underwent a series of assessments over the course of the study, 
consisting of research interviews, self-report measures, and the collection of blood and 
urine samples. For the present study, data collected at baseline, end of the 
experimental intervention (Month 6) and one year after baseline (Month 12) were used. 
Rating scales included the Brief Psychiatric Rating Scale (BPRS), the Scale for the 
Assessment of Negative Symptoms (SANS), the Social and Occupational Functioning 
Assessment Scale (SOFAS), the Montgomery-Asberg Depression Rating Scale 
(MADRS), the Young Mania Rating Scale (YMRS), the Clinical Global Impression 
(CGI) scale and the Global Functioning Social (GF-S) and Role (GF-R) scales.  
4.2.3 Biomarker Assessment/Allostatic Load  
The AL index was derived from biomarkers representing cardiovascular, 
neuroendocrine, immune and metabolic systems. Cardiovascular markers included 
heart rate (HR), systolic blood pressure (BPsys) and diastolic blood pressure (BPdia). 
Neuroendocrine markers included morning saliva cortisol. Immune markers included 
interleukin-6 (IL-6), interleukin-12 (IL-12) and CRP. Metabolic markers included 
triglycerides, total cholesterol and BMI. These markers were selected based on (i) 
representation of several physiological systems including, cardiovascular, 
neuroendocrine, immune, and metabolic parameters, (ii) use in previous AL research 
18, 23, 27, and (iii) associations with disease risk.  
Study participants provided fasting blood samples at baseline assessment and, 
following blood collection, plasma was separated from blood cells by centrifugation at 
4˚C and at 1800g for 15 mins. Samples were stored at -80C until analysis. CRP, IL-6 
and IL-12 were analysed at the University of Adelaide using cytometric bead arrays. 
Triglycerides, lipoproteins and cholesterol were analysed at Melbourne Health Shared 
Pathology. Saliva samples were collected at awakening and cortisol was analysed at 
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Melbourne Health Shared Pathology using an electrochemiluminescense assay 
(Roche Diagnostics, Indianapolis, IN, USA). 
 
For the computation of the AL index, the 75th percentile (25th percentile for HDL) of 
each biomarker was determined based on the distribution in the study sample. We 
then used a ‘scaling’ approach previously described by others and adapted by our 
group to calculate the AL index 18, 28. Briefly, for each individual, every marker with 
values above the 75th percentile was defined as ‘1’, and the sum of all markers in each 
category (cardiovascular, immune, neuroendocrine and metabolic) was divided by the 
number of markers in each category to allow for equal weighting of the four categories. 
Finally, the scores from the four categories were added and a final AL index 
calculated. For markers where the distribution differed between male and female 
controls, gender-specific cut-offs were calculated and used to compute the index 29.  
4.2.4 Statistical Analysis 
Prior to conducting statistical analyses, data for continuous variables were assessed 
for outliers and distributional assumptions. Normality of the data was ascertained by 
assessing the skewness of data distribution and the associated standard errors. 
Normality was assumed if skewness divided by the standard error of skewness was 
between -3 and +3. Scores on the CGI severity and improvement subscales were 
dichotomised as not ill/borderline ill vs. mildly ill or worse, and very much 
improved/much improved vs. minimally improved or less, respectively. Differences in 
continuous variables between the baseline and follow-up assessments were 
determined with paired-sample t-tests. Differences in dichotomous data between the 
baseline and follow-up assessments were determined with McNemar’s test. To test 
whether allostatic load was associated with change in symptom scores between 
baseline and Month 6 and baseline and Month 12, we fitted linear and logistic 
regression models with allostatic load as the predictor variable for continuous and 
binominal outcome variables, respectively, to estimate standardised coefficients and 
odds ratios and their 95% confidence intervals. Potential confounding variables were 
considered as covariates based on hypothesised association with dependent and 
independent variables, and previous use in the literature. These included age and 
smoking status as determined from a general health questionnaire administered to 
participants as well as treatment group. The Hosmer-Lemeshow goodness-of-fit test 
was used to assess model fit. All analyses were carried out using STATA 13.1 (Stata 
Corp., College Station, TX, USA). 
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4.3 Results 
A total of 106 participants were included in the analysis. Demographic and clinical 
characteristics of patients at baseline, Month 6 and Month 12 are reported in Table 
4.1. The mean age of study participants was 17.21 (SD 2.37) years at study intake. 
Mean scores of all rating instruments improved significantly during the study with the 
exception of GF-S and GF-R scores.  
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Table 4.1 Demographic and clinical characteristics of participants at baseline, 6 and 12 months 
 Baseline  
(n=106) 
6 Months  
(n=90) 
12 Months 
(n=74) 
6 
Months 
vs. 
Baseline 
12 
Months 
vs. 
Baseline 
 N % N % N % p-value p-value 
Gender (f) 70 66.04 - - - - - - 
Smoking 38 36.19 - - - - - - 
 Mean SD Mean SD Mean SD   
Age 17.21 2.37 - - - - - - 
BPRS         
   Total 43.43 8.89 37.19 8.93 35.74 7.61 <0.0011 <0.0011 
   Psychosis subscale 9.09 2.67 6.93 2.86 6.49 2.41 <0.0011 <0.0011 
SANS 17.99 9.86 14.27 11.15 12.96 10.91 <0.0011 <0.0011 
YMRS 4.39 3.14 3.04 2.86 2.67 2.39 0.0081 <0.0011 
MADRS 22.86 8.69 14.18 9.88 13.06 9.79 <0.0011 <0.0011 
SOFAS 55.70 10.93 62.57 13.28 63.22 15.87 <0.0011 <0.0011 
GF-S 6.61 1.19 6.81 1.28 6.83 1.45 0.0371 0.0981 
GF-R 6.21 1.54 6.58 1.81 6.69 1.80 0.1221 0.0521 
 N % N % N %   
CGI         
   Severity subscale       <0.0012 <0.0012 
      Not ill/borderline ill 3 2.83 25 30.86 26 40.62   
      Mildly ill or worse 103 97.17 56 69.14 38 59.38   
   Improvement subscale       - - 
      Very much improved/much improved 
      Minimally improved or less 
- 
- 
- 
- 
17 
64 
20.99 
79.01 
18 
46 
28.12 
71.88 
  
  
1Paired samples t-test, 2 Wilcoxon Signed-Rank test, BPRS=Brief Psychiatric Rating Scale, SANS=Scale for the Assessment  
of Negative Symptoms, YMRS=Young Mania Rating Scale, MADRS=Montgomery-Asberg Depression Rating Scale,  
SOFAS=Social and Occupational Functioning Assessment Scale, GF-S=Global Functioning Social Scale, GF-R=Global  
Functioning Role Scale, CGI=Clinical Global Impression Scale 
 
 95 
 
Mean and standard deviation of the AL index and the various biomarker levels are 
reported in Table 4.2.  
 
Table 4.2 Allostatic load index and biomarkers at baseline 
 M SD 
AL-Index 3.16 1.75 
Heart rate (bpm) 72.04 11.31 
Blood pressure, systolic (mmHg) 115.12 14.34 
Blood pressure, diastolic (mmHg) 73.15 10.19 
Cortisol (ng/ml) 16.25 8.52 
CRP  (mg/L) 1.61 2.42 
IL-6 (pg/ml ?) 1693.78 11.639.16 
IL-12 (pg/ml ?) 4149.59 11028.4 
Total cholesterol (mmol/L) 4.36 0.91 
Triglycerides (mmol/L) 
BMI 
1.14 
25.69 
0.78 
6.46 
AL=allostatic load, CRP=c-reactive protein, IL-6=interleukin-6,  
IL-12=interleukin-12, BMI=body mass index 
 
The AL index was not correlated with any of the rating scales at the baseline 
assessment (Table 4.3).  
 
Table 4.3 Partial correlations of the Allostatic Load Index with clinical variables at study intake 
 Pearson R (adj) p-value N 
BPRS    
   Total 0.089 0.367 106 
   Psychosis subscale 0.098 0.319 106 
SANS 0.133 0.175 106 
YMRS 0.079 0.421 106 
MADRS 0.058 0.556 106 
SOFAS -0.004 0.966 106 
GF-S -0.039 0.691 106 
GF-R 0.022 0.828 106 
CGI    
   Severity subscale 
   Improvement subscale 
-0.443 
- 
0.746 
- 
106 
- 
BPRS=Brief Psychiatric Rating Scale, SANS=Scale for the  
Assessment of Negative Symptoms, YMRS=Young Mania  
Rating Scale, MADRS=Montgomery-Asberg Depression  
Rating Scale, SOFAS=Social and Occupational Functioning  
Assessment Scale, GF-S=Global Functioning Social Scale,  
GF-R=Global Functioning Role Scale, CGI=Clinical Global  
Impression Scale, OR=odds rato, CI=confidence interval 
 
 
 
Multivariate linear and logistic regression taking into account age, smoking, treatment 
group and baseline scores showed that AL was associated with change in SOFAS 
scores between baseline and Month 6 (β =-0.224, p=0.025) but not between baseline 
and Month 12 (β =-0.094, p=0.277). Similarly, AL was associated with change in GF-S 
scores between baseline and Month 6 (β =-0.252, p=0.013) and Month 12 at trend 
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level (β =-0.222, p=0.052) and with change in GF-R scores at Month 6 (β =-0.192, 
p=0.046) but not at Month 12 (β =-0.151, p=0.161). AL was significantly associated 
with change in YMRS scores at Month 6 (β=0.207, p=0.026) but not at Month 12 
(β=0.069, p=0.496). No significant associations were observed with any of the other 
outcomes measures. Detailed results are reported in Table 4.4.  
 
Table 4.4 Linear and logistic regression analysis of allostatic load as predictor of change in 
symptom scores between baseline and month 6 and 12 
 Coefficient Beta p-value N 
BPRS1     
   Total     
     Month 6 0.187 0.041 0.685 89 
     Month 12 0.133 0.028 0.780 73 
   Psychosis subscale     
     Month 6 0.158 0.094 0.336 90 
     Month 12 0.131 0.071 0.428 77 
SANS1     
     Month 6 0.313 0.074 0.502 89 
     Month 12 -0.020 -0.003 0.997 73 
YMRS1     
     Month 6 0.404 0.207 0.026 88 
     Month 12 0.109 0.069 0.496 71 
MADRS1     
     Month 6 0.370 0.067 0.484 89 
     Month 12 0.201 0.036 0.704 73 
SOFAS1     
     Month 6 -1.737 -0.224 0.025 90 
     Month 12 -1.13 -0.125 0.277 77 
GF-S1     
     Month 6 -0.159 -0.252 0.013 90 
     Month 12 -0.159 -0.222 0.052 77 
GF-R1     
     Month 6 
     Month 12 
0.209 
-0.168 
-0.192 
-0.151 
0.046 
0.161 
90 
77 
1Adjusted for age, smoking and baseline scores of the respective outcome variable, 2 Adjusted  
for age and smoking; BPRS=Brief Psychiatric Rating Scale, SANS=Scale for the Assessment  
of Negative Symptoms, YMRS=Young Mania Rating Scale, MADRS=Montgomery-Asberg  
Depression Rating Scale, SOFAS=Social and Occupational Functioning Assessment Scale,  
GF-S=Global Functioning Social Scale, GF-R=Global Functioning Role Scale, CGI=Clinical  
Global Impression Scale, OR=odds rato, CI=confidence interval; significant results are bold 
 
 
 
4.4 Discussion 
The aim of the present study was to examine if AL is associated with clinical outcomes 
in youth at UHR for psychosis. Our data demonstrate that high AL is related to poorer 
functional capacity in this group, at least in the short term (6 months), even when 
confounding variables such as age and smoking are taken into account. In addition, 
we observed an association of higher AL with increase in manic symptoms after 6 
months. However, other hallmarks of psychosis such as positive psychotic symptoms 
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were not related to AL in the present study. To our knowledge, this is the first study to 
investigate allostatic mechanisms in individuals at UHR for psychosis. 
 
Our observations add to a growing body of research examining AL in patients with 
psychotic disorders. Previous studies on AL in patients with schizophrenia and drug-
naïve patients with first-episode psychosis have shown elevations of AL in these 
patients relative to healthy controls and strong associations with positive psychotic 
symptoms 18, 19, reduced functioning 18, 19, reduced global cortical thickness 21 and 
white matter integrity 30. Collectively, these studies provide empirical evidence in 
support of the hypothesis that AL is related to pathophysiological processes 
characterising psychotic disorders, and raise the question of whether AL can serve as 
a biomarker for psychotic disorders. Notably, few studies to date have investigated the 
prospective association of AL with longer-term outcomes. The present study aimed to 
fill this gap by applying the allostasis framework to a group of individuals at UHR for 
psychosis, who represent a viable target group for early intervention.  
 
The results of the linear regression analysis suggest that high AL is indicative of poorer 
functional capacity in the short term (6 months), both on the SOFAS scale and the two 
GF scales. Deficits in psychosocial functioning are a core feature of psychotic 
disorders and are well documented in individuals at UHR for psychosis 3, 26, 31. In 
addition to transition to psychosis as the paradigmatic outcome of interest in this 
group, functioning is gaining interest as it relates to quality of life, personal and 
vocational recovery, including in those who do not develop psychosis 2. Moreover, 
impaired functioning itself is indicative of higher risk for psychosis transition 3, 32-36. 
Although this is the first study to assess associations between AL and functioning in 
people at UHR for psychosis, other biomarker studies support the notion that 
pathological mechanisms relevant to AL relate to outcomes in UHR. For example, a 
large proportion of individuals with UHR phenotypes experience distress related to 
their condition, which is associated with adverse longer-term outcomes in UHR 36 and 
sub-threshold psychotic symptoms and aberrant salience attribution 37. Accordingly, 
aberrations in the diurnal cortisol secretion have been found to be indicative of higher 
transition risk in individuals with UHR phenotypes 11, 12. However, not all studies 
support detrimental effects of distress on functional outcomes 36. Reduced grey matter 
volume in frontal and limbic regions is associated with poor functional outcomes in 
UHR 38. Notably, several markers of immune activation, including IL-6 and TNF-α, are 
highly correlated with the AL index in patients with schizophrenia and first-episode 
psychosis 18.  In clinical trials of ω-3 PUFA, increases in the ω-3 PUFA EPA are 
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related to lower transition risk 34, which is likely in part due to their anti-inflammatory 
properties, including their role as a precursor of EPA-derived anti-inflammatory 
molecules such as resolvins or their ability to downregulate the NFkappaB pathway 39, 
40.  
 
An interesting observation of our study is that AL is associated with more severe manic 
symptoms after 6 months. While it has been hypothesised that allostatic mechanisms 
contribute to bipolar disorder in a similar fashion as discussed above for psychotic 
disorders 41-43, few studies to date have directly investigated AL in bipolar disorder. 
Kapczinski and colleagues 44 reported a systemic toxicity index that bears similarity to 
AL indices and applied it to patients with bipolar I, finding that this index was increased 
in depressed and manic patients but not in euthymic patients.  
 
Importantly, our results support a relationship of AL with functioning and manic 
symptoms only within 6 months but not at the 12-month follow-up assessment. The 
effect sizes were similar at 12 months compared to those at 6 months, suggesting that 
the negative finding may be due to lack of power, it has to be considered that AL might 
not be suitable to inform prognosis over the longer term. Similarly, AL did not predict 
overall clinical improvement in the present study.  
 
Few studies to date have provided evidence for single biomarkers with strong 
predictive potential. Multianalyte indices may overcome limitations of single biomarkers 
in psychiatry, as these are unlikely to explain complex disorders with multifactorial 
aetiology 45. Further studies testing potentially predictive biomarkers in longitudinal 
designs should consider including the AL index to further evaluate its predictive 
capacity. 
 
The results of our investigation need to be interpreted with several limitations in mind. 
Firstly, our study did not include a control group, which precludes conclusions about 
group differences in AL between people at UHR for psychosis and healthy individuals. 
Secondly, we did not test prospective associations with psychosis transition due to a 
small number of participants who converted to psychosis in this subgroup of the 
NEURAPRO trial (n=12). Strengths of this study include the follow-up study design; the 
well characterised and comparatively large sample size; the observation that AL was 
prospectively associated with all functioning rating scales in this trial, which allows 
greater confidence in our findings; and that none of our study participants received 
antipsychotic medication, preventing any confounding effects on AL.  
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In conclusion, the short-term effects of AL on functional outcomes and mania 
symptoms in this UHR cohort highlight the potential role of allostatic mechanisms in 
mediating risk for poor clinical outcomes and are broadly consistent with recent 
investigations of AL in first-episode psychosis. AL may be a potential predictor of early 
treatment response and warrants further investigation. To increase the confidence in 
our findings, these data will need to be replicated in an independent sample. 
Ultimately, peripheral biomarker signatures might assist risk predictions and 
complement clinical characteristics.  
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Preface 
In addition to immune activation and neuroendocrine dysregulation, fatty acid 
metabolism is thought to be involved in the pathophysiology of mood and psychotic 
disorders. Long-chain ω-3 PUFA are potential candidate biomarkers for psychiatric 
disorders given their key function in regulating cell membrane properties and due to 
their role as precursors of anti-inflammatory and antioxidant molecules. To date, 
several observational studies support depletion of these PUFAs in MDD and in SCZ, 
and clinical trials report superiority of PUFA supplementation over placebo for MDD. In 
light of these observations, membrane fatty acids may be promising candidate 
biomarkers. Surprisingly, while most studies have focused on chronic patients, there is 
a lack of research in patients at early stages, in particular individuals at UHR for 
psychosis, who have a high risk for psychosis conversion and frequent comorbid mood 
disorders and represent a viable target group for indicated prevention strategies. 
 
Chapter 5 uses data from the first placebo-controlled RCT of ω-3 PUFA versus 
placebo in individuals at UHR for psychosis (‘Vienna n-3 Study’) to test associations of 
erythrocyte PUFA levels at baseline with clinical outcomes at follow-up. This study was 
uniquely qualified to answer this question given the well-characterised UHR sample 
and the long follow-up time of 7 years. Furthermore, the wide range of clinical outcome 
measures allowed us to test associations with other relevant outcomes in addition to 
depressive symptoms and MDD. This paper was published in Translational Psychiatry. 
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Abstract 
While cross-sectional studies suggest that patients with mood disorders have a higher 
ratio of ω-6 to ω-3 PUFA and lower levels of omega-3 PUFAs, it is unknown if a high 
ω-6/3 ratio indicates vulnerability for depression. We tested this hypothesis in a 7-year 
follow-up study of young individuals with an UHR phenotype. We conducted a 
secondary analysis of the Vienna Omega-3 study, a longitudinal study of ω-3 PUFAs 
in individuals at UHR for psychosis (n=69). Levels of ω-6 and ω-3 PUFAs were 
measured in the phosphatidylethanolamine fraction of erythrocyte membranes at 
intake into the study. Mood disorder diagnosis was ascertained with the Structured 
Clinical Interview for DSM-IV-TR and confirmed by review of medical records and 
interviews of caregivers. A higher ω-6/3 PUFA ratio at baseline predicted mood 
disorders in UHR individuals over a 7-year (median) follow-up (odds ratio=1.89, 
95%CI=1.075–3.338, p=0.03). This association remained significant after adjustment 
for age, gender, smoking, severity of depressive symptoms at baseline, and n-3 
supplementation. Consistent results were obtained for individual PUFAs, including 
lower levels of EPA acid and docosahexaenoic acid (DHA). The predictive capacity of 
these findings was specific to mood disorders as no associations were found for any 
other psychiatric disorder. Our data provide the first prospective evidence that the ω-
6/3 PUFA ratio is associated with an increased risk for mood disorders in young 
people exhibiting an UHR phenotype. These findings may have important implications 
for treatment and risk stratification beyond clinical characteristics. 
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5.1 Introduction 
Long-chain polyunsaturated fatty acids (PUFAs) have important physiological functions 
and are key regulators of cell membrane properties. As such, they play important 
structural and functional roles in the human brain and affect monoaminergic 
neurotransmission, dendritic arborisation, synapse formation, and ion channel function 
1, 2. Ω-3 PUFA have been shown to possess anti-inflammatory 3 and antioxidant4 
properties, while ω-6 PUFAs are generally seen as pro-inflammatory, and a high ω-6/3 
PUFA ratio is thought to have adverse health effects 5. 
 
Epidemiological studies show that the dietary intake of ω-3 PUFAs through fish 
consumption is inversely correlated with the prevalence of depression 6, 7, thus 
suggesting that ω-3 PUFAs have a protective effect. While the traditional human diet 
has a ratio of ω-6/3 PUFA of approximately 1:1, contemporary Western diets are 
characterized by a ratio of around 15:1, reflecting deficient intake of n-3 fatty acids and 
excessive intake of n-6 fatty acids 8. Importantly, adherence to a Western diet is 
associated with a higher prevalence of depression 9. This has given rise to the 
hypothesis that the long-term changes in dietary patterns that have occurred in 
industrialized countries over the last centuries have led to an increase in the ω-6/3 
PUFA ratio 5, which may be causally linked to an increase in the incidence of mood 
disorders. Indeed, case-control studies have suggested that individuals with 
depression have lower levels of ω-3 PUFAs and higher ω-6/3 PUFA ratios compared 
to healthy controls  10. Recent meta-analyses of ω-3 PUFAs supplementation trials in 
patients with depression have resulted in inconsistent conclusions. Some meta-
analyses have concluded that ω-3 PUFA supplementation does not have a significant 
benefit on depressive symptoms 11, while others have found significant beneficial 
effects 12-14, which appeared to be related to higher doses of the ω-3 PUFA EPA 12, 15, 
16. Although lower levels of ω-3 PUFAs and higher ω-6/3 PUFA ratios have been 
reported in adults with depression, little is known about PUFA levels in youth, nor 
whether abnormalities in membrane lipid composition precede the onset of depression 
in this group. This is salient because even prenatal and early childhood diet appears to 
play a role in risk for mood disorders, and as such represents a potential intervention 
target 17. 
 
An important mechanistic question is whether individuals with low levels of ω-3 PUFAs 
or an increased ω-6/3 PUFA ratio are at elevated risk of developing mental disorders. 
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We have recently demonstrated that higher levels of α-linolenic acid, the ‘parent’ 
essential fatty acid of the ω-3 family, predicted short-term functional improvement 
among individuals at ultra-high risk (UHR) of developing psychosis who receive n-3 
PUFAs supplementation 18, while decreased levels of nervonic acid, a 
monounsaturated very long chain fatty acid involved in myelin synthesis, predicted 
transition to first-episode psychosis in the same study 19. In contrast, longitudinal 
studies investigating associations of ω-3 PUFAs and depressive symptoms in general 
adult population samples have not reported significant associations 20, 21. 
 
To address the hypothesis that low levels of ω-3 PUFAs or an increased ω-6/3 PUFA 
ratio precedes the onset of mood disorders in at-risk groups, we conducted a 
secondary analysis of the Vienna Omega-3 study, a 12-week (RCT) of ω-3 PUFAs or 
placebo in UHR patients 22, to test whether erythrocyte membrane levels of PUFAs 
predict mood disorders during a (median) 7-year follow-up in young individuals with 
UHR for psychosis. 
5.2 Methods and Materials 
5.2.1 Study Design 
The present study is a secondary analysis of a double-blind RCT of n-3 PUFAs for 
indicated prevention of psychosis transition in individuals at UHR for psychosis (trial 
registration: clinical trials.gov identifier: NCT00396643). Details of this RCT, including 
the trial design, interventions, randomization, inclusion and exclusion criteria, blinding, 
and study measures have been published elsewhere 22. Briefly, a 12-week intervention 
with 1.2 g per day ω-3 PUFAs (700mg EPA, 480mg DHA) or placebo was conducted 
with follow-up at 1 year and 7 years (median) after baseline. The study was approved 
by the Medical University of Vienna Ethics Committee, and written informed consent 
was obtained from all participants or participants and their legal guardians for 
participants aged <18 years. 
5.2.2 Participants 
Eighty-one treatment-seeking individuals were enrolled in the original study. All 
participants were consecutive admissions to a specialized psychosis detection and 
treatment unit at the Department of Child and Adolescent Psychiatry, Medical 
University Vienna, between 2004 and 2006. Participants were aged 13–25 years at 
first presentation and met criteria for one or more of the three operationally defined 
and well-validated risk factors for psychosis proposed by Yung et al. 23: attenuated 
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positive psychotic symptoms; transient psychosis; and genetic risk plus a decrease in 
functioning. The present study sample consists of 69 of the 81 individuals enrolled in 
the trial (85.2%; 47 female, 22 male; mean age 16.38 years, SD 1.83) who had 
information on diagnostic outcomes 7 years (median) after study entry. 
5.2.3 Psychometric Assessments 
The primary outcome measure used for this study was any occurring diagnosis of 
mood disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 
4th ed. (DSM-IV) criteria within the seven-year follow-up period, ascertained in a 
personal interview with the participant using the Structured Clinical Interview for DSM-
IV-TR Axis I disorders (SCID-I/P) at the longer-term follow-up assessment (median 7 
years after enrolment into the study). If a participant was unavailable for an interview, 
we aimed to establish psychiatric diagnoses using next of kin and/or medical record 
information. The Global Assessment of Functioning (GAF) scale was used to measure 
social, occupational, and psychological functioning at baseline and follow-up. The 
MADRS was used to assess depressive symptoms. Inter-rater reliability estimates 
were high (intra-class correlation coefficients >0.92). Cronbach’s alpha for the MADRS 
in this study was 0.89. Inter-rater reliability was maintained by using videotaped 
interviews every 3 months across the initial 12 months of the RCT and before longer-
term follow-up. 
5.2.4 Analysis of Erythrocyte Membrane PUFA Composition 
Erythrocyte membrane phospholipid composition closely reflects that of neuronal 
membranes and provides an easily accessible indicator of brain phospholipids 24. 
Erythrocytes were separated from whole blood samples and the PUFA composition of 
phospholipids of the phosphatidylethanolamine fraction was analyzed from erythrocyte 
membranes. Phosphatidylethanolamine was chosen because it contains higher levels 
of PUFAs relative to other phospholipids. We used gas chromatography to determine 
values for PUFAs and included the following into our analysis: 18:2n-6, 18:3n-6, 20:3n-
6, 20:4n-6, 22:2n-6, 22:4n-6, 18:3n-3, 20:5n-3, 22:5n-3, 22:6n-3. The detailed methods 
and rationale are published in previous reports 25. 
5.2.5 Statistical Analysis 
We included all study participants who did not meet the case definition (i.e., being 
diagnosed with a mood disorder within the follow-up period, n=43, see Table 1) as the 
comparison group, which thus consisted of individuals with no psychiatric disorder, but 
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also individuals with psychotic disorders, anxiety disorder and/or other psychiatric 
disorders. 
 
As an alternative to the conservative Kolmogorov–Smirnov test with Lilliefors 
correction, normality of data was ascertained by assessing the skewness of data 
distribution and the associated standard errors. Skewed variables were log 
transformed, and a range of <3 was used as the cut-off for the use of parametric tests. 
Unadjusted between-group differences in demographic variables and fatty acids (FAs) 
were tested with independent samples t-tests and Χ2 tests or Fisher’s exact test for 
continuous and categorical variables respectively, and group mean values were 
transformed into effect size measures (Cohen’s d) for comparison of FAs between 
diagnostic categories. We used repeated measures ANOVA to examine changes in 
scores between and within groups. Logistic regression was used to calculate odds 
ratios (OR) and 95% confidence intervals (CI) for mood disorder diagnosis within the 
7-year follow-up period. PUFAs (z-transformed values) and their composite indices 
were used as independent variables and ORs were calculated per SD increase in 
PUFA levels. All regression models were fitted as unadjusted models, models adjusted 
for age, gender and smoking, and models adjusted for age, gender, smoking, baseline 
MADRS score, and ω-3 PUFA/placebo group status. We conducted sensitivity 
analyses excluding individuals with psychotic disorder outcome from both case and 
comparison group for all tests. The Hosmer-Lemeshow test was used to test model 
calibration. All tests were 2-sided, a p-value of <0.05 was considered significant. SPSS 
version 22 was used for all analyses. 
5.3 Results 
5.3.1 Demographics and psychometric measures 
The median follow-up duration was 7.14 years (IQR=1.13 years). The sources of 
information to determine diagnostic outcome were interviews (61 with participants, 4 
with next of kin) for 94.2% (65/69) and medical records for 5.8% (4/69) of participants. 
Of these 69 participants, 26 (37.7%) received a mood disorder diagnosis during the 
follow-up period (24 major depressive disorder; 2 bipolar II disorder), 20 converted to a 
psychotic disorder, 19 received an anxiety disorder and 7 a substance use disorder 
diagnosis. No significant differences in any of the demographic variables were found 
between participants with and without mood disorder (Table 5.1). While GAF scores 
were not significantly different between the two groups at the baseline assessment, we 
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found a significant time by group interaction (F1.000=4.50, p=0.04), indicating that GAF 
scores changed differentially between individuals with and without a mood disorder 
diagnosis. Post-hoc tests revealed that GAF scores did not change significantly during 
the follow-up period in individuals with mood disorders (baseline 56.9 ± 11.1 vs. follow-
up 58.1 ± 13.2, p=0.62), whereas individuals with no mood disorders improved 
 11
Table 5.1 Demographic characteristics 
 All individuals with follow-up data Mood disorder at follow-up No mood disorder at follow-up p-value 
 (n=69) (n=26) (n=43) 
  mean SD mean SD mean SD 
Age at baseline (years) 16.3  1.8 16.3  1.7 16.4 1.8 0.879b 
 N % N % N %  
Sex (female) 47  68.1 17  65.4) 30 69.8 0.705a 
Alcohol    0.577c 
     Less than weekly 40  58.0 16  61.5 24 55.8  
     1-6 drinks per week 18  25.7 5  18.5 13 30.2  
     Daily 11  15.7 5 18.5 6 14.0  
Cannabis    0.060c 
     No 58  84.1 21 80.8 37 86.0  
     <2g per week 7  10.0 5 18.5 2 4.7  
     >2g per week 4  5.7 0 0.0 4 9.3  
Smoking  35  50.7 16 61.5 19 44.2 0.162a 
Any illicit drug 13  18.6 5 7.1 8 11.4 0.599c 
 mean SD mean SD mean SD  
MADRS score baseline 18.0  8.9 20.5 8.6 16.7 8.9 0.093b 
MADRS score long term follow-up 14.4  11.0 17.2 9.8 12.9 11.5 0.164b 
GAF score baseline 60.2  12.9 56.9 11.1 62.2 13.6 0.099b 
GAF score long term follow-up 66.2  16.7 58.1 13.2 71.1 16.9 0.001b 
Abbreviations: MADRS, Montgomery–Asberg Depression Rating Scale; GAF, Global Assessment of Functioning; SD, standard deviation 
aChi-Square; bIndependent samples t-test; cFisher’s Exact  
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significantly (baseline 62.2 ± 13.6 vs. follow-up 71.1 ± 16.9, p<0.001). No significant 
time by group interaction and no between-group differences were found in MADRS 
scores at baseline and follow-up. 
5.3.2 Between-group differences in PUFAs 
Three ω-6 PUFAs, two ω-3 PUFAs, the sum of ω-3 PUFAs, and the ω-6/3 PUFA ratio 
were differentially elevated or decreased at baseline in patients with subsequent mood 
disorders relative to the comparison group (Table 5.2). This effect was specific for 
mood disorders; no group differences were found for psychotic disorders, anxiety 
disorders or any other psychiatric disorder. Patients with mood disorders at follow-up 
had lower baseline levels of linolenic acid (18:2n-6), higher baseline levels of γ -
linolenic acid (18:3n-6) and docosadienoic acid (22:2n-6), lower levels of EPA (20:5n-
3), lower levels of DHA (22:6n-3), lower sum of ω-3 PUFAs, and a higher ω-6/3 PUFA 
ratio. No differences were found between patients with mood disorders at follow-up 
with previous mood disorder episodes relative to patients with no history of mood 
disorders (all PUFAs p>0.14). Sensitivity analyses excluding participants who 
converted to psychosis (n=20) showed that EPA (p=0.009) and the sum of ω-3 PUFAs 
(p=0.04) remained significantly lower in individuals with mood disorder compared to 
individuals without mood disorder, while linolenic acid (18:2n-6), γ-linolenic acid 
(18:3n-6), docosadienoic acid (22:2n-6), DHA (22:6n-3), and the ω-6/3 PUFA ratio 
consistently remained at trend level. To exclude the possibility of selection bias, we 
also tested for differences in PUFA concentrations between participants with and 
without follow-up data and found that their membrane PUFA profiles did not differ (all 
PUFAs p>0.277).  
5.3.3 Regression analysis of PUFAs for mood disorder 
Binary logistic regression analysis with ω-6/3 PUFA ratio as the independent variable 
demonstrated that a higher basal ω-6/3 PUFA ratio predicted mood disorder over the 
7-year follow-up period (Table 5.3). The effect remained significant when we adjusted 
the model for gender, age, baseline MADRS score and ω-3/placebo group status. This 
relationship appeared to be driven by a lower sum of ω-3 PUFAs, which was 
independently predictive of mood disorder diagnosis. A series of logistic regression 
analyses revealed that linolenic acid (18:2n-6), γ-linolenic acid (18:3n-6), 
docosadienoic acid (22:2n-6), EPA (20:5n-3), and DHA (22:6n-3) individually predicted 
mood disorders (Table 3). Sensitivity analyses excluding participants who converted to 
a psychotic disorder (n=20) showed that EPA (20:5n-3), DHA (22:6n-3) (trend level), 
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and the ω-6/3 PUFA ratio (trend level), remained predictive of mood disorders and 
were thus consistent with our main findings. The significant findings also persisted 
when the two participants with a Bipolar II diagnosis at follow-up were excluded. 
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Table 5.2 Comparison of erythrocyte membrane phosphatidylethanolamine lipid levels at baseline in patients with mood disorder, psychosis, anxity disorder or other 
psychiatric disorders after 7 years. 
 Mood vs. no mood 
(n=26 vs. n=43) 
Psychosis vs. no psychosis 
(n=20 vs. n=49) 
Anxiety vs. no anxiety 
(n=19 vs. n=50) 
Other vs. no other 
(n=11 vs. n=58) 
 Effect size 
(Cohen’s d) 
p-value Effect size 
(Cohen’s d) 
 
p-value Effect size 
(Cohen’s d) 
p-value Effect size 
(Cohen’s d) 
p-value 
LC ω -6 Fatty Acids         
      Linolenic acid (18:2n-6)a -0.553 0.035 0.139 0.543 0.003 0.990 -0.178 0.610 
      γ-Linolenic acid (18:3n-6) 0.582 0.023 -0.172 0.509 0.260  0.346 0.161 0.603 
      Dihomo-γ-linolenic acid (20:3n-6) 0.299 0.229 -0.114 0.683 -0.127 0.645 0.264 0.458 
      Arachidonic acid (20:4n-6) -0.191 0.447 -0.316 0.213 -0.211 0.410 -0.275 0.371 
      Docosadienoic acid (22:2n-6) 0.612 0.017 -0.213 0.420 0.015 0.954 -0.188 0.579 
      Adrenic acid (22:4n-6) 
 
0.243 0.327 -0.242 0.344 -0.148 0.592 -0.014 0.965 
LC ω -3 Fatty Acids         
      a-Linolenic acid (18:3n-3)a -0.073 0.775 0.106 0.696 -0.307  0.272 0.157 0.650 
      Eicosapentaenoic acid (20:5n-3)a -0.729 0.003 -0.134 0.612 -0.467 0.077 -0.233 0.497 
      Docosapentaenoic acid (22:5n-3) -0.443 0.076 0.018 0.942 -0.134 0.616 -0.058 0.877 
      Docosahexaenoic acid (22:6n-3) -0.618 0.010 -0.092 0.749 
 
-0.486 
 
0.090 
 
-0.625 
 
0.087 
 
Sums and Ratios         
      Sum of LC ω-6 fatty acidsb -0.199 0.413 -0.237 0.349 -0.149 0.565 -0.235 0.541 
      Sum of LC ω -3 fatty acidsb -0.699 0.004 -0.069 0.911 -0.436 0.111 -0.472 0.197 
      LC ω -6 to LC ω -3 fatty acids ratio 0.610 0.012 0.008 0.975 0.278 0.335 0.283 0.435 
aLog transformed; bSum comprises long-chain fatty acids ≥20 carbon atoms 
5
 11
Table 5.3 Odds ratios for mood disorder at 7 years follow-up for erythrocyte membrane phosphatidylethanolamine lipid levels at baseline in patients with mood 
disorders. 
 Unadjusted Model 1a Model 2b 
 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
ω -6 Fatty Acids       
     Linolenic acid (18:2n-6) 0.324 (0.111 – 0.942) 0.038 0.254 (0.078 - 0.827) 0.023 0.287 (0.086 – 0.950) 0.041 
      r-Linolenic acid (18:3n-6) 1.835 (1.069 – 3.150) 0.028 1.881 (1.083 – 3.268) 0.025 1.800 (1.028 – 3.150) 0.040 
     Docosadienoic acid (22:2n-6) 
 
1.856 (1.095 – 3.145) 0.022 1.810 (1.051 – 3.117) 0.033 1.776 (1.029 – 3.065) 0.039 
ω -3 Fatty Acids       
     Eicosapentaenoic acid (20:5n-3) 0.383 (0.185 – 0.793) 0.010 0.372 (0.178 – 0.781) 0.009 0.390 (0.172 – 0.883) 0.024 
     Docosahexaenoic acid (22:6n-3) 
 
0.506 (0.276 – 0.928) 0.028 0.517 (0.279 – 0.960) 0.037 0.488 (0.261 – 0.913) 0.025 
Sums and Ratios       
     Sum of ω -3 fatty acids 0.453 (0.236 – 0.869) 0.017 0.446 (0.228 – 0.874) 0.019 0.436 (0.200 – 0.950) 0.037 
      ω -6 to ω -3 fatty acids ratio 1.894 (1.075 – 3.338) 0.027 1.843 (1.035 – 3.284) 0.038 1.815 (1.024 – 3.289) 0.041 
a Adjusted for age, sex and smoking at baseline; b Adjusted for age, sex, smoking, MADRS score and ω -3 PUFA/placebo group status at baseline 
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5.3.4 Effect modification by gender 
We found a gender difference in docosapentaenoic acid (22:5n-3), such that females 
had lower levels compared to males (2.09±0.42 vs. 2.34±0.39, p=0.01). However, 
gender did not affect the relationship between any of the PUFAs and mood disorder in 
the logistic regression models (all p>0.48).  
5.4 Discussion 
In the present study we tested the hypothesis that ω-6/3 PUFA ratio is a risk biomarker 
26 for mood disorders and found that a higher ω-6/3 PUFA ratio in erythrocyte 
membranes predicts incident mood disorders in young people exhibiting an UHR 
phenotype. This predictive capacity of ω-6/3 PUFA ratio was specific for mood 
disorders in this cohort, i.e., the ω-6/3 PUFA ratio did not influence the risk of 
developing any other psychiatric disorder and persisted after adjusting our model for 
several confounders, including age, gender, smoking, baseline depressive symptoms, 
and ω-3 supplementation. Cross-sectional studies suggest that people with depression 
have higher ω-6/3 PUFA ratios compared to healthy controls, characterized by overall 
lower ω-3 levels, but normal n-6 levels 10. These observations are in line with the 
hypothesis that the changes in diet over the past 150 years may have caused an 
increase in the incidence of depression through increased ω-6/3 PUFA ratios. To the 
best of our knowledge, this study is the first to test the hypothesis that higher ω-6/3 
PUFA ratios posit a risk for future depression in a longitudinal design with a long (7-
year median) follow-up in at-risk individuals. 
 
Ω-6 PUFAs, ω-3 PUFAs, and the balance between the two are important to maintain 
physiological membrane properties 27. The n-3 PUFA content in the lipid bilayer of 
mammalian cells determines the physiological functions of the cellular membrane, 
including membrane fluidity and the function of ion channels and membrane receptors 
27, 28. As such, ω-3 PUFAs are thought to interact with several pathophysiological 
mechanisms in depression, including serotonergic neurotransmission 29 and 
decreased neurogenesis 30. Additionally, depression is characterized by oxidative 
stress, which preferentially impacts lipids, increasing the turnover of, and hence the 
demand for, critical lipids, thus aggravating this imbalance 31. Data from rodent studies 
show that dietary restriction of DHA, for instance, appears to predominantly affect DHA 
levels in the grey matter of cortical areas, the hippocampus, and the striatum 32, 33, and 
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conversely, supplementation of DHA may have a neuroprotective effect on these brain 
areas 34. 
 
A noteworthy finding is that individuals with a mood disorder during the 7-year follow-
up period had significantly lower EPA and DHA levels at baseline, and these two n-3 
PUFAs individually predicted mood disorder in our logistic regression models. This 
finding is in line with evidence from studies showing that EPA and DHA in particular 
are decreased in patients with depression 10. DHA is highly abundant in the human 
brain and constitutes up to 40% of the total brain FAs, while EPA accounts only for 1% 
35. EPA and DHA are believed to be the main active ingredients in n-3 PUFA 
supplementation, and importantly, meta-analysis suggests a dose-response 
relationship between EPA content and clinical efficacy and only supplements with a 
high EPA content appear to be effective in patients with depression 12, 16.  
 
Converging evidence from recent proteomic and transcriptomic studies suggest a 
modulatory effect of ω-3 PUFAs on immune function, including downregulation of 
transcripts for IL-1beta, IL-6, and TNF-α, and the NFkappaB pathway 36, 37. 
Consequently, low levels of ω-3 PUFAs are thought to be associated with a pro-
inflammatory phenotype 3. This view is supported by population-based studies 
demonstrating that a high ω-6/3 PUFA ratio is associated with increased pro-
inflammatory cytokines 38. Data from pre-clinical studies show that a high ω-6/3 PUFA 
ratio predisposes mice to an excessive immune reaction when confronted with a 
lipopolysaccharide immune challenge 39. Moreover, transgenic mice that express ω-3 
PUFA desaturase, an enzyme that catalyses the conversion from ω-6 to ω-3 PUFAs 
that is not naturally expressed in mammalian cells, produce less pro-inflammatory 
cytokines IL-1β, IL-6, and TNF-α in response to a 24-hour lipopolysaccharide 
challenge, show a higher proportion of more neuroprotective MHC II-positive microglial 
cells, and are protected from spatial memory deficits 40. One clinical study 
demonstrated that a high ω-6/3 PUFA ratio markedly increased production of IL-6 and 
TNF-α and patients with depressive symptoms 41. The relevance of these findings is 
supported by a recent study demonstrating that only patients with depression and high 
levels of several pro-inflammatory cytokines respond to ω-3 PUFA supplementation, 
while those patients with low inflammation do not respond 42. Collectively, these data 
suggest that the high ω-6/3 PUFA ratio and the low levels of EPA and DHA found in 
our study may exert their risk for depression partially through immune mechanisms. 
Mood disorders were the most common psychiatric diagnosis at follow-up in the 
Vienna Omega-3 study 43 and in other samples of individuals at-risk for psychosis 44, 
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affecting up to 42% of individuals who present with an UHR phenotype. Recent 
research on the frequency of the UHR phenotype in the general population also 
demonstrated a prevalence of 1.3% and 9.9% for any UHR symptom 45. Furthermore, 
based on cumulative findings from long-term follow-up studies, the UHR concept has 
become more explicitly trans-diagnostic or pluripotent (43). This highlights the 
importance of studying UHR individuals in regard to mood disorder outcomes. Unlike 
general population samples 20, 21, UHR individuals represent a viable target group for 
risk stratification using risk biomarkers 26, which adds clinical relevance to our findings. 
However, the ω-3 PUFA intervention raises the question as to whether it had an 
influence on psychiatric outcomes or if it altered the relationship between membrane 
PUFAs and psychopathology. We have previously shown that the ω-3 PUFA 
intervention, while effective in preventing psychosis, did not reduce the risk for mood 
disorders or MADRS scores 43. Patients who received ω-3 PUFA and patients who 
received placebo did not differ in their PUFA profiles at baseline 22. Finally, adjusting 
our regression models for treatment group did not change the main result. We thus 
believe that the 12-week intervention does not have implications for the interpretation 
of the findings of the present study. 
 
Several limitations need to be considered when interpreting the findings of this study. 
Most importantly, the participants in this study were recruited at a specialized service 
for early psychosis according to UHR criteria, and thus represent a specific group of 
young help-seeking individuals. The results of this study might not generalize beyond 
this setting. Secondly, the relatively small sample size increases the risk of missing 
smaller effects in some of the variables and warrants replication of our findings. 
Thirdly, we did not measure dietary intake of ω-3 PUFA during the trial and we thus 
cannot rule out the possibility that the differences in membrane PUFA composition at 
baseline in participants who later developed a mood disorder were caused by dietary 
intake. Strengths of the study include the long follow-up period of 7 years, the use of 
standardized assessment instruments, the robustness of the findings in the sensitivity 
analysis, and finally the consecutive sample of UHR individuals allowed a comparison 
group that consisted of individuals with a variety of psychiatric diagnoses and thus 
showed that our findings are specific for mood disorders. Additionally, the finding of 
reduced EPA and DHA levels in individuals who later developed a mood disorder adds 
face and biological validity, as both of these PUFAs have been implicated in the 
pathophysiology of depression. Our findings are clinically relevant since mood 
disorders are the most frequent psychiatric condition observed in UHR patients. 
Together with meta-analytic evidence showing the efficacy of supplementation with 
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EPA-predominant formulations in depression, our findings provide a rationale for 
longer-term n-3 supplementation in UHR individuals. 
 
In conclusion, our results highlight the importance of lipid biology for the identification 
of risk biomarkers among individuals with UHR states by demonstrating a longitudinal 
association between membrane PUFA levels and mood disorders 7 years later. These 
findings support the hypothesis that higher levels of ω-6 PUFAs and lower levels of n-3 
PUFAs, possibly due to long-term changes in dietary intake or differential usage, pose 
a risk for depression. In the context of young people at risk for mental disorders, these 
findings may have important implications for risk stratification beyond clinical 
characteristics. 
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Preface 
Aboriginal and Torres Strait Islander Australians and other First Nations people are 
often confronted with social challenges that can affect their mental health. The last two 
decades have seen a growing body of research supporting the notion that complex 
adversity converges on stress. Over time, chronic exposure to stress leads to altered 
release patterns of glucocorticoids and altered cross-talk between the HPA-axis and 
the immune system. While a main focus of the literature has been on social 
determinants and health and relationships between stress mediators and health have 
been examined in North American Indigenous and ethnic minority groups, biological 
stress mechanisms have not been investigated in the Australian context. Therefore, 
there is a strong need to explore the role of cortisol, immune activation and allostatic 
load among Aboriginal and Torres Strait Islander Australians, who are at two-fold 
higher risk of experiencing depression at population level. 
 
Chapter 7 is based on a cross-sectional community-based study of risk factors, 
biomarkers and depressive symptoms. This study was conducted as part of an annual 
health screening (Young Persons Check/Well Persons Health Check) in three 
Aboriginal and Torres Strait Islander communities in north Queensland in 2016. The 
aim of Chapter 7 was to examine associations between depressive symptoms and 
biomarkers of neuroendocrine dysregulation and immune activation. 
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Abstract 
Chronic stress and adversity are associated with poor mental health and are thought to 
contribute to the existing mental health gap between Aboriginal and Torres Strait 
Islander people and other Australians. Hair cortisol and allostatic load are indices of 
sustained stress and may be mediators of the effects of stress on health. The aim of 
this study was to examine the relationship between hair cortisol, allostatic load and 
depressive symptoms. This cross-sectional study comprised 329 adolescent and adult 
participants recruited at two health screening programs operating in three communities 
in north Queensland. We measured hair cortisol and calculated an allostatic load index 
from 10 biomarkers. Depressive symptoms were assessed with a version of the Patient 
Health Questionnaire-9 adapted for Aboriginal and Torres Strait Islander people 
(aPHQ-9). We found differences in cortisol and allostatic load between the screening 
programs and communities, which were not explained by depressive symptoms.  
Overall aPHQ-9 scores were unrelated to hair cortisol (p=0.246 and p=0.938) and 
allostatic load (p=0.295 and p=0.883) when age, gender and smoking were taken into 
account. However, anhedonia and insomnia sub-scores were each significantly 
associated with allostatic load in one study site. Our present data did not demonstrate 
overall associations of stress biomarkers and multisystem dysregulation with 
depressive symptoms, which suggests that the relationship between cumulative stress 
and depression may be better explained by other factors in this population. The 
specific association between anhedonia and insomnia with allostatic load indicates that 
chronic multisystem dysregulation plays a role in these features of depression in this 
population.  
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6.1 Introduction 
Chronic or repeated stress are among the best-established risk factors for depression 
and are thought to mediate in part the effects of social determinants and environmental 
adversity on mental health. For example, adverse events during childhood such as 
childhood trauma and socioeconomic disadvantage increase the vulnerability for mood 
disorders in adulthood 1-3. Moreover, individuals with a history of childhood adversity 
are more likely to develop depression when confronted with severe stress than those 
who did not experience adverse events during childhood 4, 5. The HPA axis is 
considered a key system in mediating the link between stress and depression through 
the excessive release of glucocorticoids 6. Over time, sustained exposure to adversity 
and high levels of glucocorticoids is thought to adversely affect areas of the developing 
brain relevant to depression 7, 8. The effects of stress may be particularly relevant in the 
context of mental health disparities affecting indigenous people across the globe, who 
are often confronted with social challenges that likely converge on stress and may 
contribute to existing health disparities 9, 10.  
 
Australian Aboriginal and Torres Strait Islander people suffer from a multitude of 
diseases at higher rates compared to the non-Indigenous population, including 
common and severe mental disorders 11, 12. While prevalence rate estimates vary, 
depression is thought to affect approximately 13-23% of Aboriginal and Torres Strait 
Islander people 13, 14, 1.5 – 2.3 times more than in the general population. Recently, 
Harriss and colleagues (Harriss et a. 2018, in press) noted high rates of depressive 
symptoms in a community based study of Aboriginal youth with 18% experiencing 
moderate or severe depressive symptoms while another study in the Torres Strait 
found comparatively low depression rates 15. Similarly, self reported psychological 
distress is common, with approximately a third of Aboriginal and Torres Strait Islander 
adolescents and adults reporting high or very high levels of distress 11, 16 and 
hospitalisation rates for mental illnesses are approximately twice as high than in the 
non-Indigenous population 11. The lasting effects of colonialisation and dispossession, 
including racial discrimination, trauma and other sequelae, contribute to these health 
inequalities, likely through chronic effects of stress 9, 10, 17. We have recently shown that 
chronic self reported distress and discrimination are associated with an altered pattern 
of diurnal cortisol production in Aboriginal young adults and depression is associated 
with the biological response to acute stress 18. Similar observations of altered stress 
processing have been made in other minority groups, suggesting that this mechanism 
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may be suited to explain health disparities in different contexts 19. Consequently, stress 
hormones and other mediators of chronic exposure to stress might contribute to 
depression rates in high-risk groups.  
 
Over time, stress and its biological mediators contribute to detrimental physiological 
processes known as allostasis, a concept that recognises the long-term consequences 
of stress and maladaptation 20. Sustained allostatic states may lead to increased AL, 
characterised by immune, endocrine and metabolic dysregulation and indexed by a set 
of routinely used markers including glycosylated haemoglobin, cortisol, CRP, IL6, 
triglycerides, cholesterol and blood pressure 21, 22. This set of markers has significant 
predictive value for adverse health outcomes later in life 23, 24 and together these 
markers appear to reflect metabolic changes and future risk better than individual risk 
biomarkers 22. Several studies also support a link between elevated AL and depression 
25-27, suggesting that heightened AL might contribute to depression risk. However, not 
all studies support this hypothesis 28. Importantly, ethnic minority status might be a 
mediator in the link between inflammation/immune activation and depression 29. 
Consequently, AL might be well suited to investigate the higher rates of depression in 
this population 9, 10.  
 
The aim of the present study was to explore the relationship between hair cortisol as 
well as the AL index and depressive symptoms in three Indigenous communities. We 
hypothesised that higher levels of cortisol and elevated AL are associated with more 
severe depressive symptoms.  
6.2 Methods 
6.2.1 Setting and study design 
The present study is based on two health screening programs delivered to Aboriginal 
and Torres Strait Islander communities in north Queensland and two Torres Strait 
islands by local health services in collaboration with James Cook University (JCU). The 
first program is known as the Well Persons Health Check (WPHC) and operates in the 
communities of Waiben and Mer Island. This program is part of the Zenedath Kes 
Health Partnership between the Torres and Cape Hospital and Health Service and 
JCU. The second program is the Young Persons Check (YPC), delivered by Gurriny 
Yealamucka Health Services Aboriginal Corporation (GYHSAC) and JCU in Yarrabah, 
a community situated 52km south-east of Cairns. Briefly, the aims of these programs 
are to provide screening for a range of chronic and communicable disease annually to 
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all eligible members of the communities. In 2016, a brief depression screening tool was 
added to the health assessments to estimate the prevalence of moderate to severe 
depressive symptoms in the communities and to identify participants to whom further 
mental health care should be offered. Using short screening tools in primary health 
care settings is aimed at improving the recognition of depression with subsequent 
stepped care for individuals with a need for further assessment or care 30, 31. The 
project was endorsed by the GYHSAC Board of Directors, the TCHHS and the local 
Community Councils and was approved by the Human Research Ethics Committee of 
James Cook University (H6404) and the Far North Queensland Human Research 
Ethics Committee (HREC/16/QCH/70-1059).  
6.2.2 Participants 
Study participants were recruited from all individuals aged 15-24 years who attended 
the YPC in March/April 2016 and all individuals aged 15 years or older who attended 
the WPHC in Waiben and Mer Island in October/November/December 2016, 
representing approximately 54% (Yarrabah), 6.5% (Waiben) and 29.3% (Mer Island) of 
the local Aboriginal and/or Torres Strait Islander population in the age range targeted 
by the health checks, respectively. Participants were recruited via announcements in 
local media, posters and peer recruiting. For the present analysis, participants were 
considered eligible if they identified as Aboriginal and/or Torres Strait Islander, were 
aged 15-24 years (YPC) or 15 years or older (WPHC) and provided written informed 
consent or verbal consent (n=1) if written consent could not be obtained (participant 
and parent/guardian consent for participants aged 17 years or younger). In Yarrabah, 
350 members of the community were initially approached and 122 completed the 
depression screening and consented to their participation in the present research. In 
Waiben and Mer Island, a total of 214 individuals were approached and 207 
participants from Waiben and 100 from Mer Island consented and were included in the 
present analysis.  
6.2.3 Data collection 
After providing written informed consent, each participant was asked to undergo a 
series of questionnaires and assessments in addition to the routine health screening. 
Variables relevant to the present analysis included demographic information (gender, 
age), diet and other health behaviours (smoking), depressive symptoms, a hair sample 
for hair cortisol analysis, and blood samples for several routine and research blood 
tests.  
3
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Depressive symptoms were measured with the adapted Patient Health Questionnaire 9 
(aPHQ-9), a screening instrument designed to measure depressive symptoms in 
primary care patients that has been adapted for Aboriginal people in central Australia 32 
and is currently undergoing validation 33. The aPHQ-9 measures depressive symptoms 
as a score, ranging from 0 (absence of depressive symptoms) to 27 (severe 
depressive symptoms). A score of 10 or higher in the original PHQ-9 had a sensitivity 
of 88% and specificity of 88% for a DSM-IV diagnosis of major depression in a 
validation study of over 6000 primary care patients 34. This cut-off has been adapted 
for the present study to distinguish between ‘no/mild’ and ‘moderate/severe’ depressive 
symptoms. ?
6.2.4 Biomarker Assessment/Allostatic Load  
Cortisol was analysed from 3cm hair sections, which were cut as closely to the scalp 
as possible from the posterior vertex region to assess cumulative cortisol 
concentrations of the past three months. Sample preparation and analysis was based 
on the protocol published by Stalder et al. 35 with minor modifications. Briefly, the hair 
samples were washed 3 times for 3 minutes with 2.5ml isopropanol and left to dry for 
12 hrs.  The hair samples were then weighed, frozen and subsequently ground in a 
bead beater with 3.2mm zirconium oxide beads in stainless steel micro vials for 2 
minutes. The samples were then incubated with 1.5ml methanol at room temperature 
for 24 hrs prior to centrifugation at 10000rpm for 2 mins. One ml supernatant was 
transferred into a new micro vial and evaporated under a constant stream of nitrogen 
at 50C until completely dry. Then, 0.4ml phosphate-buffered saline was added, the 
samples were vortexed for 15 s and stored at -20C before being analysed with a 
commercial immunoassay (Salimetrics, Carlsbad, CA, USA). Inter- and intra-assay 
coefficients were below 3% for all assays. The analysis was carried out at our 
laboratory (James Cook University).  
 
Cytokines were analysed using a Procarta 8-plex panel (Procarta Biosystems, 
Norwich, UK) and CRP was measured with a high-sensitivity assay (Procarta 
Biosystems, Norwich, UK) at JCU. Glucose, triglycerides, lipoproteins and cholesterol 
were analysed at a commercial pathology service (Sullivan Nicolaides, Cairns, 
Australia). Biomarkers for the AL index were selected based on (i) representation of 
several physiological systems including, neuroendocrine, immune, metabolic and 
cardiovascular parameters, (ii) use in previous AL research 21, 25, and (iii) associations 
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with disease risk. Cardiovascular markers included heart rate, systolic blood pressure 
and diastolic blood pressure. Neuroendocrine markers included hair cortisol. Immune 
markers were IL-6, TNFα and CRP. Metabolic markers included triglycerides, high-
density lipoprotein, low-density lipoprotein, total cholesterol, glucose, HbA1c and BMI.  
 
For the computation of the AL index, the risk cut-off for each individual biomarker was 
determined based on clinical reference ranges where available and based 75th 
percentile as determined based on the distribution in each study sample for all other 
markers. We then used a ‘scaling’ approach previously described by our group and 
others to calculate the AL index 36, 37. Briefly, for each individual, every marker with 
values above the cut-off (below for HDL) was defined as ‘1’, and the sum of all markers 
in each category (cardiovascular, immune, neuroendocrine, metabolic) was divided by 
the number of markers in each category to allow for equal weighting of the four 
categories. For those markers where the distribution differed between male and female 
controls, gender-specific cut-offs were calculated and used to compute the index 38.  
6.3 Statistical Analysis 
Prior to statistical analysis, the distribution of the data was assessed for normality 
assumptions and outliers. Normality of the data was ascertained by assessing the 
skewness of the data distribution and the associated standard errors. A range of <3 
was used as the cut-off for the use of parametric tests. Variables with greater 
skewness (cortisol) were log-transformed. Cross-sectional differences in demographic 
characteristics, biological variables and depression scores were tested with 
independent-sample t-tests and rank-sum tests for parametric and non-parametric 
continuous data, and with Chi2 tests for categorical data. aPHQ-9 scores were 
dichotomised using a cut-off of 10 and the strata moderate/severe and no/mild 
depressive symptoms were created to group study participants for subsequent 
analyses. To test the association of biomarker levels and allostatic load with 
depressive symptoms, logistic regression models and ordered logistic regression 
models using hair cortisol and allostatic load as independent variables and depressive 
symptoms as dependent variable were fitted. All regression models were adjusted for 
potential confounding variables including age, gender and smoking, which correlated 
with the AL index and are common covariates in the AL literature 22. The Hosmer-
Lemeshow test was used to test model calibration. All tests were 2-sided, a p-value of 
<0.05 was considered statistically significant. STATA 13.1 (Stata Corp., College 
Station, TX, USA) was used for all analyses. 
Ordered logistic regression models testing
associations between independent variabl  and the individual items of the qPHQ-9 
were adjusted for multiple comparisons with the Benjamini-Hochberg method.  
STATA 13.1 (Stata Corp., College Station, TX, USA) was used for all analyses. 
a
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6.4 Results  
6.4.1 Demographic results 
Descriptive results for demographic variables and PHQ-9 scores across the three sites 
are presented in Table 6.1. A total of 122 people participating in the YPC and 207 
people participating in the WPHC were included in the present analysis. Twenty-two 
(18%) participants of the YPC had aPHQ-9 scores above the cut-off for probable 
depression compared to 19 (10.1%) in the WPHC. The mean age of YPC participants 
was 19.1 years for participants above the cut-off for probable depression and 19.4 
years for those below. A larger proportion of participants of with YPC with probable 
depression were female, though this was not significant. Participants of the YPC above 
the cut-off were more likely to smoke although this did not reach statistical significance 
(p=0.085).  
6.4.2 Hair cortisol  
Hair cortisol levels were significantly higher among participants of the WPHC relative to 
participants of the YPC (p<0.001). Hair cortisol was correlated with age (r=0.243, 
p<0.001) but was not different between male and female participants of the YPC 
(p=0.671) or WPHC (p=0.746). Hair cortisol was not different between participants 
above and below the cut-off for depression in participants of the YPC (p=0.914) and 
the WPHC (p=0.960; Table 6.2). 
6.4.3 Allostatic load 
AL was significantly higher in participants of the WPHC compared to participants of the 
YPC (p<0.001). AL was correlated with age among participants of the WPHC (r=0.276, 
p<0.001) but not among participants of the YPC (p=0.706). AL was not different 
between male and female participants of the YPC (p=0.847) or WPHC (p=0.377). Of 
the AL biomarkers, heart rate was higher in participants above the cut-off for moderate
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Table 6.1 Demographic characteristics and depression scores of 122 participants of the Young Persons Check (YPC) and 207 participants of the Well Persons Health Check 
(WPHC) 
 YPC (n=122)  WPHC (n=207)   
 no/mild  
depressive 
symptoms 
(n=100) 
moderate/severe  
depressive 
symptoms  
(n=22) 
Total  
 
 
(n=122) 
p-value no/mild  
depressive 
symptoms 
(n=188) 
moderate/severe  
depressive 
symptoms 
(n=19) 
Total  
 
 
(n=207) 
p-value 
Age         
     mean (SD) 19.44 (3.22) 19.18 (2.30) 19.39 (3.07) 0.7221 41.14 (17.22) 32.00 (10.68) 40.30 (16.92) 0.0241 
Age group    N/A    0.0752 
     12-25 years 100 22 122  46 6 52  
     26-45 years 0 0 0  67 11 68  
     46-65 years 0 0 0  59 2 61  
     66-85 years 0 0 0  16 0 16  
Gender    0.2242    0.7883 
     Female, n (%) 54 15 69  105 10 115  
     Male, n (%) 46 7 53  83 9 82  
Smoking, dichotomized    0.0853    0.4793 
     Yes, n (%) 62 18 80  83 10 93  
Household size  s  N/A    0.5572 
     Number of people, median (IQR) N/A N/A   4 (2 – 6) 4.5 (3 – 8) 4 (2 – 6)  
Education        0.2692 
     Some primary N/A N/A   16 0 13  
     Some secondary N/A N/A   55 5 60  
     Completed secondary N/A N/A   60 6 66  
     Completed tertiary N/A N/A   56 7 63  
BMI, mean (SD) 24.89 (6.60) 26.39 (8.21) 25.16 (6.91) 0.3611 31.73 (7.19) 29.65 (7.15) 31.54 (7.19) 0.2291 
aPHQ-9         
     Total score, mean (SD) 4.18 (2.82) 16 (4.34) 5.95 (4.91) <0.0011 2.76 (2.56) 14.36 (3.93) 3.82 (4.31) <0.0011 
     Total score, median (IQR) 4 (2 – 7) 12.5 (10 – 16) 5 (2 – 9) <0.0012 2 (0 – 4) 14 (11 – 15) 3 (1 – 5) <0.0012 
1 Independent samples t-test, 2 Mann-Whitney-U-Test ,3  Chi2-Test, aPHQ-9=adapted Patient Health Questionnaire-9, BMI=body mass index, IQR=interquartile range, 
SD=standard deviation 
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Table 6.2 Allostatic load biomarkers of 122 participants of the Young Persons Check (YPC) and 207 participants of the Well Persons Health Check (WPHC) 
 YPC (n=122) WPHC (n=207) 
 no/mild 
depressive 
symptoms  
(n=100) 
moderate/severe 
depressive 
symptoms 
(n=22) 
Total 
 
 
(n=122) 
p-value no/mild 
depressive 
symptoms 
(n=188) 
moderate/sever
e 
depressive 
symptoms 
(n=19) 
Total  
 
 
(n=207) 
p-value 
Heart rate (bpm) 79.16 (13.52) 85.77 (17.62) 80.35 (14.49) 0.052 71.61 (11.60) 70.42 (10.05) 71.50 (11.45) 0.666 
Systolic blood pressure (mmHg) 117.26 (12.60) 118.27 (12.37) 117.44 (12.51) 0.732 124.55 (18.01) 122.05 (19.70) 124.32 (18.14) 0.567 
Diastolic blood pressure (mmHg) 74.03 (7.76) 75.27 (10.78) 74.25 (8.35) 0.529 78.10 (12.47) 79.73 (10.96) 78.25 (12.32) 0.584 
Hair cortisol (ng/mg) 7.79 (9.61) 7.91 (7.40) 7.81 (9.26) 0.963 14.04 (28.48) 15.74 (21.84) 14.21 (27.83) 0.818 
CRP (μg/ml), mean (SD) 0.56 (0.54) 0.44 (0.29) 0.54 (0.51) 0.355 0.97 (0.89) 0.58 (0.44) 0.94 (0.87) 0.059 
IL-6 (pg/ml), mean (SD) 9.18 (10.36) 6.86 (4.01) 8.79 (9.62) 0.339 4.25 (6.53) 3.70 (2.08) 4.20 (6.25) 0.716 
TNFa (pg/ml), mean (SD) 1.31 (2.16) 1.13 (0.65) 1.28 (1.99) 0.711 0.61 (2.12) 0.41 (0.79) 0.59 (2.03) 0.680 
Glucose (mmol/L) 4.95 (1.09) 4.61 (0.62) 4.89 (1.02) 0.181 6.21 (3.34) 5.18 (2.26) 6.10 (3.26) 0.194 
HbA1c (%) 5.21 (0.69) 5.11 (0.20) 5.19 (0.63) 0.509 6.08 (1.51) 5.75 (1.59) 6.05 (1.52) 0.364 
Triglycerides (mmol/L), mean (SD)  1.60 (1.33) 1.67 (0.84) 1.61 (1.25) 0.803 1.97 (1.08) 2.21 (2.44) 1.99 (1.28) 0.448 
Total cholesterol (mmol/L), mean (SD) 4.13 (0.85) 4.19 (1.11) 4.14 (0.90) 0.761 4.74 (1.06) 4.92 (4.40) 4.76 (1.06) 0.497 
HDL (mmol/L), mean (SD) 1.08 (0.24) 1.04 (0.26) 1.07 (0.24) 0.473 1.17 (0.36) 1.16 (0.27) 1.17 (0.35) 0.927 
LDL (mmol/L), mean (SD) 2.33 (0.65) 2.38 (0.95) 2.34 (0.71) 0.771 2.66 (0.86) 2.86 (0.75) 2.68 (0.85) 0.351 
Allostatic load index 2.52 (1.95) 2.74 (1.62) 2.56 (1.89) 0.628 3.42 (1.95) 2.80 (1.84) 3.36 (1.94) 0.185 
1 Independent samples t-test, CRP=c-reactive protein, HbA1c=glycosylated haemoglobin, HDL=high density lipoprotein, LDL=low density lipoprotein, IL-6=interleukin-6, 
SD=standard deviation 
13
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to severe depressive symptoms in the YPC at trend level (p=0.052) but not in the 
WPHC. CRP was lower among participants above the cut-off in the WPHC at trend 
level (p=0.059). Levels of the other AL biomarkers did not differ between participants 
above or below the cut-off in the YPC (all p>0.473) and the WPHC (all p>0.185).  
6.4.4 Associations between biomarkers/AL and depressive symptoms 
Adjusted for age, gender and smoking, hair cortisol was not associated with increased 
odds for moderate/severe depressive symptoms in the YPC (p=0.160) or WPHC 
(p=0.779; Table 6.3). Similarly, AL was not associated with moderate/severe 
depressive symptoms in the YPC (p=0.778) or WPHC (p=0.883). 
 
Next, we investigated if AL and hair cortisol are associated with individual sub-domains 
of the aPHQ-9. Adjusted for age, gender and smoking, AL was significantly associated 
with item 1 (anhedonia) of the aPHQ-9 in participants of the WPHC (adj. Beta=0.312 
(95%CI=0.085 – 0.539), p<0.007) and with item 3 (insomnia) in Yarrabah (adj. 
Beta=0.312 (95%CI=0.085 – 0.539), p<0.007; Figure 6.1). In participants of the YPC, a 
trend-level association with item 8 (psychomotor retardation) was found (adj. 
Beta=0.301 (95%CI=-0.003 – 0.607), p=0.053). No associations were found of cortisol 
with any of the sub-domains.  
 
Figure 6.1 Ordered logistic regression analysis of allostatic load and anhedonia in participants of the Well 
Persons Health Check (WPHC) (A) and of allostatic load and insomnia in participants of the Young 
Persons Check (YPC) (B). Regression analyses are adjusted for age, gender and smoking.  
6.5 Discussion 
The aim of the present study was to explore associations of hair cortisol and AL with 
depressive symptoms in two cohorts of Aboriginal and Torres Strait Islander people 
taking part in an annual community health check. Contrary to our hypothesis, no 
association was seen between hair cortisol levels, AL and aPHQ-9 scores. However,  
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Table 6.3 Logistic regression analysis for moderate/severe depressive symptoms in 122 participants of the Young  
Persons Check (YPC) and 207 participants of the Well Persons Health Check (WPHC) 
 Unadjusted Model 1a Model 2b 
 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
All participants (n=329)       
     Hair cortisolc 0.93 (0.66 – 1.30) 0.699 1.31 (0.80 – 2.13) 0.278 1.10 (0.54 – 2.24) 0.779 
     Allostatic load 0.91 (0.76 – 1.08) 0.296 0.98 (0.82 – 1.18) 0.912 1.06 (0.82 – 1.37) 0.624 
     Age 0.96 (0.93 – 0.98) 0.004     
     Gender 1.26 (0.64 – 2.47) 0.487     
     Smoking 1.00 (0.96 – 1.05) 0.685     
YPC (n=122)       
     Hair cortisolc 0.97 (0.56 – 1.65) 0.913 1.57 (0.77 – 3.21) 0.210 1.74 (0.80 – 3.78) 0.160 
     Allostatic load 1.06 (0.83 – 1.34) 0.625 1.16 (0.87 – 1.54) 0.295 1.04 (0.74 – 1.48) 0.788 
     Age 0.97 (0.83 – 1.13) 0.720     
     Gender 1.82 (0.68 – 4.86) 0.229     
     Smoking 0.99 (0.92 – 1.07) 0.892     
WPHC (n=207)       
     Hair cortisolc 0.98 (0.62 – 1.57) 0.960 1.05 (0.64 – 1.72) 0.829 1.10 (0.54 – 2.24) 0.779 
     Allostatic load 0.83 (0.63 – 1.09) 0.187 0.90 (0.68 – 1.19) 0.492 1.02 (0.69 – 1.52) 0.883 
     Age 0.96 (0.93 – 0.99) 0.029     
     Gender 0.87 (0.34 – 2.26) 0.788     
     Smoking 1.04 (0.97 – 1.11) 0.207     
aAdjusted for age and gender, b adjusted for age, gender, and smoking, c log transformed 
8
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anhedonia and insomnia were each significantly positively correlated with AL in one of 
the study sites. Cortisol measured from hair was unrelated to depressive symptoms in 
our study. Cortisol is believed to be relevant to the pathological mechanisms seen in 
depression for several reasons. For example, a plethora of studies provided evidence 
for altered cortisol levels in patients with MDD, although the findings are inconsistent. 
One of the largest studies to date to address this question found a significant but 
modest elevation of cortisol in patients with MDD irrespective of symptom severity 45. 
Other evidence includes findings of down regulation of glucocorticoid receptors, 
believed to be secondary to chronic hypercortisolism, and decreased glucocorticoid 
receptor function 46. While some studies found hair cortisol to be higher in patients with 
depression 47, more recent studies investigating hair cortisol do not support 
consistently elevated levels in patients with depression 48, including in children and 
adolescents 49-51. However, there is evidence for higher hair cortisol in individuals 
experiencing chronic stress 48 and low socio economic status 52, suggesting that hair 
cortisol levels are related to key risk factors for depression.  
 
An important observation was that cortisol was higher in the participants of the WPHC 
compared to those of the YPC. Clearly, age is a potential confounder in addition to 
other systematic differences between the communities 48. The relationship between 
age and hair cortisol is heterogeneous though, particularly in adolescents 53, and age 
was not correlated with cortisol levels in our study. In addition, BMI is known to be 
positively correlated with hair cortisol and might explain differences in hair cortisol 
between the screening programs 48, 53. 
 
To our knowledge, this is the first investigation of AL in relation to a mental health 
outcome in an Aboriginal and Torres Strait Islander population and one of few studies 
to investigate a potential biological mediator of the effects of stress on mental health. 
AL is commonly conceptualised as a multisystem indicator of the cumulative effects of 
chronic stress and adversity. In a population that has both high rates of mental ill-
health including depression and suicide and a high prevalence of trauma 39, biological 
stress mediators and AL may contribute to sustain health inequalities. Populations 
living under high levels of stress – in particular children - are at increased risk for poor 
mental health and are consequently a priority in mental health research 40. Our data 
support a relationship between AL and two features of depression in this group.  
Previous studies in other populations have provided mixed results concerning the 
relationship between AL and depression. Juster and colleagues 25 conducted a follow-
up study in 58 adults (mean age = 67 years) and observed prospective associations of 
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increased AL with depressive symptoms in the same year and three years later, 
although the latter was reduced to a trend when sex and age were included as 
covariates. Similarly, another study reported associations of depressive symptoms with 
a multisystem index similar to the AL used here in a Taiwanese cohort (n=958) 41. In 
contrast, a recent large (n=12272) cross-sectional study investigated AL and 
depressive symptoms in an ethnically diverse sample and found no significant 
associations irrespective of ethnicity 28. A question raised by these reports is if AL is 
relevant only in older populations. However, our data neither support a role for AL in 
older adult or adolescent participants.  
 
The association of AL with anhedonia and sleep disturbances may suggest that AL is 
selectively related to specific aspects of depression, in particular motivation, 
psychomotor drive and sleep. Recently, data from the National Health and Nutrition 
Survey (NHANES) demonstrated selective and robust associations of elevated levels 
of CRP with fatigue, sleep disturbance and altered appetite 29. There is preclinical and 
clinical evidence to suggest that inflammation and oxidative stress – as seen in 
allostatic states – impair motivation through effects on striatal dopaminergic reward 
processing 42. Two recent studies support that peripheral inflammation is selectively 
associated with anhaedonia in adult patients with depression 43 and across diagnostic 
categories in young people with psychiatric disorders 44. Additionally, the link between 
immune activation and depressive symptoms was missing in some but not all ethnic 
groups in this study, suggesting that ethnicity may be a moderator of the hypothesised 
effects of inflammation on depression 29. Together, these data provide support for the 
notion that AL may be related to deficits in motivation, psychomotor drive and sleep 
disturbance. 
 
There are several limitations to this study. First, our study was cross-sectional and 
inferences cannot be made about the temporal dynamic of hair cortisol or AL and 
depressive symptoms. Second, several health behaviours and social determinants 
relevant to AL have not been taken into account comprehensively. Our study was thus 
unable to investigate which factors determine AL. Third, while AL is conceptualised as 
the biological traces or chronic stress, perceived stress itself was not assessed. 
Finally, it is possible that severely depressed individuals were less likely to attend the 
health check and underreporting of depression may consequently affect our results. 
The study setting in a community health check setting may also imply a perceived lack 
of privacy and some study participants may have perceived this as a barrier to 
disclosing depressive symptoms due to the perceived associated stigma. The study 
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sample may thus not be representative of the wider community. Strengths of the study 
include the large sample, the diverse age range and the use of hair cortisol, which is 
not sensitive to the diurnal variation and sampling bias that can be problematic when 
measuring cortisol from saliva or plasma.  
 
These shortcomings highlight the need for future research in several domains. For 
example, it seems necessary to elucidate to what extent the previously found role of 
AL in depression depends on illness severity, study setting (population-based vs. 
clinical) or ethnicity. Similarly, inconsistencies in the operationalisation of the AL index 
open up the possibility that different findings are attributable to the weighting of the AL 
markers. Finally, conditions characterised by chronic low-grade inflammation such as 
obesity or type-2-diabetes mellitus are more common in patients with depression and 
this relationship may be partially attributable to allostatic mechanisms.   
 
In conclusion, our findings add to the few studies on the relationship between hair 
cortisol, AL and depressive symptoms in a population affected by considerable social 
and environmental stressors and putatively higher rates of depression. The 
relationship between these factors and anhedonia and psychomotor drive may indicate 
that chronic multisystem dysregulation plays a role in specific features of depression in 
this population.  
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Preface 
Besides supplementation and increased depletion, dietary intake is the main 
determinant of membrane ω-3 PUFA concentrations. Fatty fish and seafood are the 
main sources of the essential ω-3 PUFA EPA, which has been shown to be the key 
PUFA responsible for the antidepressive effect in RCTs. Consequently, a diet rich in 
natural EPA from marine sources may have protective effects against mood disorders. 
Two decades ago, Hibbeln first showed in a cross-national comparison that the 
average fish consumption correlated with the prevalence of depression. This 
observation has since been replicated in several western societies, but little research 
has focused on populations with a traditional fish-based diet and high rates of distress 
and few studies measured membrane levels of ω-3 PUFAs. The Torres Strait Islander 
people of Australia have and continue to rely on a traditional diet characterised by a 
high content of wild caught fish. Recent reports of comparatively low rates of 
depression in this population as well as the association of low ω-3  PUFA levels and 
depressive symptoms observed in Chapter 5 and other studies form the rationale for 
Chapter 6. 
 
Chapter 6 reports a cross-sectional analysis examining associations between diet, 
membrane PUFAs and depressive symptoms in two communities in the Torres Strait 
with differential access to seafood as well as processed food from fast-food outlets. 
This study refers to the same sample as reported in Chapter 7; however, the study 
sample was restricted to two sites as levels of PUFAs were not measured in the third 
site. These two communities in the Torres Strait have differential access to seafood as 
well as processed food from fast-food outlets.  
 
 
 
 
 
 
 
 
 
 
 
7
7
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Abstract 
Background Dietary intake of long-chain ω-3 PUFA represents a putative modifiable 
risk factor for depression, and a high ratio of ω-6 to ω-3 PUFA is frequently observed 
in patients with major depressive disorder. Recent reports suggest that the availability 
of fish and seafood may be associated with lower depression rates. The aim of this 
study was to investigate associations of fish consumption and PUFA levels with 
depressive symptoms.  
 
Methods Participants for this cross-sectional study (n=206) were recruited at a 
community screening program in two Torres Strait Islander communities (Mer and 
Waiben). Depressive symptoms were assessed with the adapted Patient Health 
Questionnaire-9 (aPHQ-9) and diet with a structured questionnaire. PUFA 
concentrations were measured with a capillary dried blood spot system (PUFAcoat). 
Logistic and quantile regression modelling was used to test the relationship between 
seafood consumption, membrane PUFAs and depression scores.  
 
Results A higher blood ω-6/3 PUFA ratio was associated with moderate/severe 
depression scores across both study sites (OR = 1.59 (95%CI 1.09 – 2.34), p=0.017). 
Seafood consumption was higher and the proportion of participants with aPHQ-9 
scores above the cut-off for depression was lower on Mer (n=100) compared with 
Waiben (n=106). Higher seafood consumption was associated with lower depression 
scores on Waiben (B=-0.57 (95%CI -0.98 – -0.16), p=0.006) but not on Mer.  
 
Conclusions Our findings support an association of ω-3 PUFA from natural sources 
with depressive symptoms. The availability of fresh seafood in the local diet may 
represent a protective factor for depression in this setting.
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7.1 Introduction 
The notion that dietary consumption of fish and seafood is linked to depression 
prevalence has sparked interest in the role of ω-3 PUFA in the aetiology of depression. 
ω-3 PUFA – fatty acids that have more than one double bond between carbon atoms 
with the first double bond at the third carbon atom – are key components of the cellular 
membrane and regulate cellular functions relevant to depression pathophysiology, 
including membrane fluidity, ion channel function and receptor signalling 1. In addition, 
these PUFA are precursors of metabolites that are thought to have anti-inflammatory 2, 
3 and anti-oxidant 4, 5 properties. Ω-6 PUFA in contrast are thought to be pro-
inflammatory and are highly abundant in contemporary Western diets 6.  
 
Fish and seafood are the most important sources of several essential ω-3 PUFA, in 
particular EPA and DHA. Low levels of these PUFA are a robust biological finding in 
patients with major depression 7-10. An early study provided epidemiological evidence 
for a correlation between ω-3 PUFA intake through fish consumption and depression 
prevalence, giving rise to the hypothesis that dietary intake of ω-3 PUFA may protect 
against depression 11. Importantly, contemporary Western diets are characterised by 
an abundance of ω-6 PUFA and their precursors and a relative lack of ω-3 PUFA12. 
Consequently, the ω-6/3 PUFA ratio is typically high in industrialised countries at 20:1, 
compared with the ω-6/3 PUFA ratio of people adhering to more traditional diets at 1:1. 
The high ω-6/3 PUFA ratio is believed to have resulted in increased production of pro-
inflammatory eicosanoids, downstream metabolic products of ω-6 PUFA, which are 
thought to be partially responsible for the rising incidence in chronic disease 
associated with adherence to Western diets 12. This hypothesis is supported by 
observational studies showing lower levels of ω-3 PUFA and a higher ω-6/3 PUFA 
ratio in patients with major depressive disorder as well as by a recent meta-analysis 
demonstrating lower risk for depression with higher fish-consumption 13. Moreover, 
meta-analyses of interventional trials 14-17 of ω-3 PUFA in adult patients with 
depression show small but significant beneficial effects of ω-3 PUFA supplementation 
on depressive symptoms, which appear to be related to higher doses of EPA, and 
studies in youth are currently underway (ACTRN12613001352796). We have recently 
shown that a high ω-6/3 PUFA ratio represents a risk factor for mood disorders in a 7-
year longitudinal study of youth with at-risk mental states 18. Consequently, dietary 
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intake of ω-3 PUFA from fish, seafood and supplements may serve as a potential 
modifiable risk factor for depression.   
 
Depression is among the largest contributors to the loss of Disability Adjusted Life 
Years, affecting approximately one in seven people at some point in their lives 19, 20. 
The Aboriginal and Torres Strait Islander people of Australia are disproportionately 
affected by psychological distress and mental ill-heath compared with the general 
population, which contributes to the existing health gap 21, 22. While national survey 
data indicate that Aboriginal and Torres Strait Islander people suffer from depression at 
higher rates than the general population 22, the prevalence varies between regions and 
communities and recent reports suggest lower rates in Torres Strait Islander 
communities 23. Although these health disparities are attributed to a complex set of 
social and environmental health determinants, access to fresh food and seafood is 
problematic in many rural and remote areas and may affect mental health through the 
above mechanisms.  
 
Data from non-clinical populations with varying levels of seafood consumption are 
scarce, and little is known about the role of ω-3 PUFA from traditional fish-based diets 
in Torres Strait Islander people. Consequently, the aim of the current study was to 
investigate association of ω-3 PUFA intake from fish and seafood, as well as takeaway 
food consumption, with PUFA levels and depressive symptoms in two Torres Strait 
Islander communities, with putatively low rates of depression. Based on the 
background and rationale above, we hypothesised (1) that differences in seafood and 
take-away food consumption would be reflected in the ratio between ω-6 to ω-3 PUFA, 
and (2) that there is an association between ω-6/3 PUFA ratio in blood and depressive 
symptoms. 
7.2 Methods 
7.2.1 Setting 
Data for this study were collected at a community-based screening program (Well 
Persons Health Check) in two Australian island communities situated in the waters of 
the Torres Strait between the northern most tip of Queensland and the Western 
Province of Papua New Guinea. The Well Persons Health Check is a comprehensive 
health promotion and screening program conducted by the Torres and Cape Hospital 
and Health Service (TCHHS). In 2016, the Well Persons Health Check was conducted 
as a collaboration between the TCHHS and James Cook University (Zenadth Kes 
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Health Partnership). This model of preventative health care was first introduced in 
1998 as a health screen for sexually transmitted and chronic cardiovascular and 
metabolic conditions and takes place annually in several communities in north 
Queensland 24. The detailed methodology including the rationale for the health check is 
reported in 25, 26. Participation in depression and suicidal ideation screening and use of 
health data for research purposes were optional and offered in addition to the usual 
health check. 
 
Waiben Island is a 3.5 square kilometre landmass approximately 39 kilometres north of 
the Australian mainland. It is the main administrative centre in the Torres Strait region 
with an estimated population of 2,609, of which 64.5% (n=1,684) are Indigenous 
Torres Strait Islanders. Travel to the Australian mainland is by sea, or daily direct 
commercial flights. Mer Island is situated in the eastern Torres Strait region, 210km 
northeast of Waiben and 340km west of Port Moresby. Mer is approximately 4.3 
square kilometres with a population of 365, of which 93.4% (n=341) are Torres Strait 
Islanders. Mer is accessible by light aircraft from Waiben. Commercial food supply is 
limited to one convenience store and there are no fast food outlets on Mer. ?
The study received written support from the local Community Council, Primary Heath 
Care Service and TCHHS. Ethical approval was granted by the Far North Queensland 
Human Research Ethics Committee (HREC/16/QCH/70-1059),   
7.2.2 Participants 
Study participants were recruited from all health check attendees who identified as 
Aboriginal and/or Torres Strait Islander and participated in October, November and 
December 2016. The health checks were promoted with posters, radio advertisements 
and word of mouth. Participants were aged 15 years and older and provided written 
informed consent (n=205) or verbal consent (n=1) if written informed consent could not 
be obtained. Participant and parent/legal guardian consent were obtained for 
participants aged <18 years. A total of 214 community members were screened; 106 
participants from Waiben and 100 from Mer had satisfactory data and were included in 
the present analysis. The study sample represented approximately 6.5% and 29.3% of 
the local Aboriginal and/or Torres Strait Islander population, respectively.  
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7.2.3 Data collection 
Diet, demographic and psychometric data 
Depressive symptoms were measured using the adapted Patient Health Questionnaire 
(aPHQ-9), a version of the original PHQ-9 specifically adapted for use with Aboriginal 
people in central Australian communities that has been found to be culturally 
acceptable 27. The aPHQ-9 is currently undergoing validation 28. The aPHQ-9 
measures depressive symptoms in the previous two weeks using a Likert scale, 
ranging from 0 (absence of depressive symptoms) to 27 (severe depressive 
symptoms). In a validation study of the original PHQ-9 with over 6000 people who 
presented for primary health care, a score of 10 or higher had a sensitivity of 88% and 
specificity of 88% for a DSM-IV diagnosis of major depression 29. This cut-off has been 
adapted for the present study to distinguish between ‘no/mild’ and ‘moderate/severe’ 
depressive symptoms. Participants completed a food questionnaire as part of the 
study. Fish and seafood consumption and the intake of take-away food consumed in 
the week preceding their health check were assessed with non-leading questions. Self-
reported seafood included fish, octopus, crayfish, crab, prawns, oysters and clams.  
7.2.4 Fatty acid analysis 
Whole blood was collected on a validated dried blood spot system and fatty acid 
composition was analysed by capillary gas chromatography 30. Values for the following 
classes of PUFAs were obtained and included in the present analysis: alpha-Linolenic 
acid (18:3n-3), EPA (20:5n-3), Docosapentaenoic acid (22:5n-3), DHA (22:6n-3), 
Linolenic acid (18:2n-6), Gamma-Linolenic acid (18:3n-6), Eicosadienoic acid (20:2n-
6), Dihomo-gamma-linolenic acid (20:3n-6), Arachidonic acid (20:4n-6), Docosadienoic 
acid (22:4n-6). The relative abundance (wt%) of these PUFAs was used for all 
analyses. We included the proportion of total ω-3 PUFAs, the proportion of total n-6 
PUFA, the ratio between ω-6 and ω-3 PUFA, and EPA and DHA separately due to 
their relevance to depression pathophysiology. Lipids were analysed according to 
standard protocols at the Pathology Queensland Laboratory of Cairns Base Hospital.  
7.2.5 Statistical Analysis 
Raw scores from the aPHQ-9 and dichotomised scores according to the cut-off 
published by Kroenke, Spitzer 29 were used to measure depression severity. Kruskal-
Wallis tests were performed to assess differences in depression frequency between 
age groups. Differences in continuous variables between sites and between 
participants above and below the threshold for depression were tested with t-tests and 
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with Mann-Whitney-U tests for variables that were not normally distributed. Normality 
of the data was ascertained by visual inspection of the distribution, the skewness and 
the associated standard errors. Normal distribution of the data was assumed if 
skewness divided by the standard error of skewness was between -3 and +3.  
To test whether dietary seafood intake was associated with blood PUFA composition, 
we used linear regression modelling with seafood consumption as the independent 
variable and the above PUFA parameters as dependent variables. To test the 
relationship between seafood intake, blood fatty acids and probable depression across 
both study sites and for each site separately, we fitted logistic regression models using 
dietary seafood intake, PUFA levels and their summary scores and ratios as 
independent variables, and probable depression, dichotomised using a cut-off of 10 on 
the aPHQ-9, as the dependent variable. As the number of individuals above the cut-off 
for depression was small, we also fitted quantile regression models using the same 
variables and raw aPHQ-9 scores as the dependent variable. Quantile regression was 
chosen as the dependent variable and the residuals for this dependent variable were 
not normally distributed in linear regression models. To estimate 95% confidence 
intervals for the quantile regression models, bootstrap resampling was used with 1000 
repetitions. Effect sizes are reported as odds ratios (OR) and beta coefficients (B). 
Based on the literature on ω-3 PUFAs and depression, we considered the following 
parameters as covariates, as they may affect both the blood fatty acid profile and risk 
for depression: age, gender, BMI and smoking. Covariates were included in the 
regression models if they correlated with one of the independent variables and the 
dependent variable (p<0.2). All regression models were fitted as unadjusted models, 
and as models adjusted for the above covariates. The Hosmer-Lemeshow goodness-
of-fit test was used to test the model calibration for all models. A p-value <0.05 was 
considered significant. Our study was powered (1-β=0.8) to detect OR>1.46 or 
OR<0.68 based on the distribution of the independent variables (PUFA) and our 
samples size, and OR>1.30 or <0.76 at 1-β=0.5. The power analysis was conducted 
with G*Power for Mac OS. STATA 13.1 (Stata Corp, College Station, Texas, USA) for 
Mac OS was used for all other analyses.  
7.3 Results  
7.3.1 Demographic results and diet 
Demographic and psychometric results and fatty acid concentrations are reported in 
Tables 1 and 2. The study included a total of 206 participants of whom 106 resided on 
Waiben and 100 on Mer Island (Table 1). No significant differences in age and gender 
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distribution were observed between participants at the two study sites. Study 
participants on Mer reported significantly higher seafood consumption and lower take-
away food consumption compared with participants on Waiben. Similarly, a higher 
percentage of participants on Mer Island consumed seafood twice weekly or more as 
recommended by the WHO 31, although this did not reach statistical significance. Of 
the 206 participants, 19 were identified as having moderate to severe depressive 
symptoms using the aPHQ-9 (Table 2). Of these, 3 resided on Mer and 16 on Waiben. 
Consistent with this, mean aPHQ-9 scores were lower on Mer. Participants with aPHQ-
9 scores above the cut-off for major depression were younger and had higher take 
away food consumption at trend level.  
7.3.2 Blood polyunsaturated fatty acid levels 
The relative abundance of PUFAs was different between the two study sites (Table 1), 
such that participants on Mer had higher levels of EPA, DHA and total ω-3 PUFA, and 
lower levels of total n-6 PUFA at trend level. This was also reflected in a significantly 
lower ω-6/3 PUFA ratio on Mer. Levels of LDL were lower on Mer at trend level, 
whereas triglycerides, HDL and total cholesterol did not differ between the study sites. 
Participants with aPHQ-9 scores above the cut-off for depression had a significantly 
higher ω-6/3 PUFA ratio, and a trend for higher ω-6 PUFA, lower ω-3 PUFA and lower 
levels of EPA and DHA (Table 2). Levels of lipids did not differ between participants 
with aPHQ-9 scores below and above the cut-off.  
7.3.3 Covariates 
Of the covariates considered for the analysis, age was negatively correlated with the 
ω-6/3 ratio (r=-0.519, p<0.001) and with aPHQ-9 scores (rho=-0.269, p<0.001). aPHQ-
9 scores were higher among female compared with male participants although this was 
not statistically significant (3 (IQR 1 – 6) vs. 2 (IQR 0 – 4), p=0.103); similarly the n-6/3 
ratio was higher among male participants (6.18 (95%CI 5.93 – 6.44) vs. 5.83 (95%CI 
5.57 – 6.07), p=0.047). BMI was negatively correlated with the n-6/3 ratio (r=-0.153, 
p=0.027) but BMI was not associated with aPHQ-9 scores (rho=0.008, p=0.900). 
Smoking rates were not different between participants with no/mild depressive 
symptoms and participants with moderate/severe depressive symptoms (chi2 = 0.538, 
p=0.463) and the number of cigarettes smoked per day was not different between 
participants with no/mild depressive symptoms and participants with moderate/severe 
depressive symptoms (14.9 (95%CI 9.54 – 20.25) vs. 11.08 (95%CI 9.06 – 13.10), 
p=0.210). 
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Table 7.1 Demographic characteristics and PUFA levels of 206 people attending the 2016 
Zenadth Kes Health Partnership Health Check  
 Waiben (n=106) Mer (n=100)  
     p-value 
Age, mean (SD) 38.69 (15.06) 42.19 (18.58) 0.1391 
Gender     0.8172 
     Female, n (%) 60 (56.60) 55 (55)  
     Male, n (%) 46 (43.40) 45 (45)  
Smoking, dichotomized     0.9242 
     Yes, n (%) 47 (44.33) 45 (45)  
BMI, mean (SD) 31.29 (7.30) 31.82 (7.15) 0.6001 
Depressive symptoms      
     aPHQ-9, mean (SD) 4.45 (5.07) 3.19 (3.24) 0.0351 
    a PHQ-9, median (IQR) 3 (0 – 7) 3 (1 – 4) 0.4373 
aPHQ-9 score, dichotomized#     0.0034 
     Moderate/severe, n (%) 16 (16.7) 3 (3)  
     No/mild, n (%) 90 (83.3) 97 (97)  
Takeaway (weekly)      
     Mean (SD) 1.13 (1.41) 0.54 (0.96) <0.0011 
     Median (IQR) 1 (0 - 2) 0 (0 – 1) <0.0013 
Seafood (weekly)      
     Mean (SD) 2.06 (1.75) 3.03 (2.85) 0.0031 
     Median (IQR) 2 (1 – 3) 2 (1 – 5) 0.0143 
  Dichotomized     0.0782 
     <2/week, n (%) 74 (68.51) 57 (57)  
     >=2/week, n (%) 33 (31.49) 43 (43)  
Fatty Acids      
     EPA (wt%), mean (SD) 0.57 (0.23) 0.65 (0.25) 0.0211 
     DHA (wt%), mean (SD) 2.35 (0.51) 3.00 (0.69) <0.0011 
     Total n-3 (wt%), mean (SD) 4.60 (0.80) 5.43 (1.01) <0.0011 
     Total n-6 (wt%), mean (SD) 29.40 (3.37) 28.65 (2.91) 0.0871 
     n6/3 ratio, mean (SD) 6.56 (1.22) 5.45 (1.15) <0.0011 
Lipids      
     Triglycerides, mean (SD) 2.02§ (1.53) 1.95&  (0.99) 0.7001 
     LDL, mean (SD) 2.79§ (0.92) 2.56& (0.77) 0.0651 
     HDL, mean (SD) 1.17§  (0.36) 1.17& (0.35) 0.9881 
     Total cholesterol, mean (SD) 4.89§ (1.15) 4.62& (0.96) 0.0911 
1 Independent samples t-test, 2 Chi2-Test, 3 Mann-Whitney-U-Test, 4Fisher’s Exact, §n=90, 
&n=94 #no/mild=aPHQ-9 score <10, moderate/severe=aPHQ-9 score >=10; BMI=body mass 
index, EPA=eicosapentaenoic acid, DHA=docosahexaenoic acid, HDL=high density lipoprotein, 
IQR=interquartile range, LDL=low density lipoprotein, aPHQ-9=Patient Health Questionnaire-9, 
SD=standard deviation 
 
 
  156
Table 7.2 Demographic characteristics and PUFA levels of 206 people attending the 2016 
Zenadth Kes Health Partnership Health Check by depressive symptom score 
 Moderate/severe 
(n=19) 
No/mild (n=187)  
     p-value 
Age, mean (SD) 32.00 (10.68) 41.24 (17.21) 0.0221 
Gender     0.8072 
     Female, n (%) 10 (52.63) 105 (56.14)  
     Male, n (%) 9 (47.37) 82 (43.86)  
Smoking, dichotomized     0.4662 
     Yes, n (%) 10 (52.63) 82 (43.85)  
BMI, mean (SD) 29.65 (7.15) 31.74 (7.21) 0.2291 
Depressive symptoms      
     aPHQ-9, mean (SD) 14.36 (3.93) 2.77 (2.56) <0.0011 
     aPHQ-9, median (IQR) 14 (11-15) 2 (0 – 4) <0.0013 
Takeaway (weekly)      
     Mean (SD) 1.36 (1.73) 0.79 (1.18) <0.0531 
     Median (IQR) 1 (0 - 2) 0 (0 – 1) <0.2043 
Seafood (weekly)      
     Mean (SD) 2.31 (2.26) 2.55 (2.41) 0.6741 
     Median (IQR) 2 (1 – 4) 2 (1 – 3.5) 0.5293 
  Dichotomized     0.6142 
     <2/week, n (%) 13 (68.42) 117 (62.56)  
     >=2/week, n (%) 6 (31.58) 70 (37.44)  
Fatty Acids      
     n6/3 ratio, mean (SD) 6.72 (1.06) 5.95 (1.32) 0.0141 
     Total n-6 (mol%), mean 
(SD) 
30.04 (2.91) 28.93 (3.18) 0.1481 
     Total n-3 (mol%), mean 
(SD) 
4.59 (0.92) 5.04 (1.00) 0.0571 
     EPA (mol%), mean (SD) 0.52 (0.22) 0.62 (0.24) 0.1241 
     DHA (mol%), mean (SD) 2.38 (0.63) 2.69 (0.68) 0.0551 
Lipids      
     Triglycerides, mean (SD) 2.21 (2.44) 1.96§ (1.08) 0.4351 
     LDL, mean (SD) 2.86 (0.75) 2.65§ (0.86) 0.3461 
     HDL, mean (SD) 1.16 (0.27) 1.17§ (0.36) 0.9181 
     Total cholesterol, mean 
(SD) 
4.92 (1.06) 4.74§ (1.06) 0.4871 
1 Independent samples t-test, 2 Chi2-Test, 3 Mann-Whitney-U-Test, 4Fisher’s Exact, §n=165; 
BMI=body mass index, EPA=eicosapentaenoic acid, DHA=docosahexaenoic acid, HDL=high 
density lipoprotein, IQR=interquartile range, LDL=low density lipoprotein, aPHQ-9=Patient 
Health Questionnaire-9, SD=standard deviation
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7.3.4 Relationship between diet and blood fatty acids 
Linear regression modelling using seafood intake and takeaway food consumption as 
independent variables and total ω-3 PUFA as the dependent variable was significant 
(F(2, 204)=7.84, p<0.001; adjusted R2 = 0.062) and showed small but significant effects 
for takeaway food consumption (B=-0.21, p=0.002) and for seafood intake at trend 
level (B=0.13, p=0.050) across both study sites and all participants. Consistent results 
were obtained for EPA and DHA, and an inverse association was observed with total 
ω-3 PUFAs (data not shown).  
7.3.5 Relationship between diet, blood fatty acids and depressive symptoms 
Across both sites, being above the cut-off for depression was associated with a higher 
ω-6/3 ratio (OR = 1.58 (95%CI 1.09 – 2.34), p=0.017; Table 3). This association 
remained significant when the analysis was adjusted for gender and BMI, and 
remained consistent at trend level when age was included as a covariate. There was a 
trend for an association of lower DHA and depressive symptoms (OR = 0.46 (95%CI 
0.21 – 1.02), p=0.057) as well as lower total ω-3 PUFAs and depressive symptoms 
(OR = 0.58 (95%CI 0.33 -1.01), p=0.058). Similarly, we observed a trend for an 
association between takeaway food consumption and depressive symptoms (OR = 
1.33 (95%CI 0.98 – 1.80), p=0.064). No significant association was found between 
seafood intake and depressive symptoms (p=0.673). The directionality of these 
associations was consistent when study participants were stratified by site. None of the 
lipid markers were associated with depressive symptoms.  
 
For study participants on Waiben, higher seafood intake was associated with lower 
levels of depressive symptoms, which persisted at trend level when age, gender and 
BMI were included as covariates (Table 4) whereas, higher takeaway food 
consumption was significantly associated with higher levels of depressive symptoms. 
No significant association was found between membrane PUFAs and depressive 
symptoms. In study participants on Mer, a higher ω-6/3 ratio and lower levels of EPA 
were significantly associated with depressive symptoms but no significant associations 
were found between diet (seafood, takeaway) and depressive symptoms. These 
associations remained at trend level when the analysis was adjusted for gender and 
BMI, but did not persist when age was taken into account. However, no association 
was observed between seafood intake and depressive symptoms.  
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Table 7.3 Odds ratios (95%CI) for the association between seafood intake, blood polyunsaturated fatty acid levels and moderate/high depressive symptoms for 206 
people attending the 2016 Zenadth Kes Health Partnership Health Check 
 Unadjusted Model 1a Model 2b 
 OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
All participants (n=206)       
Dietary intake       
     Seafood  0.95 (0.76 – 1.18) 0.673 0.95 (0.76 – 1.19) 0.715 0.95 (0.74 – 1.21) 0.696 
     Takeaway 1.33 (0.98 – 1.80) 0.064 1.33 (0.98 – 1.80) 0.063 1.26 (0.93 – 1.71) 0.132 
ω -3 Fatty Acids       
     Eicosapentaenoic acid (20:5n-3) 0.13 (0.01 – 1.72) 0.123 0.14 (0.01 – 1.84) 0.136 0.35 (0.02 – 5.46) 0.457 
     Docosahexaenoic acid (22:6n-3) 0.46 (0.21 – 1.02) 0.057 0.48 (0.22 – 1.08) 0.079 0.58 (0.24 – 1.39) 0.229 
Sums and Ratios       
     Sum of ω -3 fatty acids 0.58 (0.33 – 1.01) 0.058 0.59 (0.33 – 1.04) 0.072 0.68 (0.36 – 1.28) 0.241 
     Sum of ω -6 fatty acids 1.12 (0.95 – 1.31) 0.149 1.12 (0.95 – 1.31) 0.163 1.05 (0.88 – 1.25) 0.530 
      ω -6 to ω -3 fatty acids ratio 1.58 (1.09 – 2.34) 0.017 1.62 (1.08 – 2.43) 0.020 1.45 (0.92 – 2.30) 0.106 
Waiben (n=106)       
Dietary intake       
     Seafood  0.79 (0.55 – 1.14) 0.218 0.79 (0.55 – 1.14) 0.222 0.80 (0.54 – 1.17) 0.253 
     Takeaway 1.20 (0.86 – 1.68) 0.266 1.20 (0.85 – 1.68) 0.280 1.15 (0.82 – 1.62) 0.404 
ω -3 Fatty Acids       
     Eicosapentaenoic acid (20:5n-3) 0.39 (0.02 – 5.25) 0.481 0.35 (0.23 – 5.34) 0.454 0.63 (0.03 – 10.67) 0.750 
     Docosahexaenoic acid (22:6n-3) 0.67 (0.23 – 1.96) 0.475 0.69 (0.23 – 2.03) 0.512 0.77 (0.25 – 2.40) 0.663 
Sums and Ratios       
     Sum of ω -3 fatty acids 0.82 (0.41 – 1.63) 0.578 0.80 (0.40 – 1.62) 0.548 0.88 (0.42 – 1.85) 0.755 
     Sum of ω -6 fatty acids 1.04 (0.88 – 1.22) 0.629 1.06 (0.89 – 1.25) 0.491 1.02 (0.84 – 1.22) 0.830 
      ω -6 to ω -3 fatty acids ratio 1.22 (0.78 – 1.91) 0.370 1.32 (0.80 – 2.15) 0.265 1.20 (0.70 – 2.06) 0.494 
Mer (n=100)       
Dietary intake       
     Seafood  1.22 (0.97 – 1.54) 0.083 1.19 (0.95 – 1.49) 0.132 1.92 (0.97 – 3.82) 0.062 
     Takeaway 1.14 (0.39 – 3.30) 0.816 1.07 (0.33 – 3.45) 0.906 1.18 (0.36 – 3.93) 0.778 
ω -3 Fatty Acids       
     Eicosapentaenoic acid (20:5n-3) 0.01 (0.01 – 29.44) 0.258 0.01 (0.01 – 26.04) 0.244 0.14 (0.01 – 997.33) 0.665 
     Docosahexaenoic acid (22:6n-3) 0.95 (0.18 – 5.07) 0.953 0.85 (0.15 – 4.75) 0.855 3.71 (0.28 – 49.70) 0.323 
Sums and Ratios       
     Sum of ω -3 fatty acids 0.66 (0.18 – 2.45) 0.539 0.66 (0.18 – 2.50) 0.544 1.81 (0.29 – 11.18) 0.523 
     Sum of ω -6 fatty acids 1.48 (0.92 – 2.37) 0.102 1.49 (0.89 – 2.51) 0.130 1.28 (0.74 – 2.21) 0.375 
      ω -6 to ω -3 fatty acids ratio 1.79 (0.66 – 4.87) 0.255 1.67 (0.64 – 4.35) 0.297 0.87 (0.22 – 3.46) 0.846 
a adjusted for gender and BMI, b adjusted for age, gender and BMI; OR=odds ratio, CI=confidence interval 8
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Table 7.4 Quantile regression models for the association between seafood intake, blood polyunsaturated fatty acid levels and moderate/high depressive symptoms 
for 206 people attending the 2016 Zenadth Kes Health Partnership Health Check 
 Unadjusted Model 1a Model 2b 
 B (95% CI) p-value B (95% CI) p-value B (95% CI) p-value 
All participants (n=206)       
Dietary intake       
     Seafood  -0.15 (-0.35 – 0.04) 0.122 -0.16 (-0.36 – 0.42) 0.119 -0.08 (-0.30 – 0.13) 0.442 
     Takeaway 1.00 (0.58 – 1.41) <0.001 0.84 (0.16 – 1.52) 0.015 0.75 (0.11 – 1.40) 0.022 
ω -3 Fatty Acids       
     Eicosapentaenoic acid (20:5n-3) 0 (-3.50 – 3.50) 1.000 0 (-2.07 – 2.07) 1.000 2.10 (0.02 – 4.19) 0.047 
     Docosahexaenoic acid (22:6n-3) 0 (-1.04 – 1.04) 1.000 0 (-0.87 – 0.87) 1.000 0.35 (-0.48 – 1.19) 0.411 
Sums and Ratios       
     Sum of ω -3 fatty acids 0 (-0.73 – 0.73) 1.000 0 (-0.58 – 0.58) 1.000 0.26 (-0.25 – 0.77) 0.320 
     Sum of ω -6 fatty acids 0.12 (-0.01 – 0.26)  0.084 0.15 (-0.02 – 0.32) 0.085 0.04 (-0.06 – 0.14) 0.430 
      ω -6 to ω -3 fatty acids ratio 0 (-0.62 – 0.62) 1.000 0 (-0.55 – 0.55) 1.000 -0.10 (-0.51 – 0.30) 0.606 
Waiben (n=106)       
Dietary intake       
     Seafood  -0.50 (-0.95 – -0.04) 0.031 -0.32 (-0.82 – 0.17) 0.200 -0.31 (-0.79 – 0.15) 0.190 
     Takeaway 1.00 (0.41 – 1.58) 0.001 1.12 (0374 – 1.86) 0.003 1.09 (-0.50 – 1.68) <0.001 
ω -3 Fatty Acids       
     Eicosapentaenoic acid (20:5n-3) 2.72 (-2.29 – 7.75) 0.284 1.52 (-3.98 – 7.02) 0.585 3.80 (-2.11 – 9.71) 0.205 
     Docosahexaenoic acid (22:6n-3) 0 (-2.91 – 2.91) 1.000 0 (-2.44 – 2.44) 1.000 0.49 (-2.07 – 3.07) 0.702 
Sums and Ratios       
     Sum of ω -3 fatty acids 0 (-1.75 – 1.75) 1.000 0 (-1.67 – 1.67) 1.000 0.21 (-1.21 – 1.65) 0.762 
     Sum of ω -6 fatty acids 0 (-0.33 – 0.33) 1.000 0 (-0.28 – 0.28) 1.000 -0.01 (-0.29 – 0.27) 0.935 
      ω -6 to ω -3 fatty acids ratio 0 (-0.87 – 0.87) 1.000 0 (-0.97 – 0.97) 1.000 -0.09 (-1.04 – 0.86) 0.851 
Mer (n=100)       
Dietary intake       
     Seafood  0.20 (-0.39 – 0.39) 1.000 -0.14 (-0.45 – 0.16) 0.362 -0.04 (-0.27 – 0.18) 0.712 
     Takeaway 0 (-1.31 – 1.31) 1.000 0.49 (-0.68 – 1.67) 0.407 0.12 (-1.13 – 1.38) 0.846 
ω -3 Fatty Acids       
     Eicosapentaenoic acid (20:5n-3) -2.31 (-4.47 - -0.14) 0.037 -1.51 (-3.77 – 0.74) 0.185 0.36 (-1.81 – 2.55) 0.740 
     Docosahexaenoic acid (22:6n-3) 0 (-1.12 – 1.12) 1.000 -0.39 (-1.14 – 0.36) 0.307 0.32 (-0.46 – 1.11) 0.413 
Sums and Ratios       
     Sum of ω -3 fatty acids 0 (-0.85 – 0.85) 1.000 -0.35 (-0.96 – 0.25) 0.252 0.20 (-0.28 – 0.69) 0.402 
     Sum of ω -6 fatty acids 0.17 (-0.04 – 0.39) 0.119 0.28 (0.13 – 0.43) <0.001 0.18 (0.02 – 0.39) 0.076 
      ω -6 to ω -3 fatty acids ratio 0.86 (0.10 – 1.63) 0.026 0.62 (-0.08 – 1.33) 0.084 0.11 (-0.70 – 0.94) 0.777 
a adjusted for gender and BMI, b adjusted for age, gender and BMI, CI=confidence interval9
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7.4 Discussion 
In this community-based cross-sectional study we tested the hypothesis that fish 
consumption and the consumption of takeaway food rich in ω-6 PUFA are inversely 
associated with blood PUFA status and depressive symptoms. We found significant 
positive associations of fish and seafood consumption with levels of ω-3 PUFA, a 
negative association of takeaway food consumption with ω-3 PUFA, and an 
association of the ω-6/3 PUFA ratio and low levels of ω-3 PUFA with depressive 
symptoms. To the best of our knowledge, this is the first study to address this question 
in a community study of Torres Strait Islander people with a diet consisting of a high 
proportion of local fish and seafood.  
 
Our findings are consistent with a meta-analysis 8 and subsequent observational 
studies 7, 32-34 of ω-3 PUFA in patients with major depressive disorder, dietary 
interventions with ω-3 PUFA 35 and with studies in other clinical populations 36. 
Collectively, these studies support the notion that depression is accompanied by low 
levels of ω-3 PUFA levels. Moreover, population-based studies observed an 
association of low ω-3 PUFA levels with depressive symptoms, including a large 
prospective cohort study of elderly people in Japan 37 and the National Health and 
Nutrition Examination Survey in the United States 38. The Netherlands Study of 
Depression and Anxiety (NESDA) reported depleted levels of ω-3 PUFA in acute but 
not in remitted depression, which were correlated with depression severity 39, 
suggesting a dose-response relationship. Conversely, supplementation with ω-3 
PUFAs has been found to be effective for major depressive disorder, with higher doses 
of EPA having greater effects 14-16, suggesting that ω-3 PUFA administration can 
alleviate depressive symptoms.  
 
Contrary to our initial hypothesis, we did not observe a consistent direct association 
between dietary intake of fish and seafood and depressive symptoms. This may seem 
surprising, given that fish and seafood are the primary sources of EPA and DHA. 
However, the lack of association is consistent with previous large-scale studies that 
failed to observe associations of dietary fish intake and depression while showing 
significant associations of ω-3 PUFA levels with depression 37, 38, 40. Several reasons 
might explain the lack of association in our study. Besides a true absence of 
association, the dietary questionnaire used in the present study only assessed fish and 
seafood intake in the past week. Consequently, the longer-term effects of dietary 
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habits may not be adequately represented in our study. Secondly, ω-3 PUFA from 
other dietary sources as well as supplementation may additionally confound the effect 
of dietary fish intake. Finally, it is conceivable that a ceiling effect is present at least in 
the community with higher fish consumption, beyond which an effect of dietary intake 
on the risk for depression cannot be observed. The observation of a significant 
relationship between the ω-6/3 PUFA ratio and depression in the quantile regression 
model in the study site with lower seafood intake could potentially indicate a ceiling 
effect, whereby a relationship between ω-3 PUFA and depressive symptomatology 
exists only below a certain level of dietary ω-3 PUFA intake. The fact that the results 
from the quantile regression models are only partially consistent with the logistic 
regression models may indicate that the observed relationship between membrane 
PUFAs and depression might only apply to more severe depression, but not to 
depressive symptoms below the threshold for major depression.  
 
While ω-3 PUFA have been recognised as a specific dietary component linked to 
depression and other conditions, the role of foods that are high in saturated and n-6 
fatty acids is less clear. Our results indicate that the consumption of take-away food is 
associated with higher aPHQ-9 scores on Waiben where takeaway food was more 
readily available and consumption significantly higher. Similarly, takeaway food 
consumption was also associated with lower ω-3 PUFA levels and a higher ω-6/3 
ratio. This suggests that foods high in ω-6 PUFA (for example, linolenic acid) have 
opposing effects on the levels of ω-3 PUFA but also directly on depression. This is in 
line with the view that ‘Western’ diets high in ω-6 PUFA and low in ω-3 PUFA are 
associated with higher rates of depression 12, 41. Collectively, these findings support the 
emerging notion that diet is a modifiable risk factor for depression 42.  
 
The question whether low levels of ω-3 PUFA precede or indicate risk for depression 
cannot be answered in our cross-sectional study. Indeed, it is possible that depression 
predisposes to an unhealthy diet and low intake of fresh seafood and reverse 
causation or a bi-directional relationship are possible. However, we have previously 
shown in a longitudinal study that low levels of ω-3 PUFA and a high ω-6/3 PUFA ratio 
are risk factors for mood disorders in young people with at-risk mental states, 
suggesting that low membrane PUFA levels precede the onset of depression in this 
group 18. While at-risk mental states are characterised by ongoing sub-clinical 
psychopathology and differ from the community sample in the present study, the 
specificity of the observed association for mood disorders in this previous study 18 
suggests that low levels of ω-3 PUFA indeed represent a risk factor for depression.   
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Aboriginal and Torres Strait Islander Australians continue to experience depression 
and other mental disorders at higher rates relative to the general population. While the 
social and environmental determinants of the excess psychiatric morbidity are complex 
and no single intervention is likely to ameliorate all determinants of mental health, our 
data suggest that a diet that is rich in ω-3 PUFA and low in ω-6 PUFA may be 
beneficial. While longitudinal studies are needed to establish whether diet can have a 
lasting impact on depression risk and it is premature to draw firm conclusions from the 
currently available data, sustainable access to healthy food in rural and remote 
communities should be a priority and may be beneficial not only to physical health but 
also to mental health and wellbeing.  
 
Several limitations warrant consideration in the interpretation of these findings. First, 
as mentioned above, we did not take ω-3 PUFA supplementation into account, which 
limits the conclusions that can be drawn from the association of dietary intake of fish 
and seafood with PUFA levels and depression. Second, a multitude of risk factors for 
mood disorders are known to interact with the complex aetiology of the disorder, many 
of which were not taken into account in the present study. Third, the study setting 
opens up the possibility for underreporting of depression, since it is plausible that 
severely depressed individuals were less likely to attend. Participants may have been 
less likely to disclose symptoms in this setting due to a perceived lack of privacy in a 
community health check setting, and due to perceived associated stigma. The study 
sample may thus not be representative of the wider community. Fourth, the sub-group 
of study participants with aPHQ-9 scores above the cut-off for probable depression 
was small (n=18) and the results of our logistic regression analysis is limited by this 
fact. Finally, although the PHQ-9 is an often used and well validated instrument to 
assess depression in primary care settings and is a sensible choice as a brief 
depression screener in health checks 43, the validity of the adapted instrument used in 
our study remains unknown. The version adapted for Central Australian Aboriginal 
people used in our study is currently undergoing validation 28.  
 
In conclusion, the association of dietary intake of fish/seafood and takeaway food, ω-3 
PUFA levels and depressive symptoms in our cross-sectional study in two Torres 
Strait Islander communities highlights the potential role of traditional fish-based diet as 
a protective factor for depression. A growing body of literature supports the notion that 
diet is an important modifiable risk factor for depression and our findings align with this 
view and represent a potential explanatory model for epidemiological differences in 
depression prevalence in Indigenous populations.  
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8 General Discussion 
The overarching aim of this thesis was to examine potential biomarkers in two distinct 
high-risk populations. Specifically, the hypotheses of this thesis were that AL would be 
elevated in patients with mental disorders and concomitantly related to illness severity 
and progression; and that similarly ω-3 PUFA are indicative of poor outcomes in 
depression. By combining evidence from meta-analysis, secondary analyses of clinical 
trials and a cross-sectional study conducted in three Aboriginal and Torres Strait 
Islander communities, this thesis tested the above hypotheses and contributes novel 
knowledge relevant to high-risk groups.  
 
The findings of this thesis demonstrate unique associations of AL with psychotic 
disorders. The main findings relevant to AL are dysregulation of primary AL mediators 
in psychotic disorders (Chapter 2), elevated AL in psychosis that is related to illness 
severity and functioning (Chapter 3) and indicative of poor functioning in people at 
UHR for psychosis (Chapter 4). No consistent evidence was found for the role of AL in 
depression (Chapter 6). Low levels of ω-3 PUFA as well as a high ω-6/3 PUFA ratio 
were found to be indicative of a higher risk for mood disorders in people at UHR for 
psychosis (Chapter 5) and related to depressive symptoms in otherwise healthy 
individuals (Chapter 7). Collectively, these findings address current knowledge gaps 
and add to a growing body of research aimed at identifying risk biomarkers in 
psychiatry.  
 
In this final chapter I will synthesise and discuss the main findings of this thesis and 
place them in the context of existing and emerging literature. Strengths and limitations 
of the individual chapters will be discussed in the wider context of this body of work 
and related research. Finally, this chapter concludes with recommendations for future 
research and a discussion of clinical implications for the work presented in this thesis.  
 
Chapters 3 and 4 provided novel insights into the role of AL in patients with psychotic 
disorders and young people at UHR for psychosis. In the last decade several authors 
have argued that the AL framework is highly relevant to psychiatric populations 1-6. The 
main arguments that emerged in the literature can be broadly grouped into those that 
propose AL as a tool to understand and predict cardiovascular and other prevalent 
physical comorbidities in people living with severe mental illnesses 1, 6, and those that 
discuss AL as a framework to understand the pathophysiology of mental disorders 2-4. 
A third important are of research is the uncertainty surrounding the suitability of AL 
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determine risk for illness progression, treatment resistance and other clinical outcomes 
of interest. The research presented in Chapters 3 and 4 directly addresses this third 
research concern by measuring AL in clinical populations and by testing associations 
with symptoms (Chapter 3) and prospective associations with clinical outcomes 
(Chapter 4).  
 
The main finding of Chapter 3 was that the AL index is elevated in patients relative to 
health controls matched for age and gender, with a gradual increase in AL from 
controls to first-episode patients and then to patients with SCZ. Chapter 3 also showed 
that AL is related to the severity of positive psychotic symptoms and impaired 
functional capacity. These observations suggest AL is related to illness severity in 
acutely ill patients. The observation that AL decreased with six weeks treatment also 
supports this notion. An important aim of this chapter was to test if AL could be 
predictive of treatment response and remission criteria. This hypothesis, however, was 
not supported by the data, which may be attributable to the relatively small sample size 
of this study and the consequent lack of power to detect small effects in subsets of the 
sample.  
 
The study undertaken in Chapter 3 confirms and extends the only previous 
investigation of AL in SCZ and healthy controls 7. During the same time period when 
our study was under investigation, another study reporting AL in patients with SCZ was 
published 7. The authors of this study measured AL in 30 patients with SCZ (mean 
age: 32.5 years) and 20 healthy controls and found elevated AL in patients compared 
to controls and significant correlations with both positive psychotic symptoms (Brief 
Psychiatric Rating Scale) and impaired functional capacity (UCSD Performance-Based 
Skills Assessment-2). Similarly to the data reported in Chapter 3, no associations were 
observed with other psychiatric symptoms. The authors also assessed self-reported 
stress in the past month (Perceived Stress Scale) and found it to be unrelated to AL, 
suggesting that the stressful experience of psychosis itself does not sufficiently explain 
heightened AL. This latter observation is also consistent with a recent study in which 
we reported that insulin resistance in first-episode patients is unrelated to chronic 
stress and cortisol levels 8. Chapter 3 thus confirms the only other direct measurement 
of AL in patients with SCZ and adds important knowledge by including (drug-naïve) 
patients with FEP and by assessing AL at three time points.  
 
An important question raised by Chapter 3 involved determining if AL precedes 
psychosis and can be used to inform risk prediction (e.g. for poor outcomes) in 
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individuals at UHR for psychosis. This question is salient because heightened AL may 
contribute to the underpinnings of the pathophysiology observed in psychotic disorders 
and, if present before the onset, might be an indicator of risk for psychosis transition or 
other associated outcomes. This question informed the study reported in Chapter 4, 
which found that AL was indicative of poor functioning (assessed with SOFAS, GF-S 
and GF-R). This was the first study to examine prospective associations of AL with 
clinical outcomes in people at UHR for psychosis and confirms the importance of 
multisystem dysregulation for functional outcomes. While no associations were 
observed with psychotic symptoms, the relationship between AL and functioning 
indicates that AL may not only be associated with poor functioning in acutely psychotic 
patients, but also indicative of poor functioning in people at UHR for psychosis, who 
have a 20% (95%CI 17-25%) risk of developing psychosis within two years 9. This is a 
highly relevant finding, as everyday functioning is an important outcome for patients 
with psychosis 10. Together, Chapters 3 and 4 address a critical gap in knowledge and 
provide the first evidence of the role of AL before and at the onset of psychosis.  
 
Chapter 6 demonstrated no association of AL with depressive symptoms (measured 
with the aPHQ-9) in adolescents or adults. The evidence for elevated AL in patients 
with clinical depression as well as for a relationship with depressive symptoms in 
otherwise healthy adults is somewhat inconsistent. While some studies found AL to be 
increased 11 and related to future depressive symptoms 12, other studies did not 
confirm this with a recent large cross-sectional study (n=12272) reporting no 
association of depressive symptoms (measured with the PHQ-9) with AL 13. An 
important question that arises from the data presented in Chapters 3, 4 and 6 is if 
elevated AL is specific to psychotic disorders. Clearly, the differences in study 
population and methodology do not allow direct comparisons between the studies. 
Moreover, given the limited number of studies particularly in patients with psychosis, it 
seems premature to attempt to answer this question. While it is possible that AL is 
involved in psychotic disorders to a higher degree than in depression, alternative 
explanations are that studies in psychosis tended to recruit more severely ill individuals 
while most studies in depressed individuals relied on population-based cohorts. This 
question should be further addressed in future studies.  
 
A theoretical advantage of the AL index, when applied in psychiatric populations, is 
that it acknowledges the multitude of pathomechanisms that contribute to many 
psychiatric disorders. This may have advantages over individual biomarkers, which 
may be of limited benefit in complex disorders characterised by heterogeneous 
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pathophysiology. The AL index used in several chapters of this thesis might help to 
overcome this problem as it clusters and reduces the dimensionality of the information 
contained in the multiple biomarkers. Moreover, the theoretical framework of allostasis 
provides a biological rationale for this approach that may apply transdiagnostically. In 
contrast to such an approach, over the past decade, discovery-driven approaches 
have seen a tremendous rise in popularity within psychiatric research. These include 
biological tools (“-omics” techniques) but also statistical and mathematical modelling 
approaches such as machine learning or joint modelling 14, 15.  
 
One aim of this thesis was to examine whether lipid biology is related to clinical 
outcomes has been explored in Chapter 5. Using data from the Vienna Omega-3 
Study 16, we were able to examine prospective associations of several classes of 
PUFAs with clinically relevant outcomes. At the time of publication, these were some 
of the longest follow-up data in UHR cohorts available and allowed important insights 
into the role of PUFAs, which were measured at the baseline assessment of this study. 
Chapter 5 reported strong associations (OR=1.89, 95%CI 1.07 – 3.33) of the balance 
between ω-6 and ω-3 PUFA with mood disorders at the 7-year assessment. Mood 
disorders were prevalent in this study and in other UHR studies 17 with 37% of 
participants being diagnosed with a mood disorder diagnosis (major depressive 
disorder or bipolar I disorder) at some point during the follow up. Somewhat 
surprisingly, no significant associations were observed with other outcomes, including 
psychotic disorders.  
 
A key observation of Chapter 5 was that low levels of EPA and DHA were similarly 
predictive of mood disorders. This is relevant as only interventions with a high content 
of EPA appear to be effective in patients with major depressive disorder 18, 19. In 
contrast, for people at UHR for psychosis, fish oil (840mg EPA and 560mg DHA per 
day) was found to be ineffective at reducing depressive symptoms in the NEURAPRO 
study 20. However, the primary analysis of this study focused on depressive symptoms 
(MADRS) as a secondary outcome but not on an Axis I diagnosis. It is conceivable that 
study participants with MDD could have been in remission at the primary outcome 
assessment and that consequently, a SCID diagnosis may be a more appropriate 
outcome compared to a momentary assessment of severity scores for this particular 
question. Moreover, if low levels of EPA and DHA as well as the ω-6/3 PUFA ratio are 
indicative of the risk for mood disorders, it is plausible that only individuals at UHR for 
psychosis with low levels of these ω-3 PUFA would benefit from fish oil. Consequently, 
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pre-treatment levels of EPA or other n-3 PUFA should be considered as part of the 
inclusion criteria in future studies.  
 
Chapter 7 examined the role of PUFAs for depression from a different perspective in a 
sub-group of participants from the WPC study. A major aim of the WPC was to identify 
risk and protective factors for depressive symptoms. Motivated by the results of 
Chapter 5, we investigated whether blood PUFA levels, fish consumption, and 
depressive symptoms were associated in a healthy population sample. Indeed, the ω-
6/3 PUFA ratio was associated with being above the cut-off for depression on the 
aPHQ-9 (unadjusted OR=1.58, 95%CI 1.09 – 2.34), although this was reduced to a 
trend when age, sex and BMI were included as covariates. The power of this analysis 
was limited by the small group of participants with aPHQ-9 scores above this (n=19). 
Consistent with Chapter 5, EPA and DHA were independently associated with 
depressive symptoms at trend level (unadjusted OR=0.13, 95%CI 0.01 – 1.72 and 
OR=0.46, 95%CI 0.21 – 1.02, respectively), highlighting their relevance for depression. 
Importantly, the two Torres Strait Islander communities participating in this study 
represent a unique and distinct cohort due to their geographical location, their access 
to fresh seafood and the limited availability of fast food in one of the study sites. The 
findings of this study, together with other recent evidence supported by our data that 
the prevalence of depression is comparatively low in this population 21, raise the 
question if the high fish and seafood consumption could be a protective factor for 
depression. This is especially relevant as prevalence estimates for several mental 
disorders including MDD are higher for Aboriginal and Torres Strait Islander people 
than for the general population 22-25. Caution is warranted if these findings are to be 
directly generalised to other populations. While the mechanisms by which ω-3 PUFA 
are thought to reduce depression risk may be universal, a multitude of social health 
determinants are known to influence the risk for mental health and these have not 
been comprehensively addressed in this study.  
 
The cross-sectional design of this study precludes conclusions about the directionality 
of these associations or assumptions about causation. However, in light of the 
evidence from longitudinal studies, including in people at UHR for psychosis as 
presented in Chapter 5, it seems reasonable to propose that ω-3 PUFA from diet and 
other sources modify the risk for depression in clinical cohorts and for depressive 
symptoms in otherwise healthy individuals at population level. The growing 
understanding of the biology of PUFA and their role in modulating key cellular 
functions relevant to psychiatric disorders adds biological validity to this hypothesis. 
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However, a bi-directional relationship, whereby depressed individuals are less likely to 
consume adequate amounts of these essential fatty acids, is possible but cannot be 
confirmed based on the data presented in this thesis. Loss or increase of appetite are 
both diagnostic criteria of major depressive disorder according to the DSM-V 26 and 
ICD-10 27, and several studies support the notion that healthy diets are generally 
associated with lower depression risk 28-30. 
 
Ultimately, a biomarker or risk index that is useful for clinical practice will have to (1) 
relate to defined outcomes of interest (e.g. psychosis transition or treatment response), 
(2) significantly exceed the predictive capacity of clinical characteristics alone, (3) be 
predictive in at least a well-defined sub-group of patients, (4) be cost-effective and 
feasible to collect in practice. While a common criticism of AL is that the multitude of 
relevant biomarkers is expensive and difficult to collect routinely, the 10-biomarker AL 
index used in this thesis and in similar constellation in other studies 7, 31 is collected 
relatively easily, as some elements are routinely measured in clinical practice (e.g. 
blood pressure, lipids, HbA1c, CRP) while most others can be quantified from a blood 
test (e.g. IL-6). Only cortisol requires special attention, as plasma cortisol is subject to 
the diurnal rhythm of the HPA-axis, which may be overcome by measuring hair cortisol 
from hair (see Chapter 6). Similarly, fatty acids (Chapters 5 and 7) can be measured 
from a dried blood spot with a method similar to a simple blood glucose test 32.  
 
The findings reported in this thesis suggest several avenues for future research: 
 
? The association of AL with psychosis (Chapters 3 and 4) indicates a need for 
future investigation to determine if lowering AL can ameliorate the illness. While 
the effects of lower AL for mental illness have not been directly studied to date, 
there is evidence to suggest that lower AL is associated with reduced mortality 
in older adults 33. Few studies to date have directly addressed potential 
avenues to reduce AL. Given that commonly described determinants of AL 
include potentially modifiable risk factors such as low childhood SES 34, 
adverse childhood experiences 35, or discrimination and associated social 
gradients in health 36, 37, addressing these might provide opportunities to 
change the trajectory of allostasis in vulnerable populations. For example, 
direct interventions addressing the effects of chronic stress have been 
evaluated for example in school-aged children 38 and future studies may with to 
investigate AL in this population.  
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? The observation that low levels of ω-3 PUFA and a high ω-6/3 PUFA ratio are 
associated with depressive symptoms (Chapter 7) and that these indices place 
youth at UHR for psychosis at higher risk for developing mood disorders 
(Chapter 5) strengthen the rationale for biomarker-guided intervention studies. 
In this context, using low levels of ω-3 PUFA as an inclusion criterion for RCTs 
of fish oil may be more appropriate than including participants irrespective of 
their PUFA status. In fact, a very recent finding of the NEURAPRO clinical trial 
was that participants with a n-3 indexii <3% showed greater rates of favourable 
overall clinical improvement compared to those with higher ω-3 indices, and 
that fish oil was significantly more beneficial than placebo when only 
participants with low n-3 indices were included in the analysis 39. This is 
particularly relevant as the primary intention-to-treat analysis showed no 
superiority of fish oil over placebo 20, likely due to an effective background 
intervention, low adherence and ω-3 intake from other sources in the placebo 
group 40.  
? While there is already rapidly growing interest surrounding the role of nutrition 
on mental health in the scientific community (e.g. ref 41), Chapter 7 adds 
evidence in support of the notion that diet is a modifiable risk factor for 
depression. While this study was cross-sectional and does not permit 
inferences about the causality of the relationship between dietary intake of n-3 
PUFA and depressive symptoms, the robustness of this observation and the 
biological validity of the relationship strongly suggest that a carefully improved 
diet might be beneficial for patients with MDD and possibly to reduce the risk 
for depression before the onset.  
? While inception cohort studies such as birth cohort studies are particularly 
suited to identify risk factors and would overcome many of the limitations of the 
research presented in this thesis, there are several difficulties in applying such 
designs to biomarker studies, including the cost of measuring a range of 
biomarkers in very large samples and the relatively low incidence of UHR 
states. Adequately powered clinical cohort studies recruiting help-seeking 
individuals with ARMS may be more appropriate for risk prediction.  
? Ultimately, future studies should aim to combine information from various 
biomarkers to evaluate their predictive capacity in longitudinal studies, 
particularly also in relation to individual biomarkers. Risk calculators 42, 43 are 
one such approach and combine different parameters into a single risk index, 
                                               
ii The n-3 index is calculated as EPA + DHA. 
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yet biomarker information has not been considered so far. The aim of such 
undertakings would be to assist in developing personalised approaches of 
developing individualised approaches with a decision support system. 
 
Taken together, the studies presented in this thesis provide novel insights into two 
candidate risk mechanisms for mental disorders and contribute to the understanding of 
AL and lipid biology with relevance to people with at-risk mental states and Indigenous 
mental health. Applying the AL framework to a clinical population has revealed clinical 
correlates of multisystem dysregulation in patients with psychotic disorders and 
provided evidence for AL as an indicator of poor functional outcomes in youth at UHR 
for psychosis. Similarly, demonstrating that the balance of ω-6 to ω-3 PUFA indicates 
risk for mood disorders over a long follow-up period is critical as the ω-6/3 PUFA ratio 
is highly modifiable and as such provides a rationale for biomarker-guided 
interventions. These insights highlight new candidate risk biomarkers and provide 
scope to further evaluate them in clinical populations. While conversion to psychosis 
has been the primary outcome of interest in this group, mood disorders are common 
and will need to be addressed in future studies. Identifying candidate risk biomarkers is 
not only an essential prerequisite for better prediction of risk and need for care but also 
add to our understanding of the potentially modifiable social and biological risk factors 
and their effects on the developing brain 44. Ultimately, this may lead to the 
development of novel benign treatments and personalised treatment strategies 
appropriate for young people.  
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Appendix 
Appendix A - Supplementary Materials for Chapter 3 
Methods 
Alternative allostatic load index 
We replicated our main results using a traditional allostatic load index in order to allow 
better comparisons to original validation studies (Seeman et al., 2001). This index 
consisted of heart rate, systolic blood pressure, diastolic blood pressure, waist-to-hip 
ratio, cholesterol, high-density lipoprotein, low-density lipoprotein, glycosylated 
hemoglobin, cortisol, metanephrine and normetanephrine.  
‘Scaled’ allostatic load index 
The scaling approach may have advantages over more ‘traditional’ count-based 
calculations of allostatic load as it weighs the contribution of individual biomarkers in 
relation to the number of included biomarkers. Consequently, each ‘system’ (e.g. 
cardiovascular, immune, lipid and glucose metabolism) contributes equally to the 
allostatic load index. Our approach of including a larger number of parameters also 
reduces the contribution of individual ones and thus avoids maximizing differences of 
individual biomarkers that are differentially elevated or decreased (e.g. blood pressure 
as an indicator of acute/fluctuating stress activation) and those of outliers. 
 
Additional Results 
Simplified allostatic load index 
Adjusting for age and smoking, allostatic load was significantly different between the 
three groups (F(2, 95)=11.78, p<0.001). Allostatic load was highest in patients with 
schizophrenia (6.10 ± 2.88), followed by patients with first-episode psychosis (4.38 ± 
2.14) and controls (3.35 ± 1.86). Across all patients, allostatic load was significantly 
positively correlated with positive psychotic symptoms (r=0.312, p=0.042) but no clear 
association was found with GAF scores (r=-114, p=0.46).  
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